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Sir2 (silencing information regulator 2) family of enzymes (or sirtuins) are 
nicotinamide adenine dinucleotide (NAD
+
)-dependent protein lysine deacylases and 
play a variety of roles in biological systems. SIRT6 is one of the seven mammalian 
sirtuins and has diverse biological functions such as maintaining genomic stability, 
controlling glucose homeostasis and suppressing tumor growth. Enzymatically, SIRT6 
has been shown to have lysine deacetylation, lysine defatty-acylation and mono-
adenosine diphosphate (ADP)-ribosyltransferase activities. However, the contribution 
of each activity to the various functions of SIRT6 is poorly understood. 
In Chapter 2, I describe the dissection of functional contribution of the defatty-acylase 
activity of SIRT6 by utilizing a SIRT6 mutant (Gly60Ala), which has efficient defatty-
acylase activity but no detectable deacetylase and mono-ADP-ribosyltransferase 
activities. Using this mutant, I found that SIRT6‟s defatty-acylase activity regulates 
the secretion of numerous proteins in mouse embryonic fibroblasts. Interestingly, 
SIRT6 defatty-acylase activity regulates the sorting of many ribosomal proteins into 
exosomes for secretion. 
In Chapter 3, I found that SIRT6 defatty-acylase activity contributes to its tumor 
suppressor function. To identify SIRT6 defatty-acylation targets, I utilized a fatty acid 
reporter to metabolically label the proteome followed by affinity enrichment and mass 
spectrometry analysis. I found that R-Ras2 is a SIRT6 defatty-acylation target that 
accounts for its tumor suppressor function. Mechanistically, lysine fatty-acylation of 
  
R-Ras2 promotes its plasma membrane localization and increases its interaction with 
PI3K. The increase in R-Ras2 and PI3K association leads to elevated Akt activation 
and increased cell proliferation. 
In Chapter 4, I describe an interactome study of KRas4a and KRas4b, which led to the 
identification of many previously unknown KRas4a and KRas4b interacting proteins. 
Interestingly, I found that KRas4a interacts more with Raf1 than KRas4b does, which 
may contribute to the more anchorage-independent colony formation in KRas4a 
transformed NIH 3T3 cells than in KRas4b transformed NIH 3T3 cells. Moreover, 
mTOR was identified as a KRas4a/b interaction protein. Different from well-
established mTORC1 and mTORC2, KRas4a/b forms a new mTOR complex without 
raptor or rictor in cells. 
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CHAPTER 1 
AN OVERVIEW OF SIRT6 AND RAS PROTEINS 
 
My thesis work is focused on demonstrating the physiological relevance of SIRT6 
defatty-acylase activity, and investigating the novel signaling outputs of KRas4a and 
KRas4b. In this chapter, I review the research progress of SIRT6 and Ras proteins, 
including their enzymatic activities, structural and biochemical features, and biological 
functions. 
 
Introduction of SIRT6 
Sir2 (silencing information regulator 2) family of enzymes (or sirtuins) are a class of 
proteins that exist in bacteria, archaea, and eukaryotes and possess multiple enzymatic 
activities, including nicotinamide adenine dinucleotide (NAD
+
)-dependent protein 
lysine deacylase and mono-ADP ribosyltransferase activities
1-10
. In mammals, there 
are seven sirtuins (SIRT1-7), they have different enzymatic activities, subcellular 
localizations, and biological functions
11-13
. Mammalian SIRT6 was initially reported 
as a NAD
+
-dependent protein lysine deacetylase
1
 and played important roles in 
maintaining genomic stability
14
. Later, numerous studies showed that SIRT6 has many 
other pivotal biological functions such as promoting DNA repair
15,16
, regulating 
glucose homeostasis
17
, suppressing tumorgenesis
18
, and increasing lifespan
19,20
. SIRT6 
knockout (KO) mice are born normally, but around 3 weeks after birth they develop 
lymphopenia, loss of subcutaneous fat, suffer from severe metabolic defects, and die 
before 4 weeks of age
14
. Clearly, SIRT6 has very important biological functions. 
 
Enzymatic activities of SIRT6 
SIRT6 was first characterized as a NAD
+
-dependent histone deacetylase that targets 
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histone H3 lysine K9, K18, and K56
1,21-23
. Later studies showed that SIRT6 
deacetylation targets also include non-histone proteins such as CtIP
16
 and GCN5
24
. 
Recently, SIRT6 was found to possess lysine defatty-acylase activity that targets 
TNFα lysine K19, 208, suggesting that SIRT6 has multiple enzymatic activities. 
Similar to other sirtuins, SIRT6 utilizes NAD
+
 for its deacylation reaction that yields 
deacylated peptide/protein product, O-acyl-ADP ribose and nicotinamide (Figure 1.1). 
Sirtuin-catalyzed deacylation is thought to undergo several different intermediates 
(Figure 1.2). In the first step, the acyl lysine residue attacks the anomeric carbon of 
ribose, generating nicotinamide and 1‟-O-alkylamidate intermediate. In the second 
step, a catalytic histidine (His133 for SIRT6) serves as general base to deprotonate the 
2‟-hydroxyl group of ribose, which promotes an intramolecular nucleophilic attack 
and forms a 1‟,2‟-cyclic ADP-ribose intermediate. The 1‟,2‟-cyclic intermediate reacts 
with water and forms 2‟-O-acyl-ADP ribose and 3‟-O- acyl-ADP ribose as final 
products. 
 
 
Figure 1.1. NAD
+
-dependent protein lysine deacylation reaction of SIRT6. 
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Figure 1.2. Proposed mechanism of SIRT6 deacylation reaction. 
 
Besides lysine deacylase activities, SIRT6 was also reported to have mono-ART 
activity that targets itself, PARP1 and KAP1
15,25,26
. However, several in vitro studies 
showed that this activity is weak
27,28
, suggesting that this activity could depend on 
specific substrates or conditions. Currently, biochemical studies that uncover the 
mechanism of SIRT6 mono-ART activity is still lacking, but it is thought to have the 
same mechanism as proteins from the poly-(ADP-ribose) polymerase family, with 
SIRT6 mediating the attack of nucleophilic amino acids to the anomeric carbon of the 
ribose, generating nicotinamide and mono-ADP-ribose covalently modified proteins 
(Figure 1.3). However, the identity of the nucleophilic amino acids is not known. 
 
 
Figure 1.3. Proposed mechanism of SIRT6 mono-ADP-ribosyltransferase activity. 
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Structural and biochemical features of SIRT6 
Human SIRT6 has 355 amino acids. It has a conserved catalytic core with N- and C-
terminal extensions (NTE and CTE). Biochemical studies showed that NTE is 
important for both its catalytic activity and chromatin association, and CTE is required 
for proper nucleus localization
29
. 
Several crystal structures of SIRT6 were reported to provide important insights into 
the mechanism for its deacylase activity and substrate specificity. The first SIRT6 
crystal structure at 2.0 Å resolution was reported in 2011
30
. Denu and coworkers used 
human SIRT6 (3-318) construct purified from Escherichia coli (E.Coli) for 
crystallization because it has higher yield (10-20 mg per liter) than full length protein 
without diminishing the deacetylase activity. Similar to other sirtuins, SIRT6 has two 
domains: a large Rossmann fold domain and a small Zn
2+
-binding motif (Figure 1.4). 
The Rossmann fold domain (residues 25-128 and 191-266) consists of a six parallel β 
sheets surrounded by six α helices (two on one side and four on the other side). The 
Zn
2+
-binding motif (residues 129-190) is structurally more variable and consists of 
three antiparallel β sheets and two loops. The two loops provide four cysteine residues 
that bind to Zn
2+
. The Zn
2+
 in SIRT6 does not directly participate in catalysis and 
plays a structural role. The NAD
+
 binding pocket is largely conserved between SIRT6 
and other sirtuins. One interesting feature of SIRT6 structure is that SIRT6 can bind to 
NAD
+
 without binding to acetylated substrate, which is different from other sirtuins 
that require peptide substrate binding prior to NAD
+
 binding. Although there are many 
SIRT6 crystal structures reported, there is no SIRT6 crystal structure co-crystalized 
with acetyl peptide substrate. Indeed, in the first SIRT6 structure paper, the authors 
attempted to co-crystallize SIRT6 with acetyl H3K9 peptide and NAD
+
 but did not 
observe the acetyl H3K9 peptide in SIRT6 structure
30
, suggesting the weak binding 
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between SIRT6 and its acetyl substrate. 
 
 
Figure 1.4. Structure of human SIRT6 in complex with ADP-ribose (PDB: 3PKI). 
Green, Zn
2+
 binding motif. Orange, Rossman fold domain. The image was made using 
PyMOL. 
 
In 2013, our group reported that SIRT6 is a lysine defatty-acylase
8
. In vitro kinetic 
studies showed that SIRT6 can remove myristoyl and palmitoyl groups more 
efficiently than acetyl groups from lysine residue (Table 1.1). Co-crystal structure of 
SIRT6 with myristoyl H3K9 peptide and ADP-ribose reveals a large hydrophobic 
pocket near the active site. The accommodated myristoyl group forms van der Waals 
interactions with several hydrophobic residues in the pocket, including Ala 11, Pro 60, 
Phe 62, Trp 69, Pro 78, Phe 80, Phe 84, Val 113, Leu 130, Leu 184, and Ile 217 
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(Figure 1.5). This structure explains why SIRT6 is a better lysine defatty-acylase than 
lysine deacetylase in vitro-SIRT6 can bind fatty-acyl lysine much better, leading to 
decreased Km values and thus increased catalytic efficiency (Table 1.1). 
 
Table 1.1 Catalytic efficiencies of SIRT6 on different acyl peptides
8
 
Acyl peptide kcat (s
-1
) Km (μM) kcat/Km (s
-1
 M
-1
) 
Acetyl H3K9 0.00396 ± 0.0006 810 ± 160 4.8 
Myristoyl H3K9 0.00496 ± 0.0004 3.4 ± 0.9 1.4 × 10
3
 
Palmitoyl H3K9 0.00276 ± 0.0002 0.9 ± 0.4 3.0 × 10
3
 
Myristoyl TNFα K19 0.00206 ± 0.0002 2.4 ± 0.6 8.3 × 102 
Myristoyl TNFα K20 0.00506 ± 0.0004 4.5 ± 1.1 1.1 × 103 
 
 
Figure 1.5. Key hydrophobic residues in SIRT6 hydrophobic pocket (PDB: 3ZG6) 
that accommodate the myristoyl group. The image was made using PyMOL. 
 
The weak deacetylase activity of SIRT6 in vitro originally raised a concern about the 
physiological relevance of SIRT6‟s deacetylation in vivo. Two later studies 
 7 
 
investigated this topic and found that SIRT6 deacetylase activity can be significantly 
enhanced by nucleosome or free fatty acids in vitro
31,32
, suggesting the physiological 
relevance of SIRT6 deacetylation might depend on specific context. These findings 
are also consistent with other features of SIRT6. For example, SIRT6 has been 
characterized as a chromatin regulator, indicating that it needs to associate with 
nucleosome to exhibit histone deacetylation. In addition, the large hydrophobic pocket 
in SIRT6 may accommodate the free fatty acids, the binding of free fatty acids may 
induce a conformation change that allow it to bind acetyl peptide better, which may 
explain the activation effect of free fatty acids on SIRT6 deacetylation. Also, free fatty 
acids inhibit SIRT6 defatty-acylase activity
31
, suggesting that free fatty acids may be 
important physiological molecules that switch SIRT6 to a lysine deacetylase. A recent 
study showed that nucleosome can activate SIRT6 defatty-acylase activity in vitro
33
, 
suggesting that nucleosome and free fatty acids may use different mechanisms to 
activate SIRT6. Currently, there are still many questions to be addressed, such as how 
nucleosome and free fatty acids activate SIRT6 deacetylase activity, and why SIRT6 
can only deacetylate histone H3K9, K18 and K56, but not other residues of histone H3 
and other histones. Future structural studies may help answer these questions. 
 
Biological functions of SIRT6 and the underlying molecular mechanisms 
The diverse biological functions of SIRT6 were initially discovered from transgenic 
mice either deleting or overexpressing SIRT6. SIRT6 KO mice suffer from severe 
metabolic defects and develop lymphopenia, osteopenia and hypoglycemia
14
. They die 
around 4 weeks of age after birth
14
. Conversely, SIRT6 overexpression increases 
lifespan in male mice
20
. Neural-specific SIRT6 KO mice show postnatal growth 
retardation after birth and ultimately become obese at 6 months
34
. Hepatic-specific 
SIRT6 KO mice have increased low-density lipoprotein (LDL)-cholesterol, while 
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SIRT6 overexpression in high fat diet (HFD)-fed mice lowers LDL-cholesterol
35
. The 
mechanistic studies showed that SIRT6 regulates different signaling pathways through 
both deacetylase and defatty-acylase activities to achieve its diverse biological 
functions. 
Silencing transcription. SIRT6 acts as a gene silencer by deacetylating histone H3K9, 
K18, and K56 at promoter regions that co-represses several transcriptional factors, 
including HIF-1α17, Myc18, c-Jun36, FoxO335 and NF-κB19. Transcriptional 
suppression plays important roles in SIRT6‟s biological functions. For example, 
SIRT6 maintains glucose homeostasis by suppressing HIF-1α controlled transcription 
via H3K9 deacetylation
17
. SIRT6 acts as a tumor suppressor by suppressing MYC 
controlled transcription via H3K56 deacetylation
19
.  
DNA repair and genome stability. SIRT6 is a key player in DNA repair. It is reported 
that SIRT6 is important for both base excision repair (BER)
14
 and DNA double-strand 
breaks (DSBs) repair
16
. Although the underlying mechanism of SIRT6‟s function in 
DNA repair is not fully understood, it is thought that SIRT6 promotes DNA end 
resection by deacetylating CtIP
16
. It is reported that SIRT6 also promotes DNA repair 
by mono-ADP-ribosylating PARP1 and increases PARP1 activity
15
. Another study 
suggests that SIRT6 recruits the chromatin remodeler SNF2H to DSBs and 
deacetylates H3K56, which serves as an early step in the DNA damage response
37
. 
Besides the role in DNA repair, SIRT6 is also known to maintain telomeric chromatin 
structure by deacetylating H3K9
1
. SIRT6 depletion causes telomere dysfunction with 
end-to-end chromosomal fusions, which further leads to the cellular senescence. At 
telomeric chromatin, SIRT6 stabilizes Werner syndrome ATP-dependent helicase 
(WRN) by deacetylating H3K9 and prevents replication-associated telomere defects. 
Glucose and lipid homeostasis. SIRT6-deficient mice have increased glucose uptake 
and decreased insulin secretion
14,17
, suggesting a crucial role of SIRT6 in glucose 
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homeostasis. It is found that SIRT6 suppresses glycolysis by repressing HIF-1α 
controlled transcription via H3K9 deacetylation
17
. SIRT6 also inhibits 
gluconeogenesis by different mechanisms. One study shows that SIRT6 interacts with 
Forkhead box protein O1 (FoxO1), a key transcription factor that activates 
gluconeogenesis. This interaction causes FoxO1 deacetylation and export to the 
cytoplasm to be inactive
38
. Another study finds that SIRT6 activates the 
acetyltransferase GCN5, likely by deacetylating it on K549, which further induces 
acetylation on its substrate peroxisome proliferator-activated receptor γ coactivator 1-
α (PGC-1α). PGC-1α is a transcriptional co-activator that regulates the genes involved 
in gluconeogenesis, and lysine acetylation is known to suppress PGC-1α activity24. In 
addition to regulating glucose metabolism, SIRT6 also plays important roles in lipid 
homeostasis. SIRT6 overexpression in mice results in reduced cholesterol and 
triglyceride levels. Mechanistically, SIRT6 represses lipogenic transcription factors 
Sterol regulatory element binding proteins 1 and 2 (SREBP1 and SREBP2) by both 
suppressing SREBP1/2 transcriptions and inhibiting their cleavage
39
. 
Defatty-acylation regulated biological functions. Compared with the biological 
functions attributed by SIRT6 deacetylase activity, the cellular functions attributed by 
SIRT6‟s defatty-acylation have just started to be uncovered. No other defatty-
acylation substrate or function of SIRT6 was known before my thesis work. One of the 
major focuses of my thesis work was to uncover new functions and new substrates for 
the defatty-acylation activity of SIRT6. 
 
Introduction of Ras proteins 
The Ras superfamily of small guanosine triphosphatases (GTPases) consists of over 
150 members in humans
40
. There are five major branches of the Ras superfamily on 
the basis of their sequence and functional similarities: Ras, Rho, Rab, Ran, and Arf. 
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These proteins serve as essential players for numerous biological processes, including 
cell growth, membrane trafficking, nuclear export/import, and cytoskeletal 
dynamics
40,41
. Small GTPases act as binary switches. They are active in the guanosine 
triphosphate (GTP)-bound state and inactive in the guanosine diphosphate (GDP)-
bound state (Figure 1.6). Guanine nucleotide exchange factors (GEFs) promote the 
exchange of GDP with GTP, thereby serving as the activators of small GTPases
42
. On 
the other hand, small GTPases have very low intrinsic GTP hydrolysis activity, but it 
can be significantly accelerated by GTPase-activating proteins (GAPs)
42
. In the GTP-
bound state, small GTPases can interact with and activate different effector proteins 
(Figure 1.6), which contribute to different functional outputs. In addition, Ras 
superfamily of small GTPases are regulated by diverse post-translational 
modifications (PTMs), such as cysteine farnesylation, cysteine palmitoylation, and 
serine phosphorylation. These PTMs play important roles in both subcellular 
localizations and signaling transduction
41
. As the founding members of Ras 
superfamily of small GTPases, Ras proteins (HRas, NRas, KRas4a, and KRas4b) have 
been the subject of intense research because of their high mutation rates and relevance 
in human cancer
43
. Activated Ras proteins interact with distinct downstream effector 
proteins, such as Raf, phosphatidylinositol 3-kinase (PI3K), and Ral guanine 
nucleotide dissociation stimulator (RalGDS)
44
. These effector proteins regulate diverse 
cellular functions such as cell proliferation, survival, and differentiation
44
. 
 
 11 
 
 
Figure 1.6. Ras superfamily of small GTPases act as binary molecular switches. 
 
RAS mutations in human cancer 
In humans, there are three RAS genes (HRAS, NRAS, and KRAS) encoding four Ras 
proteins: HRas, NRas, KRas4a, and KRas4b (KRas4a and KRas4b are two alternative 
splice variants from KRAS gene). They constitute the most frequently mutated 
oncogenes in human cancer
43
. RAS constitutively active mutations are found in 60-90% 
of pancreatic cancer, 36% of colorectal cancer, and 19% of lung cancer
45,46
. Overall, 
approximately 30% of all tumor samples have RAS mutations (COSMIC, the 
Catalogue Of Somatic Mutations In Cancer). It is well established that mutant Ras 
proteins are cancer drivers. Additional generic mutations (such as p53 and APC) are 
often found to cooperate with mutant Ras to fully transform cells
47,48
. Once the tumor 
is established, continuous expression of mutant Ras proteins is also important for 
maintaining the tumor
49
. 
RAS genes have different mutation frequencies and distributions
45
. Among all RAS-
driven cancers, KRAS is the most frequently mutated RAS (86%), followed by NRAS 
(11%) and HRAS (3%) (COSMIC database). Pancreatic, colon, and rectal cancers 
have been found to have high KRAS mutation rate. Specifically, pancreatic ductal 
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adenocarcinoma (PDAC), which accounts for ~90% of all pancreatic cancers, have 
almost 100% KRAS mutations. Lung adenocarcinoma (LAC), which accounts for one 
third of all lung cancers, also possesses almost 100% KRAS mutations. Conversely, 
NRAS is the most frequently mutated RAS in cutaneous melanomas (94%) and acute 
myelogenous leukaemias (AML, 59%). Although HRAS is the least frequently 
mutated RAS, it has been shown that in bladder and head and neck squamous cell 
carcinomas (HNSCC), HRAS mutations are predominant (57% in bladder cancer and 
86% in HNSCC). 
RAS mutation usually occurs on a single amino acid. 98% of these mutations are 
found on one of three residues: Gly12, Gly13, and Gln61. These mutations block 
GAP-mediated (Gly12 and Gly13 mutations) or Ras intrinsic (Gln61 mutation) GTP 
hydrolysis, resulting in GTP-locked state of Ras proteins
50
. Gly12 mutation is mainly 
found on KRAS and HRAS, while Gln61 mutation is predominant on NRAS. For 
Gly12 mutation, the substituted residues differ in different cancers. For example, 
Gly12Asp (G12D) is the predominant mutant in PDAC, Gly12-Cys (G12C) is the 
predominant mutation in non-small cell lung cancer (NSCLC)
43
. 
 
Structural and biochemical features of Ras proteins 
Ras proteins have a highly conserved catalytic domain (residues 1-166) and C-
terminal hypervariable region (HVR, residues 167-189 on HRas, NRas and KRas4a, 
residues 167-188 on KRas4b). The catalytic domains of four Ras proteins share high 
sequence identity (89%), while the C-terminal HVR have low sequence identity (8%) 
(Figure 1.7). The C-termini of all Ras proteins end with a CAAX motif (C, cysteine; 
A, aliphatic amino acid; X, any amino acid). After synthesis on ribosomes, Ras 
proteins undergo a three-step processing on the CAAX motif to form mature Ras 
proteins. The cysteine residue on the CAAX motif is first modified by a C15 farnesyl 
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isoprenoid lipid (farnesylation), which is catalyzed by cytosolic farnesyltransferase 
(FTase).Then RAS-converting enzyme 1 (RCE1) catalyzes the proteolytic removal of 
the AAX tripeptide. Finally, isoprenylcysteine methyltransferase (ICMT) catalyzes 
carboxylmethylation of the newly formed C-terminal farnesylated cysteine
41
. Cysteine 
farnesylation of Ras proteins is important for membrane targeting
41
. However, 
biochemical studies suggest that farnesylation itself cannot provide enough binding 
affinities to fully target membranes
51,52
. A second membrane targeting signal is 
needed. HRas, NRas, and KRas4a utilize cysteine palmitoylation in the HVR as the 
second membrane targeting signal
53,54
, while KRas4b is thought to use a poly-basic 
lysine cluster in the HVR as the second membrane targeting signal
55
. 
 
 
Figure 1.7. Multiple sequence alignment of KRas4a (P01116), KRas4b (P01116-2), 
HRas (P01112), and NRas (P01111). Alignment was made using Clustal Omega. 
 
The first Ras structure (HRas) was reported in 1988
56
, which showed HRas catalytic 
domain in complex with GDP. Later, several papers reported HRas catalytic domains 
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in complex with a GTP analog GppNHp (5'-Guanylyl imidodiphosphate) (Figure 1.8), 
thus providing more structural information of Ras proteins
57-59
. Currently, there are 
many reported Ras protein structures, including different Ras mutants and Ras in 
complex with different effector proteins
59-62
. However, there is only one reported 
crystal structure of NRas (PDB: 3CON) and no reported KRas4a structure. Of note, 
most crystal structures of Ras proteins are for catalytic domains only, because the C-
terminal HVR is too flexible to show electron density. Recently, the first crystal 
structure of full-length KRas4b protein was reported (PDB: 5TAR)
63
. The full-length 
KRas4b was co-crystalized with phosphodiesterase-δ (PDEδ), which has been 
reported to bind to farnesyl group on Ras proteins and stabilize them
64
.  
The crystal structures of HRas reveal three functional regions that serve as binding 
sites for GTP/GDP, Mg
2+
, and effector proteins: P-loop (residues 10-17), switch I 
(residues 30-38), and switch II (residues 59-76) (Figure 1.8). These three regions have 
100% sequence identity across the four Ras proteins. Switch I and II are also the 
regions that change conformation during GDP-GTP cycling, therefore contributing to 
the effector binding. The Mg
2+
 is coordinated with oxygen atoms of the β- and γ-
phosphates and also interacts with Thr35 (from switch I) and Ser17 (from P-loop) 
(Figure 1.9). 
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Figure 1.8. Structure of HRas in complex with GTP analog GppNHp (PDB: 5P21). 
Green, P-loop (residues 10-17); orange, switch I (residues 30-38); blue, switch II 
(residues 59-76). The images were made using PyMOL. 
 
Biochemical and structure studies have shown that mutation of Ser17 to Asn (S17N) 
abolishes Mg
2+
 binding capacity of Ras protein (and thus nucleotide binding capacity) 
and therefore serves as a dominant negative control to study Ras signaling and 
functions
65
. Two of the three most frequently oncogenic mutated residues, Gly12 and 
Gly13, are located in the P-loop, while another frequently mutated residue Gln61 is 
located in the switch II region (Figure 1.9). The catalytic arginine finger of GAP is 
placed adjacent to Gly12/13 to stabilize the α- and β-phosphates of GTP to promote 
GTP hydrolysis
66,67
 (Figure 1.10). Mutation of Gly12 or Gly13 to any residue other 
than proline would sterically block the access of GAP arginine finger to GTP and 
therefore lock Ras proteins in the GTP-bound state. Gln61 is the catalytic amino acid 
that positions the water molecule for attacking γ-phosphate (Figure 1.11), it also helps 
to stabilize the transition state of GTP hydrolysis reaction
68
. Mutation of Q61 would 
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block intrinsic and GAP-mediated GTP hydrolysis
67
. 
 
Figure 1.9. HRas crystal structure (PDB: 5P21) showing the positions of Ser17, 
Thr35, Gly12, Gly13, and Gln61. The images were made using PyMOL. 
 
 
Figure 1.10. HRas and GAP complex showing the arginine finger (Arg789) on GAP 
(PDB: 1WQ1). The images were made using PyMOL. 
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Figure 1.11. Proposed mechanism of GTP hydrolysis of HRas. The images were made 
using PyMOL (PDB: 5P21). 
 
Signaling of Ras proteins 
Ras proteins are known to regulate diverse signaling pathways by interacting with 
different effector proteins, including Raf, PI3K, and RalGDS (Figure 1.12). All 
reported Ras effector proteins share a conserved Ras binding domain (RBD). 
Biochemical studies show that GTP-binding induces a conformational change on 
switch I and allows Ras-GTP to strongly interact with RBD with high affinity (Kd 
value is in the range of 0.01-3 μM)69. 
 
 
Figure 1.12. Overview of Ras effector pathways. 
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Ras-Raf-MEK-ERK pathway. The first well-established Ras signaling pathway is 
Ras-Raf-MEK-ERK pathway. In mammals, Raf family contains three proteins: A-Raf, 
B-Raf and C-Raf (also known as Raf1), all of which have been reported to bind GTP-
loaded Ras proteins
70,71
. Early studies showed that C-Raf contains a RBD (residues 
55-131) that binds to GTP-bound HRas
70,71
. The binding between Ras and Raf recruits 
Raf to the membrane and also promotes Raf dimerization, which is the active form of 
B-Raf and C-Raf. Activated Raf further phosphorylates and activates its substrate 
MEK1/2, and activated MEK1/2 phosphorylates and activates ERK1/2. Active 
ERK1/2 is the kinase that phosphorylates a number of transcription factors, which play 
important roles in diverse cellular processes, such as cell cycle progression, 
differentiation, protein translation, and evasion from cell death
72
. One well studied 
ERK substrate is transcription factor E26 oncogene homology 1-like gene 1 (ELK-1), 
ERK phosphorylates and activates ELK-1, leading to increased cell proliferation
73
. 
Ras-PI3K-Akt pathway. After the discovery of the Ras-Raf-MEK-ERK pathway, 
more effector pathways of Ras proteins were discovered. Phosphatidylinositol 3-
kinase (PI3K) is a heterodimer that comprises a p110 catalytic subunit and a p85 
regulatory subunit
74
.  The p110 catalytic subunit is highly conserved among different 
classes of PI3K proteins and contains a RBD, which binds GTP-bound Ras. Several 
biochemical studies show that PI3K can directly bind to Ras in a GTP-dependent 
manner
75,76
.  The binding between PI3K and Ras is weaker than that between Raf and 
Ras. The Kd value for PI3Kγ-HRas-GppNHp binding is 3.2 ± 0.5 μM
61
 (The Kd value 
for RafRBD-HRas-GppNHp binding is 0.018 μM77). The binding of GTP-bound Ras 
to PI3K leads to the recruitment of PI3K to the plasma membrane, where it converts 
phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-
bisphosphate (PIP3). The newly formed PIP3 recruits both 3-phosphoinositide-
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dependent kinase 1 (PDK1) and Akt to the plasma membrane, where PDK1 
phosphorylates and activates Akt. Activated Akt can further activate mammalian 
target of rapamycin (mTOR) by phosphorylating its substrate tuberous sclerosis 
proteins TSC1/2, which is the GAP of another GTPase Rheb. The activated mTOR 
then increases protein translation and thus promotes cell survival and proliferation. 
Ras-RalGDS-Ral pathway. Ral guanine nucleotide dissociation stimulator (RalGDS) 
is another well studied Ras effector protein that mediates Ras-driven tumor 
formation
78-80
. RBD is located at the C-terminus of RalGDS which serves as the 
binding site for Ras proteins. It is thought that RalGDS RBD and Raf RBD interact 
with the similar regions on Ras proteins, suggesting that they may compete for binding 
to Ras proteins. RalGDS is the GEF of another two small GTPases, RalA and RalB. 
After RalA and RalB are activated by RalGDS, they can further interact with and 
activate their effectors, such as Sec5
81,82
, RalBP1
83
 and ZONAB
84
. These effector 
proteins regulate a number of biological functions, such as endocytosis, exocytosis, 
and metastasis
81,84,85
. 
Other effector proteins. Other Ras effector proteins also play important roles in Ras-
mediated biological functions (Figure 1.12). Some effector proteins are GEFs for 
other Ras family proteins, such as T cell lymphoma invasion and metastasis 1 
(Tiam1), a GEF for Rac GTPases
86
, and Ras and Rab interactor (RIN), a GEF for Rab 
GTPase
87
. Phospholipase C-ε (PLCε) is another reported Ras effector protein88, it 
converts PIP2 to inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 interacts 
with its receptor on the endoplasmic reticulum (ER), which releases calcium to the 
cytosol
89
. DAG recruits and activates protein kinase C (PKC), which plays important 
roles in several signaling cascades
90
. 
 
Summary of my thesis research 
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SIRT6 was initially identified as a NAD
+
-dependent lysine deacetylase. This activity 
has been widely studied in the past decade. In contrast, SIRT6 lysine defatty-acylase is 
a newly discovered enzymatic activity and its physiological relevance is still under 
appreciated. Investigating the function of SIRT6‟s lysine defatty-acylation activity and 
dissecting the functional contributions of SIRT6 deacetylase and defatty-acylase 
activities is the focus of my thesis work, which will be discussed in Chapter 2 and 3. 
My work on SIRT6 also led me to the Ras family of proteins. Among four Ras 
proteins, KRas has been well established as a tumor driver and its signaling and 
biological functions are also widely studied. However, most studies of KRas focus on 
one of its isoforms, KRas4b, and the biological significance of the other isoform 
KRas4a is still poorly understood. I have investigated and compared the signaling and 
biological functions of KRas4a and KRas4b by studying the state-dependent KRas4a 
and KRas4b interactome, which will be discussed in Chapter 4. 
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CHAPTER 2 
IDENTIFYING THE FUNCTIONAL CONTRIBUTION OF THE 
DEFATTY-ACYLASE ACTIVITY OF SIRT6
a
 
 
Abstract 
Mammalian sirtuin 6 (SIRT6) exhibits many pivotal functions and multiple enzymatic 
activities, but the contribution of each activity to the various functions is unclear. We 
identified a SIRT6 G60A mutant that possesses efficient defatty-acylase activity, but 
has significantly decreased deacetylase activity in vitro and no detectable deacetylase 
activity in cells. The G60A mutant has decreased ability to bind NAD
+
, but the 
presence of fatty-acyl lysine peptides restores NAD
+
 binding, explaining the retention 
of the defatty-acylase activity. Using this mutant, we found that SIRT6‟s defatty-
acylase activity regulates the secretion of numerous proteins. Interestingly, many 
ribosomal proteins were secreted via exosomes from Sirt6 KO mouse embryonic 
fibroblasts, and these exosomes increased NIH 3T3 cell proliferation compared with 
control exosomes. Our data supports that distinct activities of SIRT6 regulate different 
pathways, and that the G60A mutant is a useful tool to study the contribution of the 
defatty-acylase activity to SIRT6‟s various functions. 
 
 
 
 
 
 
 
a
 This is a revised version of our published paper: Zhang, X. et al. Identifying the functional 
contribution of the defatty-acylase activity of SIRT6. Nat. Chem. Biol., 12 (2016) 614-620. 
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Introduction 
Mammalian sirtuin 6 (SIRT6) belongs to the Sir2 (silencing information regulator 2) 
family of enzymes (or sirtuins), which were initially reported as nicotinamide adenine 
dinucleotide (NAD
+
)-dependent protein lysine deacetylases. SIRT6 has attracted a lot 
of interest because it has pivotal biological functions in regulating genome stability
1,2
, 
DNA repair
3,4
, metabolism
5,6
, and longevity
7,8
. There are three reported enzymatic 
activities of SIRT6: deacetylation
2,9
, defatty-acylation
10,11
, and mono-adenosine 
diphosphate (ADP)-ribosylation
4,12
. SIRT6 has poor deacetylase activity in vitro, but 
the deacetylase activity can be significantly enhanced by nucleosomes or fatty acids in 
vitro
10,13
. SIRT6 is also reported to exhibit ADP-ribosyltransferase (ART) activity, but 
this activity is very weak in vitro
14
 and the physiological relevance of this activity has 
not been independently validated by other laboratories. We and others have recently 
identified lysine defatty-acylation as an efficient enzymatic activity of SIRT6
10,11
. 
Sirt6 knockout (KO) mice exhibit many phenotypes. They develop lymphopenia, loss 
of subcutaneous fat, and suffer from severe metabolic defects
1,5
. Now that we know 
SIRT6 has multiple enzymatic activities, an important question emerges: What is the 
contribution of each activity to the various functions of SIRT6? 
Here we report that a point mutant of SIRT6, Gly60Ala (G60A), maintains efficient 
defatty-acylase activity but shows no detectable deacetylase activity in cells and no 
ART activity in vitro. Utilizing this G60A mutant, we were able to identify the 
contribution of defatty-acylation to several functions of SIRT6. We found that the 
defatty-acylase activity plays little role in regulating gene transcription while it is 
important for regulating the secretion of many proteins. In particular, in Sirt6 KO 
mouse embryonic fibroblasts (MEFs), many ribosomal proteins were secreted via 
exosomes and their secretion was blocked by SIRT6 WT or the G60A mutant re-
expression. We believe this SIRT6 G60A mutant will be a valuable tool for probing 
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many of the other biological functions of SIRT6. 
 
Results and discussion 
SIRT6 G60A is a lysine defatty-acylase in vitro 
To find a SIRT6 mutant that only has one of the three catalytic activities, we first 
tested four reported mutants used in other studies: S56Y, G60A, R65A, and H133Y
4
. 
S56, G60, R65 are either in or close to the active site of SIRT6, and H133 is the 
catalytic base necessary for deacylation and is conserved among all seven mammalian 
sirtuins. It is reported that SIRT6 S56Y and H133Y lack both deacetylase and ART 
activities, whereas G60A only shows deacetylase activity, and SIRT6 R65A only 
shows ART activity. We decided to test whether any of these SIRT6 mutants purified 
from Escherichia coli (E.coli) showed lysine defatty-acylase activities using a H3K9 
myristoyl peptide. One of the mutants, SIRT6 G60A, exhibited approximately 50% of 
SIRT6 WT defatty-acylase activity, but none of the other three mutants showed 
defatty-acylase activities (Figure 2.1a). We also tested other fatty-acyl peptides 
(H3K9 palmitoyl, TNFα myristoyl and H3K9 octanoyl), and the results showed that 
SIRT6 G60A had robust defatty-acylase activities on different peptide substrates 
(Figure 2.2a-f). 
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Figure 2.1. In vitro deacetylation and defatty-acylation activities of SIRT6 WT and 
mutants. (a) The defatty-acylase activities of SIRT6 WT and mutants analyzed using a 
H3K9 myristoyl peptide. SIRT6 (1 µM) was incubated with 25 µM Myr-H3K9 and 1 
mM NAD
+
 at 37˚C for 20 min. (b) The deacetylase activities of SIRT6 WT and 
mutants analyzed using a H3K9 acetyl peptide. SIRT6 (4 µM) was incubated with 25 
µM Ac-H3K9 and 1 mM NAD
+
 at 37˚C for 4 hours (left). Alternatively, 2 µM SIRT6 
was incubated with 25 µM Ac-H3K9, 1 mM NAD
+, and 300 µM palmitic acid at 37˚C 
for 2 hours (right). (c) Deacetylation of H3K9 and K56 on chromatin histones by 
SIRT6 WT and G60A. SIRT6 WT or mutants (1 µM) was incubated with chromatin 
fractions isolated from HEK293T cells in the presence of 1 mM NAD
+
 at 37˚C for 120 
min. (d) Deacetylation of H3K9 and H3K56 on chromatin histones with different 
concentrations of SIRT6 WT and G60A. SIRT6 at different concentrations was 
incubated with chromatin fractions isolated from HEK293T cells in the presence of 1 
mM NAD
+
 at 37˚C for 120 min. 
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Figure 2.2. In vitro defatty-acylase activities of SIRT6 WT and mutants on different 
fatty-acyl peptide substrates. (a) Defatty-acylase activities of SIRT6 WT and mutants 
on H3K9 myristoyl peptide. (b) Defatty-acylase activities of SIRT6 WT and mutants 
on H3K9 palmitoyl peptide. (c) Defatty-acylase activities of SIRT6 WT and mutants 
on TNFα myristoyl peptide. (d) Defatty-acylase activities of SIRT6 WT and mutants 
on H3K9 octanoyl peptide. (e, f) Conversion rates of SIRT6 WT and mutants on 
different fatty-acyl peptides. Error bars indicate s.d. from the mean for three replicates. 
The equation used for calculating the conversion rate is: 
                
                                                
                                            
 
 
We then tested the deacetylase activities of SIRT6 WT and mutants using a H3K9 
acetyl peptide as substrate. We did not observe any deacetylase activity for any of the 
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mutants (Figure 2.1b). To ensure that we did not miss any weak deacetylase activity, 
we added 300 µM palmitic acid in the reactions because it was recently reported that 
fatty acid can increase SIRT6 deacetylase activity in vitro
10
. With 300 µM palmitic 
acid, 2 µM SIRT6 WT was able to hydrolyze 22% of 25 µM H3K9 acetyl peptide in 2 
hours (Figure 2.1b). However, SIRT6 G60A only converted approximately 1.8% of 
H3K9 acetyl peptide to H3K9 peptide, which was close to our HPLC detection limit 
(Figure 2.1b). To further confirm this result, we also purified SIRT6 WT and mutants 
from HEK293T cells and tested their activities. SIRT6 G60A from HEK293T cells 
showed comparable defatty-acylase activity with WT (25.6% versus 34.8% substrate 
conversion) but undetectable deacetylase activity (Figure 2.3a-d). 
 
 
Figure 2.3. In vitro deacylase activity assay using SIRT6 purified from HEK 293T 
cells. (a) Defatty-acylase activities of SIRT6 WT, S56Y, G60A, R65A, and H133Y on 
a H3K9 myristoyl peptide. SIRT6 (0.2 µM) was incubated with 5 µM Myr-H3K9 and 
1 mM NAD
+
 at 37˚C for 60 min. (b) Deacetylase activities of SIRT6 WT, S56Y, 
G60A, R65A, and H133Y on a H3K9 acetyl peptide. SIRT6 (0.4 µM) was incubated 
with 5 µM Ac-H3K9 and 1 mM NAD
+
 in the presence of 300 µM palmitic acid at 
37˚C for 2.5 hours. (c) SDS-PAGE analysis of SIRT6 WT and mutants purified from 
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HEK293T cells. (d) Western blot analysis of SIRT6 WT and mutants purified from 
HEK293T cells. 
 
To make quantitative comparisons, we performed kinetic studies for SIRT6 WT and 
G60A on H3K9 myristoyl and H3K9 acetyl peptides. The kcat/Km of the 
demyristoylation activity of SIRT6 WT was 9,100 M
-1
s
-1
, which was 3.4-fold higher 
than that of SIRT6 G60A (2,700 M
-1
s
-1
 Table 2.1 and Figure 2.4a). The decreased 
catalytic efficiency was due to decreased kcat (1.9-fold) and increased Km (1.8-fold). 
The kcat/Km of the deacetylation activity of SIRT6 WT was 3.4 M
-1
s
-1
. This catalytic 
efficiency is approximately 19-fold better than that of SIRT6 G60A (0.18 M
-1
s
-1
, 
Table 2.1 and Figure 2.4b). When we used 300 µM palmitic acid to activate SIRT6 
deacetylase activity, the kcat/Km for deacetylation of SIRT6 WT was 101 M
-1
s
-1
, ~30 
times faster than that for deacetylation in the absence of palmitic acid (Table 2.1 and 
Figure 2.4c).  However, 300 µM palmitic acid only increased the kcat/Km for 
deacetylation of SIRT6 G60A 3.6 times (0.65 M
-1
s
-1
, Table 2.1). Therefore, in the 
presence of 300 µM palmitic acid, the catalytic efficiency of SIRT6 WT deacetylation 
was approximately 155-fold better than that of SIRT6 G60A. 
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Table 2.1. The kcat, Km and kcat/Km values for SIRT6 WT and G60A demyristoylase 
and deacetylase activities. Each value is the mean of three replicates ± s.d. n.d.: The 
kcat and Km values cannot be accurately determined because V~[S] curve is linear, thus 
only kcat/Km value can be achieved.  PA: palmitic acid. 
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Figure 2.4. Steady-state kinetic study of SIRT6 WT and G60A on H3K9 myristoyl 
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and H3K9 acetyl peptides. (a) Initial velocity (vinitial) versus Myr-H3K9 concentration 
(with 1 mM NAD
+
) showing SIRT6 WT and G60A demyristoylation kinetics. (b) 
Initial velocity (vinitial) versus Ac-H3K9 concentration without fatty acid (with 1 mM 
NAD
+
) showing SIRT6 WT deacetylation kinetics. (c) Initial velocity (vinitial) versus 
Ac-H3K9 concentration with 300 µM palmitic acid (with 1 mM NAD
+
) showing 
SIRT6 WT deacetylation kinetics. PA: palmitic acid. (d) Initial velocity (vinitial) versus 
NAD
+
 concentration (with 25 µM Myr-H3K9) showing NAD
+
 kinetics of SIRT6 WT 
and G60A on H3K9 myristoyl peptide. Error bars indicate s.d. from the means for 
three replicates. (e) Equations showing how to use the Km,NAD+ value to estimate the 
Kd value. 
 
We then used physiologically relevant substrates of SIRT6, histones, to test the 
deacetylase activities of SIRT6 WT and mutants. We isolated chromatin fractions 
from HEK293T cells and incubated with SIRT6 and NAD
+
 in vitro.  SIRT6 WT 
could almost completely deacetylate histone H3K9 and H3K56, while none of the 
mutants showed deacetylase activities (Figure 2.1c). The deacetylase activity of 
SIRT6 WT showed dose-dependent effects on H3K9Ac and H3K56Ac while SIRT6 
G60A had no activity at any of the concentrations tested (Figure 2.1d). 
A previous study showed that SIRT6 R65A had ART activity
4
. To confirm that SIRT6 
G60A has no ART activity, we tested the ART activities of SIRT6 WT and mutants. 
SIRT6 WT and R65A showed weak self ADP-ribosylation activities while SIRT6 
G60A had no observable ART activity (Figure 2.5).Therefore, we identified SIRT6 
G60A as a mutant with efficient lysine defatty-acylase activity but significantly 
decreased lysine deacetylase activity on histone peptide, no detectable deacetylase 
activity on chromatin histones, and no ART activity. 
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Figure 2.5. In vitro mono-ADP-ribosyltransferase activity assay of SIRT6 WT and 
mutants. 2.5 µM SIRT6 WT or mutants was incubated with 50 µM NAD
+
 or 6-alkyne-
NAD
+
 at 30˚C for 30 min. Then click chemistry was performed by incorporating 
BODIPY-N3 for fluorescence visualization. 
 
Fatty-acyl peptides promote SIRT6 G60A binding to NAD
+
 
We next investigated how SIRT6 G60A could maintain defatty-acylase activity but 
had little deacetylase activity. G60 is on the NAD
+
 binding loop (Ala58-Glu75) 
(Figure 2.6a), suggesting that the G60A mutation may change NAD
+
 binding affinity. 
We measured the binding affinities of SIRT6 WT and mutants to NAD
+
. SIRT6 
contains two tryptophan residues (Trp71 and Trp188) that are close to the active site. 
It has been reported that SIRT6 tryptophan fluorescence signal decreases after NAD
+
 
binding
15
. Thus, we determined the dissociation constants (Kd) of SIRT6 WT and 
mutants for NAD
+ 
by measuring the tryptophan fluorescence.  In the absence of any 
acyl lysine peptide, the Kd values of SIRT6 WT and H133Y for NAD
+
 were 16.7 ± 1.5 
µM and 3.2 ± 0.7 µM, respectively (Figure 2.7), which were similar to the reported 
values
15
. However, the Kd value of SIRT6 G60A for NAD
+
 was 564 ± 84 µM (Figure 
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2.7), suggesting that the G60A mutation significantly decreased NAD
+
 binding. We 
employed another method to confirm that the G60A mutation decreased NAD
+
 
binding. In this assay, the SIRT6 and NAD
+
 solution was filtered with a 10 kDa cutoff 
membrane. Thus NAD
+
 that bound to SIRT6 was retained on the membrane and the 
unbound NAD
+
 would pass through the membrane. When 10 µM SIRT6 WT or the 
H133Y mutant was incubated with 10 µM NAD
+
, 34 ± 3% and 59 ± 3% of NAD
+
 
were bound to SIRT6, respectively (Figure 2.8). However, almost no NAD
+
 was 
bound to SIRT6 G60A (2.0 ± 0.7%, Figure 2.8), again suggesting that SIRT6 G60A 
bound NAD
+
 very weakly. 
 
 
Figure 2.6. Mechanistic study on how SIRT6 G60A maintains defatty-acylation but 
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loses deacetylation. (a) The location of G60A in the NAD
+
 binding loop (Ala58-
Glu75) on the crystal structure of SIRT6 (PDB: 3ZG6). (b) Tryptophan fluorescence 
emission spectra of 3 µM of SIRT6 WT or G60A with or without saturating amount of 
Ac-H3K9 (1 mM) or Myr-H3K9 (0.1 mM). Each spectrum was repeated three times. 
(c) Thermal shift assay showing that SIRT6 G60A was stabilized by Myr-H3K9 (0.1 
mM) but not by Ac-H3K9 (1 mM). 
 
 
Figure 2.7. The dissociation constants of SIRT6 WT and G60A for NAD
+
 with or 
without 1 mM Ac-H3K9, and saturation binding curves of SIRT6 WT, S56Y, G60A, 
R65A and H133Y binding to NAD
+
. 0-500 µM of NAD
+
 were added to 5 µM of 
SIRT6 WT and 0-5 mM of NAD
+
 were added to 5 µM of SIRT6 G60A. Saturation 
binding curves were fitted to a one-site binding equation. Each value is the mean of 
three replicates ± s.d. The Kd values were calculated after fitting the curves to a one-
site binding equation. Error bars indicate s.d. from the means for three replicates. 
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Figure 2.8. Measurement of SIRT6 WT, G60A and H133Y binding to NAD
+
 using 
concentrators with 10 kDa cutoff membranes. (a) The HPLC trace showing SIRT6 
binding to NAD
+
. Purple HPLC trace is NAD
+
 without SIRT6, green HPLC trace is 
NAD
+ 
with SIRT6. The percentages are the differences of area between the two peaks 
and represent how much NAD
+
 is bound to SIRT6. For SIRT6 G60A, the purple and 
green traces are largely overlapped. (b) The histogram showing NAD
+ 
binding 
percentage for each protein. Error bars indicate s.d. from the means for three 
replicates. 
 
To probe how SIRT6 G60A could maintain defatty-acylation but had little deacetylase 
activity, we further measured the binding affinities of SIRT6 WT and G60A for NAD
+
 
in the presence of acetyl or myristoyl peptides. In the presence of 1 mM H3K9 acetyl 
peptide, the Kd values of SIRT6 WT or G60A for NAD
+
 were 30.3 ± 3.2 µM and 634 
± 91 µM, respectively (Figure 2.7), similar to that without the acetyl peptide. The 
weak affinity of G60A mutant for NAD
+
 in the presence of acetyl peptide explained 
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the significantly decreased deacetylase activity of G60A. We then aimed to measure 
the binding affinities of SIRT6 WT and G60A for NAD
+
 in the presence of the H3K9 
myristoyl peptide. However, due to the efficient defatty-acylase activities of SIRT6 
WT and G60A, NAD
+
 would be consumed quickly in the presence of the myristoyl 
peptide. Thus we measured NAD
+
 kinetics and used the Km,NAD+ value to estimate the 
Kd value. In steady-state, the Kd value is smaller than the Km value and we can use the 
Km value as an upper estimate for the Kd value (Figure 2.4e). The Km,NAD+ value of 
SIRT6 WT was 33 ± 2 µM (Figure 2.4d), similar to the Kd value of SIRT6 WT for 
NAD
+
 without the myristoyl peptide. Strikingly, the Km,NAD+ value of SIRT6 G60A 
was 47 ± 9 µM (Figure 2.4d), which was much lower than the Kd value of SIRT6 
G60A for NAD
+
 without the myristoyl peptide. The significantly decreased Km,NAD+ 
value suggested that in the presence of fatty-acyl substrates, SIRT6 G60A could bind 
NAD
+
 tightly and perform defatty-acylation. 
Tryptophan fluorescence emission spectra of SIRT6 WT and G60A without any 
substrate suggested that the G60A mutation changed the conformation of the active 
site (Figure 2.6b). Thermal shift assays revealed that SIRT6 G60A had decreased 
thermal stability (Figure 2.6c). These data suggested that the G60A mutation induces 
a conformational change that affects SIRT6 stability. The structural changes may 
affect the NAD
+
 binding pocket, leading to loss of NAD
+
 binding ability. Furthermore, 
the altered stability and fluorescence of G60A were not affected by 1 mM H3K9 
acetyl peptide (Figure 2.6b, c). However, when we added 0.1 mM H3K9 myristoyl 
peptide, the stability and fluorescence of G60A became similar to those of SIRT6 WT 
(Figure 2.6b, c), suggesting that fatty-acyl substrates could restore the conformation 
of SIRT6 G60A similar to that of WT and allow SIRT6 G60A to regain high NAD
+
 
binding ability. 
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SIRT6 G60A catalyzes only defatty-acylation in cells 
We next validated the activity of SIRT6 G60A in cells by detecting the acylation 
levels of known targets of SIRT6. We chose acetyl-H3K9 and acetyl-H3K56 as 
cellular readouts for deacetylation since it has been reported that overexpression of 
flag-tagged SIRT6 is able to decrease acetyl-H3K9 and acetyl-H3K56 levels in 293T 
cells
16
. We used CRISPR to generate SIRT6 KO in 293T cells (Figure 2.9a) and then 
overexpressed flag-tagged SIRT6 WT and mutants. Only expression of SIRT6 WT 
was able to decrease H3K9 and H3K56 acetylation levels (Figure 2.9b). The cellular 
results were therefore consistent with the in vitro activity assay results and supported 
that SIRT6 G60A has no detectable deacetylase activity in cells. 
For defatty-acylation, we used TNFα as the cellular readout. We stably expressed 
SIRT6 WT and the different mutants in Sirt6 KO mouse embryonic fibroblasts 
(MEFs) and then transiently transfected TNFα into these cells. The fatty-acylation 
levels on TNFα were then detected using a fatty acid probe, Alk14, as previously 
reported
11. Both SIRT6 WT and G60A expression decreased TNFα lysine fatty-
acylation (Figure 2.9c), while none of the other mutants did. This result demonstrated 
that SIRT6 G60A exhibits defatty-acylase activity in cells. 
 
SIRT6 promotes TNF secretion by defatty-acylation 
We previously reported that SIRT6 defatty-acylates TNF and promotes its secretion. 
With the G60A mutant available, we further tested whether the defatty-acylase activity 
of SIRT6 is sufficient for the regulation of TNF secretion. We stably expressed 
SIRT6 WT, G60A and H133Y in Sirt6 KO MEFs and examined TNFα secretion in 
these cells. SIRT6 WT and G60A expression in Sirt6 KO MEFs promoted TNFα 
secretion, while SIRT6 H133Y expression in Sirt6 KO MEFs had no effect on TNFα 
secretion (Figure 2.9d). These results supported that the regulation of TNF secretion 
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is achieved through the defatty-acylase activity of SIRT6, which is consistent with our 
previous report. 
 
SIRT6 suppresses gene transcription by deacetylation 
SIRT6 can suppress the transcription activities of various transcription factors, such as 
NF-κB, HIF-1α and c-Myc. To investigate whether the defatty-acylase activity of 
SIRT6 contributes to the transcriptional regulation, we chose several genes (IAP2, 
GLS, RPL3 and MnSOD) that are known to be regulated by SIRT6 and detected their 
mRNA levels after overexpression of SIRT6 WT or G60A in Sirt6 KO MEFs. For all 
the genes tested, SIRT6 WT overexpression could restore the transcriptional 
suppression while SIRT6 G60A could not (Figure 2.9e). This result suggests that the 
defatty-acylase activity does not contribute to SIRT6‟s role in transcriptional 
regulation of these genes. 
It is reported that SIRT6 can suppress glycolysis by inhibiting HIF-1α transcriptional 
activity. Because of the glycolysis suppression function, Sirt6 KO MEFs are more 
sensitive to glucose starvation than WT MEFs. Using the sensitivity to glucose 
starvation, we tested different SIRT6 mutants to find out whether the defatty-acylase 
activity contributes to this phenotype. SIRT6 WT expression in Sirt6 KO MEFs 
rescued glucose starvation-caused cell death, while neither SIRT6 G60A nor H133Y 
did (Figure 2.9f). Given that SIRT6 G60A has defatty-acylase activity but lacks ART 
activity and has no detectable deacetylase activity in cells, this result suggests that the 
defatty-acylase activity is not important for suppressing glucose starvation induced 
cell death. However, since SIRT6 G60A has weaker lysine defatty-acylase activity and 
lower stability than SIRT6 WT, we could not completely rule out that the failure of 
SIRT6 G60A to restore this phenotype is due to decreased protein stability or 
decreased defatty-acylase activity. 
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Figure 2.9. In-cell validation of the deacetylase and defatty-acylase activities of 
SIRT6 WT and mutants. (a) Western blot of endogenous SIRT6 in HEK293T control 
KO and Sirt6KO cells. (b) Left: Western blot analysis of H3K9 and H3K56 
acetylation levels in HEK293T Sirt6 KO cells after transient transfection of SIRT6 
WT or mutants.  Middle and right: quantification of the Western blot results. Values 
with error bars indicate mean ± s.d. of three replicates. **p < 0.01, for comparing 
pCMV4a with all the other groups. “ns”, not significant. (c) Left: In-gel fluorescence 
 45 
showing TNFα lysine fatty-acylation levels in Sirt6 KO MEFs expressing SIRT6 WT 
or mutants. Right: quantification of the fluorescence gel. Values with error bars 
indicate mean ± s.d. of three replicates. **p < 0.01 for comparing pCDH with all the 
other groups. (d) Secretion of TNFα in MEFs with or without SIRT6 WT and mutants. 
Values with error bars indicate mean ± s.d. of three replicates. **p < 0.01 and ***p < 
0.005  for comparing SIRT6 WT with all the other groups. (e) Real-time PCR 
analysis of RPL3, IAP2, GLS and MnSOD in MEFs with or without Sirt6WT and 
mutants. Values with error bars indicate mean ± s.d. of three replicates. *p < 0.05 and 
***p < 0.005 for comparing Sirt6KO with all the other groups. (f) Cell viability was 
assayed and calculated by crystal violet staining. Values with error bars indicate mean 
± s.d. of three replicates. *** indicates p < 0.005, which is for comparing Sirt6KO 
with all the other groups. ns, not significant. Right: Western blot showing SIRT6 WT, 
G60A, and H133Y levels in the cells used for the cell viability assay. 
 
SIRT6 regulates the secretion of many proteins 
Given that SIRT6 promotes TNFα secretion by defatty-acylation, we wondered 
whether its defatty-acylase activity regulates the secretion of other proteins. We first 
detected total secreted proteins in Sirt6 WT and KO MEFs. As shown in Figure 2.10a, 
the patterns of total secreted proteins in Sirt6 WT and KO MEFs were different. In 
contrast, the patterns of total cellular proteins were similar in Sirt6 WT and KO MEFs 
(Figure 2.10a). This result suggests that SIRT6 likely regulates the secretion of many 
proteins. 
By performing SILAC (stable isotope labeling with amino acids in cell culture) in 
Sirt6 WT and KO MEFs (Figure 2.10b), we identified the secreted proteins that are 
regulated by SIRT6. We identified 497 secreted proteins with minimal 2 peptides. 
Among them, 106 proteins showed high (>1.5) Heavy/Light (H/L) ratios, suggesting 
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that SIRT6 decreased the secreted amounts of these proteins, while 117 proteins 
showed low H/L ratios (<0.667), suggesting SIRT6 increased the secreted amounts of 
these proteins. 
 
 
Figure 2.10. Identification of secreted proteins regulated by SIRT6. (a) The 
Coomassie blue stained gel of total secreted (left) and intracellular (right) proteins in 
Sirt6 WT and KO MEFs. For secreted proteins, the two lanes for each cell line were 
biological replicates. (b) Schematic overview of the SILAC design. 
 
To further confirm that the secreted proteins with high or low H/L ratios were indeed 
regulated by SIRT6 and to find out which activity of SIRT6 is important for regulating 
these secreted proteins, we stably expressed SIRT6 WT, G60A, or H133Y in Sirt6 KO 
MEFs and performed another three SILAC experiments: SILAC1 was Sirt6 KO MEFs 
vs. Sirt6 KO MEFs expressing SIRT6 WT; SILAC2 was Sirt6 KO MEFs vs. Sirt6 KO 
MEFs expressing SIRT6 G60A; SILAC3 was Sirt6 KO MEFs vs. Sirt6 KO MEFs 
expressing SIRT6 H133Y (Figure 2.11a). 
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We identified 395 proteins with at least 2 peptides detected in all three SILAC 
experiments. We further filtered the data using the following criteria: H/L ratio in 
control SILAC3 was close to 1 (0.8-1.25), which served as a quality control as SIRT6 
H133Y expression should not change the secreted protein levels. After the filtering, 
225 secreted proteins were left. These proteins were further divided into the five 
groups (Figure 2.11a): (1) H/L > 1.5 in both SILAC1 and SILAC2 (50 proteins; 
SIRT6 defatty-acylase activity decreased the secreted levels of these proteins); (2) H/L 
< 0.667 in both SILAC1 and SILAC2 (12 proteins; SIRT6 defatty-acylase activity 
increased the secreted levels of these proteins); (3) H/L > 1.5 in SILAC1, H/L is ~1 
(0.8-1.25) in SILAC2 (6 proteins; SIRT6 deacetylase/ART activity decreased the 
secreted levels of these proteins); (4) H/L < 0.667 in SILAC1, H/L is ~1 (0.8-1.25) in 
SILAC2 (7 proteins; SIRT6 deacetylase/ART activity increased the secreted levels of 
these proteins); (5) H/L is ~ 1 (0.8-1.25) in both SILAC1 and SILAC2 (SIRT6 does 
not regulate the secreted levels of these proteins). Theoretically there should not be 
proteins that show high H/L ratios in SILAC1 but low H/L ratios in SILAC2 (or vice 
versa). The analysis of the SILAC data showed that no proteins fell into this category 
(Figure 2.11b). There were 75 proteins in Group 1 to 4 (Table 2.2 and Table 2.3), 
suggesting SIRT6 regulates 33% (75 out of 225) of the secreted proteins identified. 
Datasets of SILAC1 and SILAC2 proteins with altered secretion levels (H/L>1.5 and 
H/L<0.667) were also analyzed by DAVID Functional Annotation Tool (Figure 
2.11c). Based on the datasets analysis, SIRT6 defatty-acylase activity likely regulates 
pathways involved in ribosome, ECM-receptor interaction, focal adhesion, systemic 
lupus erythematosus, and cytokine-cytokine receptor interaction, while SIRT6 
deacetylase/ART activity likely regulates pathways involved in 
glycolysis/gluconeogenesis, glutathione metabolism, cysteine and methionine 
metabolism, and metabolism of xenobiotics by cytochrome P450. 
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Figure 2.11. Analysis of secreted proteins by SILAC. (a) Schematic overview of the 
SILAC design. (b) Log2-transformation of H/L ratios of proteins identified from 
SILAC1 (x-axis) and SILAC2 (y-axis) experiments are plotted. Proteins regulated by 
the defatty-acylase activity of SIRT6 (Group 1 and 2) are in the blue rectangles. 
Proteins regulated by the deacetylase/ART activity of SIRT6 (Group 3 and 4) are in 
the red rectangles. (c) KEGG pathway analysis of SILAC1 and SILAC2 proteins with 
H/L>1.5 and H/L<0.667. Data was analyzed by DAVID Functional Annotation Tool 
(https://david.ncifcrf.gov/). 
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Table 2.2. The list of secreted proteins (Group 1) that are regulated by SIRT6  
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Table 2.3. The list of secreted proteins (Group 2, 3, 4) that are regulated by SIRT6 
 
 
To further validate the SILAC proteomic results for proteins in Group 1 to 4, we chose 
a few proteins from each group (Figure 2.12a) and detected their secreted levels and 
levels in total cell lysates. For Group 1 secreted proteins (RPL17, RPS7, and VCP), 
the secreted levels were higher in Sirt6 KO cells than in Sirt6 WT cells while the 
levels in total cell lysate were similar (Figure 2.12b). Overexpression of SIRT6 WT 
or G60A mutant in Sirt6 KO cells decreased the secreted levels to that in Sirt6 WT 
cells, suggesting that the defatty-acylase activity of SIRT6 suppresses the secretion of 
these proteins. We further tested their mRNA levels and found that they were similar 
with or without SIRT6 (Figure 2.12c, d). These results are consistent with the SILAC 
data and suggest that SIRT6 defatty-acylase activity suppresses the secretion of these 
proteins but not the transcription of the corresponding mRNA. 
For Group 2 secreted proteins (COL6A1, COL5A1 and CXCL1), the secreted levels 
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were lower in Sirt6 KO cells than in Sirt6 WT cells while the levels in total cell lysate 
were similar (Figure 2.12b). Overexpression of SIRT6 WT or the G60A mutant in 
Sirt6 KO cells restored the secreted levels to that in Sirt6 WT cells, suggesting that the 
defatty-acylase activity of SIRT6 promotes the secretion of these proteins. SIRT6 KO 
or overexpression did not change their mRNA levels (Figure 2.12c, d), supporting 
that SIRT6 defatty-acylase activity promotes the secretion of these proteins but not the 
transcription of the corresponding mRNA. For the secreted proteins in Group 2, we 
originally thought that SIRT6 may directly defatty-acylate them and promote their 
secretion, similar to the regulation of TNFα secretion. We tested two of them, 
COL6A1 and COL5A1, but did not observe any fatty-acylation on these proteins 
(Figure 2.13), suggesting that SIRT6 may defatty-acylate other proteins which in turn 
control the secretion of these proteins. 
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Figure 2.12. Validation of secreted proteins that are regulated by SIRT6. (a) 
Representative secreted proteins regulated by SIRT6. (b) Intracellular (cell lysates) 
and extracellular (secreted) levels of representative proteins in different cells. (c) The 
mRNA levels of representative proteins in Sirt6 WT MEFs, Sirt6 KO MEFs, and Sirt6 
KO MEFs expressing SIRT6 WT, G60A, or H133Y. (d) Quantitative real-time PCR 
analysis of the indicated mRNAs in Sirt6 WT MEFs, Sirt6 KO MEFs, and Sirt6 KO 
MEFs expressing SIRT6 WT, G60A, or H133Y. Each value is the mean of three 
replicates ± s.d. Significance is presented as *p < 0.05 **p < 0.01, which is for 
comparing Sirt6KO with all the other groups. ns, not significant. 
 
 
Figure 2.13. In-gel fluorescence showing Alk14 labeling of endogenous COL5A1 and 
COL6A1 in Sirt6 WT and KO MEFs. Alk14 labeling of overexpressed TNFα in HEK 
293T cells was shown as a positive control. Western blots showing the 
immunoprecipitated COL5A1 and COL6A1 are shown on the right. 
 
Although we do not know the exact mechanisms how SIRT6 defatty-acylation 
regulates the secretion of Group 1 and Group 2 proteins, the sites for this function are 
likely organelle and plasma membranes. We performed sub-cellular fractionation and 
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imaging experiments and found that overexpressed SIRT6 WT, G60A and H133Y 
existed in the cytoplasm, nucleus, and membranes (Figure 2.14). Since protein 
lipidation is known to mediate membrane association, the defatty-acylation likely take 
place in organelle membranes or the plasma membrane. 
 
 
Figure 2.14. Sub-cellular localization of overexpressed SIRT6 WT, G60A and H133Y 
in Sirt6 KO MEFs. (a) Western blot showing nucleus, membrane and cytosol localized 
SIRT6 WT, G60A and H133Y. (b) Confocal imaging showing cellular localization of 
overexpressed SIRT6 WT, G60A and H133Y. Scale bars, 10 µm. 
 
For Group 3 secreted proteins (Annexin A1 and Tenascin), the secreted levels were 
higher in Sirt6 KO cells than in Sirt6 WT cells (Figure 2.12b). Different from Group 
1 and 2 proteins, the protein levels in total cell lysate were also higher in Sirt6 KO 
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cells than in Sirt6 WT cells (Figure 2.12b). Only overexpression of SIRT6 WT in 
Sirt6 KO cells decreased the secreted levels or the intracellular levels to that in Sirt6 
WT cells, suggesting that the deacetylase/ART activity of SIRT6 suppresses the 
production of Annexin A1 and Tenascin. This suppression was due to transcriptional 
regulation of Annexin A1 and Tenascin as the mRNA levels were regulated similarly 
(Figure 2.12c, d). These results support that SIRT6 deacetylase/ART activity (most 
likely the deacetylase activity) decreases the secreted levels of Group 3 proteins by 
suppressing their transcription. 
For Group 4 secreted proteins (Rangap1 and Ran), the secreted levels were lower in 
Sirt6 KO cells than in Sirt6 WT cells (Figure 2.12b). Surprisingly, the protein levels 
in total cell lysate and the corresponding mRNA levels were similar (Figure 2.12c, d). 
Only overexpression of SIRT6 WT in Sirt6 KO cells restored the secreted levels of 
Rangap1 and Ran to those in Sirt6 WT cells, suggesting that the deacetylase/ART 
activity of SIRT6 promotes the secretion of these proteins. This data is consistent with 
the SILAC result and suggested that SIRT6 promotes the secretion of these proteins 
post-transcriptionally. 
 
Ribosomal proteins are secreted via exosomes 
Among the 50 proteins that are down-regulated by the defatty-acylase activity of 
SIRT6 (Group 1), 41 are ribosomal proteins, which are not known as classical secreted 
proteins. We investigated whether these ribosomal proteins were secreted through 
extracellular vesicles. It is known that SIRT6-deficient cells are tumorigenic
5
. Cancer 
cells release microvesicles and exosomes to enhance cell-cell communication and 
deliver oncogenic contents to other cells
17-19
. We isolated microvesicles and exosomes 
from Sirt6 KO MEFs that could carry ribosomal proteins (Figure 2.15a). We used two 
ribosomal proteins (RPL17 and RPS7) as readout and found that they both existed in 
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exosomes, but not in microvesicles (Figure 2.15b). We then validated whether RPL17 
and RPS7 secretion via exosomes is regulated by the defatty-acylase activity of 
SIRT6. We isolated exosomes from Sirt6 KO MEFs and Sirt6 KO MFEs expressing 
SIRT6 WT, G60A, or H133Y. RPL17 and RPS7 can be detected in exosomes from 
Sirt6 KO MEFs and Sirt6 KO MEFs expressing SIRT6 H133Y, but not in exosomes 
from Sirt6 KO MEFs expressing SIRT6 WT or G60A mutant (Figure 2.15c). This 
data suggested that SIRT6 defatty-acylase activity inhibits ribosomal protein sorting to 
the exosomes. We also found that SIRT6 defatty-acylase activity affects many other 
proteins sorting to the exosomes (Figure 2.15d). 
 
 
Figure 2.15. SIRT6 defatty-acylase activity inhibits ribosomal protein sorting to the 
exosomes. (a) Methods to isolate miscrovesicles, exosomes and vesicle-free medium 
from Sirt6 KO MEFs. (b) Western blot analysis of RPL17 and RPS7 in different 
fractions (vesicle free medium, microvesicles, exosomes, and total cell lysates) in 
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Sirt6 KO MEFs. (c) Western blot analysis of RPL17 and RPS7 in exosomes from 
Sirt6 KO MEFs and Sirt6 KO MEFs expressing SIRT6 WT, G60A, or H133Y. HSP90 
was used as the loading control. (d) The Coomassie blue stained gel shows total 
proteins from cell lysates, vesicle free medium and exosomes in Sirt6 KO MEFs 
expressing pCDH vector control, SIRT6 WT, G60A, or H133Y. (e) NIH 3T3 cell 
proliferation after treating with the same number of exosomes from Sirt6 WT MEFs, 
Sirt6 KO MEFs and Sirt6 KO MEFs expressing SIRT6 WT, G60A or H133Y. Cell 
number was determined by crystal violet staining. Error bars indicate mean ± s.d. of 
three replicates. *p < 0.05 for comparing Sirt6WT exosomes with other exosomes. 
 
Sirt6 KO exosomes better promote cell proliferation 
We further tested whether the different exosome cargo content could affect the 
function of exosomes. We isolated the exosomes from Sirt6 WT MEFs, Sirt6 KO 
MEFs, and Sirt6 KO MEFs expressing SIRT6 WT, G60A, or H133Y, and then treated 
NIH 3T3 cells with the same number of exosomes. Compared with the cells without 
exosomes treatment, all exosomes-treated cells showed increased proliferation (Figure 
2.15e). Particularly, NIH 3T3 cells treated with exosomes from Sirt6 KO MEFs and 
Sirt6 KO MEFs expressing SIRT6 H133Y had significantly higher cell proliferation 
rate than those treated with exosomes from Sirt6 WT MEFs and Sirt6 KO MEFs 
expressing SIRT6 WT or G60A (Figure 2.15e). These results suggested that the 
exosomes from MEFs lacking SIRT6 defatty-acylase activity had stronger ability to 
promote cell proliferation, likely due to the different cargo content, such as the 
ribosomal proteins. 
In this study, we found that the SIRT6 G60A mutant exhibits efficient defatty-acylase 
activity. Although we observed weak deacetylase activity of SIRT6 G60A on peptide 
substrate in vitro when using high enzyme concentrations, we did not observe any 
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deacetylase activity on chromatin histone H3K9 and K56 in vitro or in cells. Our result 
is, at least in part, different from a previous study that identified SIRT6 G60A 
originally as a mutant that retained lysine deacetylase activity
4
. The previous report 
focused on the ART activity of SIRT6 and did not include in-depth quantitative study 
about deacetylase activity of SIRT6 G60A. It is possible that the deacetylase activity 
of the G60A mutant in the previous report is also very weak. Alternatively, slight 
differences in the sequences of the SIRT6 constructs used (e.g. the linker sequences 
between SIRT6 and the purification tags) may affect the deacetylase activity of the 
G60A mutant expressed.  Luckily for us, our SIRT6 G60A mutant maintains efficient 
defatty-acylase activity but lack detectable deacetylase activity in cells and therefore is 
a useful tool to dissect the contribution of defatty-acylation to the various functions of 
SIRT6. 
The unique capability of SIRT6 G60A mutant to remove fatty-acyl groups but not 
acetyl groups can be explained by the fact that the G60A mutation dramatically 
decreases the NAD
+
 binding affinity, but the NAD
+
 binding affinity is restored in the 
presence of fatty-acyl peptides. This is a very interesting phenomenon that presumably 
originates from the strong binding affinity of fatty-acyl peptides to SIRT6 - part of the 
binding energy may be used to change the SIRT6 conformation, allowing tight binding 
of NAD
+
. 
Using this mutant, we investigated the contribution of the defatty-acylase activity to 
the biological functions of SIRT6. In the Sirt6 KO MEFs, if we could restore WT 
phenotype by expressing SIRT6 G60A, then we interpret that the defatty-acylase 
activity is important for that phenotype.  If only expressing SIRT6 WT could restore 
the WT phenotype, then we interpret that the defatty-acylase activity is not important 
and likely the deacetylase or ART activity is important for the phenotype. However, 
two caveats should be pointed out. First, since SIRT6 G60A showed slightly weaker 
 58 
defatty-acylase activity and lower stability than SIRT6 WT in vitro, overexpression of 
SIRT6 G60A may not be able to restore the function in Sirt6 KO cells even if that 
function is regulated by defatty-acylation. Second, for any function that can be 
restored by expressing SIRT6 G60A, it can be argued that the remaining weak 
deacetylase activity is sufficient. Nonetheless, based on the test cases with known 
targets of SIRT6 deacetylation (histone H3 K9 and K56) and defatty-acylation 
(TNF), we believe that our interpretations are reasonable. 
We found that the defatty-acylase activity of SIRT6 regulates the secretion of 
numerous proteins. Previously, the only known biological function of the defatty-
acylase activity of SIRT6 was to promote TNF secretion. Thus, our current finding 
has significantly expanded the role of the defatty-acylase activity of SIRT6. 
Particularly, many ribosomal proteins are secreted through exosomes in Sirt6 KO 
MEFs, and these exosomes can significantly increase NIH 3T3 cell proliferation 
compared with the exosomes from MEFs expressing SIRT6 WT or G60A. SIRT6 has 
previously been reported to have tumor suppression function
5
. The proliferation 
promoting effect of exosomes from Sirt6 KO cells may partly explain the tumor 
suppression function of SIRT6. For the secreted proteins in Group 2, we noticed that 
the secreted levels of many collagens were up-regulated by SIRT6 defatty-acylase 
activity. Recently it is reported that collagens mediate extracellular matrix remodeling 
and are important for longevity
20
. Promoting collagen secretion by SIRT6 defatty-
acylase activity may be a mechanism underlying the lifespan extension effect of 
SIRT6 overexpression
8
. 
As more and more biological functions of SIRT6 are discovered, a deep and 
fundamental understanding of the role of SIRT6 in biological processes is getting 
more desirable. We believe the SIRT6 G60A mutant with efficient defatty-acylase 
activity but having no detectable deacetylase activity in cells is a useful tool that will 
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provide important insights to help understand the role of SIRT6 in biology. 
 
Methods 
SIRT6 G60A is a lysine defatty-acylase in vitro 
Reagents. Anti-Flag affinity gel (#A2220) and anti-Flag antibody conjugated with 
horseradish peroxidase (#A8592) were purchased from Sigma. Human/mouse SIRT6 
antibody (#12486), histone H3 (#4499), histone H3K9 acetyl (#9671), histone H3K56 
acetyl (#4243), RanGAP1 (#14675), Ran (#4462), Annexin A1 (#8691), Tenascin 
(#12221), VCP (#2649), HSP90 (#4877), Na,K-ATPase (#3010) and Lamin A/C 
(#4777) antibodies were purchased from Cell Signaling Technology. β-Actin (sc-
4777), GAPDH (sc-20357), COL5A1 (sc-20648) and COL6A1 (sc-20649) antibodies 
were purchased from Santa Cruz Biotechnology. RPL17 (14121-1-AP) and RPS7 
(14491-1-AP) antibodies were purchased from Proteintech. CXCL1 (PA1-29220) 
antibody was purchased from Thermo Fisher. Brefeldin A, palmitic acid, 3X FLAG 
peptide, protease inhibitor cocktail, [
13
C6, 
15
N2]-L-lysine and [
13
C6, 
15
N4]-L-arginine 
were purchased from Sigma. Sequencing grade modified trypsin and FuGene 6 
transfection reagent were purchased from Promega. ECL plus western blotting 
detection reagent and universal nuclease for cell lysis were purchased from Thermo 
Scientific Pierce. Sep-Pak C18 cartridge was purchased from Waters. Amicon Ultra 
centrifugal filter unit with ultracel-10 membrane was purchased from EMD Millipore. 
Sirt6 wild type (WT) and knockout (KO) MEFs were kindly provided by Prof. Raul 
Mostoslavsky at Massachusetts General Hospital Cancer Center, Harvard Medical 
School. Acyl peptides (H3K9 acetyl, H3K9 acetyl without tryptophan, H3K9 
myristoyl, H3K9 myristoyl without tryptophan, H3K9 palmitoyl, H3K9 octanoyl, 
TNFα K20 myristoyl and H3K9 free lysine), Alk14, and 6-alkyne-NAD were 
synthesized according to reported procedures
21-23
. 
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Cell Culture. Sirt6 WT, KO MEFs and Sirt6 KO MEFs expressing SIRT6 WT, S56Y, 
G60A, R65A, or H133Y were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) with 10% heat inactived fetal bovine serum (FBS). Human Embryonic 
Kidney (HEK) 293T cells and HEK 293T SIRT6 KO cells were cultured in DMEM 
medium with 10% heat inactived FBS. NIH 3T3 cells were cultured in DMEM 
medium with 15% heat inactived FBS and MEM non-essential amino acids. All the 
cell lines have been tested for mycoplasma contamination and showed no mycoplasma 
contamination. 
Cloning, expression and purification of SIRT6 WT, S56Y, G60A, R65A and 
H133Y from Escherichia coli (E.Coli). Full-length human SIRT6 was inserted into 
pET28a vector. SIRT6 S56Y, G60A, R65A and H133Y mutations were made by 
QuikChange. All the plasmids were transformed into E.coli BL21 (DE3) cells and the 
proteins were purified according to reported procedures
11
. 
Cloning, expression and purification of SIRT6 WT, S56Y, G60A, R65A and 
H133Y from HEK 293T cells. Full-length human SIRT6 WT or mutant was inserted 
into pCMV-Tag 4a vector with C-terminal Flag tag. The SIRT6 WT and different 
mutant plasmids were transfected into HEK 293T cells using FuGene 6 transfection 
reagent according to the manufacturer‟s protocol. pCMV-Tag 4a empty vector was 
used as negative control. The cells were collected at 500 g for 5 min and then lysed in 
Nonidet P-40 lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% glycerol and 
1 % Nonidet P-40) with universal nuclease (1:1000 dilution) and protease inhibitor 
cocktail (1:100 dilution) at 4  C for 30 min. After centrifuging at 15,000 g for 15 min, 
the supernatant was collected and incubated with 20 µL of anti-Flag affinity gel at 4 
˚C for 2 h. The affinity gel was washed three times with washing buffer (25 mM Tris-
HCl pH 7.4, 150 mM NaCl, 0.2% Nonidet P-40) and then eluted by 3X FLAG peptide 
(dissolved in 25 mM Tris-HCl pH 7.4, 150 mM NaCl and 10% glycerol). Eluted 
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SIRT6 proteins were buffer exchanged three times using Amicon Ultra-0.5 centrifugal 
filter unit with ultracel-10 membrane. SIRT6 proteins after buffer exchange were used 
for the deacylation assay. 
SIRT6 deacylase activity assay. For the defatty-acylation assay using SIRT6 WT and 
mutants purified from E. coli, 1 µM of SIRT6 WT, S56Y, G60A, R65A or H133Y 
was incubated in 40 µL of reaction mixture (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 
mM DTT, 1 mM NAD
+
, 25 µM H3K9 myristoyl peptide) at 37  C for 20 min. For the 
deacetylation assay (no fatty acid activation) using SIRT6 WT and mutants purified 
from E. coli, 4 µM of SIRT6 WT, S56Y, G60A, R65A or H133Y was incubated in 40 
µL of reaction mixture (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT, 1 mM 
NAD
+
, 25 µM H3K9 acetyl peptide) at 37  C for 4 hours. For the deacetylation assay 
(with fatty acid activation) using SIRT6 WT and mutants purified from E. coli, 2 µM 
of SIRT6 WT, S56Y, G60A, R65A or H133Y was incubated in 40 µL of reaction 
mixture (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT, 1 mM NAD
+
, 25 µM 
H3K9 acetyl peptide, 300 µM palmitic acid) at 37  C for 2 hours. To quench the 
reactions, 40 µL of cold acetonitrile was added into the reaction mixture. After 
centrifuging at 15,000 g for 15 min, the supernatant was collected and analyzed by 
HPLC using Kinetex 5u EVO C18 100A column (150 mm × 4.6 mm, Phenomenex). 
Solvents used for HPLC were water with 0.1% trifluoroacetic acid (solvent A) and 
acetonitrile with 0.1% trifluoroacetic acid (solvent B). The gradient for HPLC 
condition: 0% B for 2 min, 0-20% B in 2 min, 20-40% B in 13 min, 40-100% B in 2 
min, and then 100% B for 5 min. The flow rate was 0.5 mL/min. 
For the defatty-acylation assay using SIRT6 WT and mutants purified from HEK 
293T cells, 0.2 µM of SIRT6 WT, S56Y, G60A, R65A or H133Y was incubated in 40 
µL of reaction mixture (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT, 1 mM 
NAD
+
, 5 µM H3K9 myristoyl peptide) at 37  C for 60 min. For the deacetylation assay 
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using SIRT6 WT and mutants purified from HEK 293T cells, 0.4 µM of SIRT6 WT, 
S56Y, G60A, R65A or H133Y was incubated in 40 µL of reaction mixture (25 mM 
Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT, 1 mM NAD
+
, 5 µM H3K9 acetyl peptide, 
300 µM palmitic acid) at 37  C for 2.5 hours. To quench the reactions, 40 µL of cold 
acetonitrile was added into the reaction mixture. After centrifuging at 15,000 g for 15 
min, the supernatant was collected and analyzed by HPLC using the same method 
described above. 
Kinetics assay for SIRT6 WT and G60A on acetyl and myristoyl peptides. For the 
demyristoylation kinetics, 0.1 µM of SIRT6 WT or G60A was incubated with 
different concentrations of H3K9 myristoyl peptides (0.5-64 µM) in 40 µL of reaction 
mixture (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT, 1 mM NAD
+) at 37˚C 
for 10 min (SIRT6 WT) or 15 min (SIRT6 G60A). For the deacetylation kinetics 
without fatty acid, 6 µM of SIRT6 WT or 15 µM of SIRT6 G60A was incubated with 
different concentrations of H3K9 acetyl peptides (10-320 µM) in 40 µL of reaction 
mixture (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT, 1 mM NAD
+) at 37˚C 
for 60 min (SIRT6 WT) or 90 min (SIRT6 G60A). For the deacetylation kinetics with 
300 µM palmitic acid, 0.8 µM of SIRT6 WT or 4 µM of SIRT6 G60A was incubated 
with different concentrations of H3K9 acetyl peptides (5-160 µM) in 40 µL of reaction 
mixture (25 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM DTT, 1 mM NAD
+
) at 37˚C 
for 30 min (SIRT6 WT) or 90 min (SIRT6 G60A). To quench the reactions, 40 µL of 
cold acetonitrile was added into the reaction mixture. After centrifuging at 15,000 g 
for 15 min, the supernatant was collected and analyzed by HPLC using the same 
method described above. For all the reactions, the conversions of acyl H3K9 to H3K9 
were < 10%. 
In vitro histone deacetylation assay. Chromatin was purified from HEK 293T cells. 
Briefly, the cells were collected at 500 g for 5 min and then lysed in Nonidet P-40 
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lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% glycerol and 1 % Nonidet 
P-40) with protease inhibitor cocktail (1:100 dilution) at 4  C for 5 min. After 
centrifuging at 15,000 g for 5 min, the pellets were collected and washed with the 
Nonidet P-40 lysis buffer. Then Nonidet P-40 lysis buffer with universal nuclease 
(1:1000 dilution) and protease inhibitor cocktail (1:100 dilution) were added to the 
pellets and incubated at 25   C for 10 min. After centrifuging at 15,000 g for 15 min, 
the supernatant was collected as chromatin proteins. For the histone deacetylation 
assay, 1 µM of SIRT6 WT, S56Y, G60A, R65A or H133Y was incubated with 3 µg of 
chromatin proteins in 30 µL of reaction mixture (25 mM Tris-HCl pH 8.0, 50 mM 
NaCl, 1 mM DTT, 1 mM NAD
+
) at 37  C for 120 min. Then the SDS loading buffer 
was added. The whole reaction mixture was heated at 95 ˚C for 5 min and then used 
for western blot analysis. 
In vitro mono-ADP-ribosylation assay. In vitro mono-ADP-ribosylation assay was 
performed according to reported procedures
14
. Briefly, 2.5 µM of SIRT6 WT, S56Y, 
G60A, R65A or H133Y was incubated in 30 µL of reaction mixture (25 mM Tris-HCl 
pH 8.0, 50 mM NaCl, 1 mM DTT, 50 µM 6-alkyne-NAD) at 30  C for 30 min. For 
negative control, 50 µM of NAD
+
 was added to replace 6-alkyne-NAD. Then click 
chemistry was performed. BODIPY-N3 (1 µL of 4.5 mM solution in DMF), Tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (1.8 µL of 10 mM solution in DMF), 
CuSO4 (1.5 µL of 40 mM solution in H2O) and Tris(2-carboxyethyl)phosphine (1.5 
µL of 40 mM solution in H2O) were added into the reaction mixture. The click 
chemistry reaction was allowed to proceed at room temperature for 30 min. Then SDS 
loading buffer was added and the mixture was heated at 95 ˚C for 5 min. The reaction 
mixture was resolved by 12% SDS-PAGE. Protein gel was incubated in destaining 
buffer (50% methanol, 40% water, 10% acetic acid) at room temperature for 2 h. 
BODIPY fluorescence signal was then recorded by Typhoon 9400 Variable Mode 
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Imager (GE Healthcare Life Sciences) with PMT 550 V and normal sensitivity. After 
recording the fluorescence, the gel was stained by Coomassie blue buffer (0.2% 
Coomassie brilliant blue R-250 dye, 50% methanol, 40% water, 10% acetic acid) to 
quantify the protein loading. 
Stable overexpression of SIRT6 WT, S56Y, G60A, R65A or H133Y in Sirt6 KO 
MEFs. Full-length human SIRT6 WT and mutants were inserted into lentiviral vector 
(pCDH-CMV-MCS-EF1-Puro) without tag. Lentivirus was generated by co-
transfection of SIRT6, pCMV-dR8.2, and pMD2.G into HEK 293T cells. The medium 
was collected 48 h after transfection and was used to infect Sirt6 KO MEFs. To obtain 
the SIRT6 stable overexpressed cells, the cells were treated by 1.5 mg/mL of 
puromycin 48 h after infection. Empty pCDH vector was used as the negative control. 
Detection of lysine fatty-acylation on TNFα by in-gel fluorescence. Human full-
length TNFα cDNA with N-terminal Flag tag was inserted into pCMV-Tag 4a vector. 
The TNFα plasmid was transfected into Sirt6 KO MEFs and Sirt6 KO MEFs 
expressing SIRT6 WT, S56Y, G60A, R65A, or H133Y by FuGene 6 transfection 
reagent. After 18 h, the cells were treated with 50 µM Alk14 and 4 µg/mL brefeldin A 
for another 6 h. The cells were collected at 500 g for 5 min and then lysed in Nonidet 
P-40 lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% glycerol, and 1 % 
Nonidet P-40) with protease inhibitor cocktail (1:100 dilution) at 4  C for 30 min. After 
centrifuging at 15,000 g for 15 min, the supernatant was collected and incubated with 
20 µL of anti-Flag affinity gel at 4 ˚C for 2 h. The affinity gel was washed three times 
with washing buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.2% Nonidet P-40) 
and then re-suspended in 18 µL of washing buffer. BODIPY-N3 (0.7 µL of 4.5 mM 
solution in DMF), Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (1.2 µL of 10 
mM solution in DMF), CuSO4 (1 µL of 40 mM solution in H2O) and Tris(2-
carboxyethyl)phosphine (1 µL of 40 mM solution in H2O) were added into the 
 65 
reaction mixture. The click chemistry reaction was allowed to proceed at room 
temperature for 30 min. Then SDS loading buffer was added and heated at 95 ˚C for 
10 min. After centrifugation at 15,000 g for 2 min, the supernatant was collected, 
treated with 400 mM hydroxylamine, and heated at 95 ˚C for 10 min. The samples 
were resolved by 12% SDS-PAGE. BODIPY fluorescence signal was recorded by 
Typhoon 9400 Variable Mode Imager (GE Healthcare Life Sciences) with PMT 550 V 
and normal sensitivity. 
Generation of SIRT6 KO in HEK 293T cells by CRISPR/Cas9 technology. SIRT6 
KO HEK 293T cells were generated according to reported procedures
24
. The guide 
RNAs were cloned into pLKO2 vector. The sequences of guide RNAs are: 
SIRT6 Nickase pair 3_A:  5'- CACCGTCCATGGTCCAGACTCCGTG-3'; 
SIRT6 Nickase pair 3_A': 5'- AAACCACGGAGTCTGGACCATGGAC-3'; 
SIRT6 Nickase pair 3_B: 5'- CACCGACACCACCTTTGAGAGCGCG-3'; 
SIRT6 Nickase pair 3_B': 5'-AAACCGCGCTCTCAAAGGTGGTGTC-3'. 
Western blot. Proteins were resolved by 12% or 15% SDS-PAGE and transferred to 
polyvinylidene fluoride (PVDF) membrane. The membrane was blocked with 5% 
BSA in TPBS (0.1% Tween-20 in PBS solution) at room temperature for 60 min. The 
antibody was diluted with fresh 5% BSA in TPBS (1:5000 dilution for Flag, β-Actin, 
GAPDH, HSP90, Ac-H3K9, Ac-H3K56 and histone H3, 1:1000 dilution for Na, K, 
ATPase, Lamin A/C, SIRT6, RanGAP1, Ran, Annexin A1, Tenascin, COL5A1, 
COL6A1, VCP, RPL17, RPS7 and CXCL1) and then incubated with membrane at 
room temperature for 1 h (Flag, β-Actin, GAPDH and histone H3) or at 4 ˚C for 12 h 
(Ac-H3K9, Ac-H3K56, SIRT6, RanGAP1, Ran, Annexin A1, Tenascin, COL5A1, 
COL6A1, VCP, RPL17,RPS7, CXCL1, Na, K, ATPase, Lamin A/C and HSP90). For 
histone H3, Ac-H3K9, Ac-H3K56, SIRT6, RanGAP1, Ran, Annexin A1, Tenascin, 
COL5A1, COL6A1, VCP, RPL17,RPS7, CXCL1, Na, K, ATPase, Lamin A/C and 
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HSP90 western blots, after washing the membrane three times by TPBS, the 
secondary antibody (1:3000 dilution in 5% BSA in TPBS) was added and then 
incubated at room temperature for 1 h. The chemiluminescence signal in membrane 
was recorded after developing in ECL plus western blotting detection reagents using 
Typhoon 9400 Variable Mode Imager (GE Healthcare Life Sciences). 
ELISA analysis of TNFα secretion in MEFs. After transient transfection of TNFα 
into Sirt6 WT MEFs, Sirt6 KO MEFs and Sirt6 KO MEFs expressing SIRT6 WT, 
G60A, or H133Y for 18 h, the medium was changed to fresh medium. The cells were 
incubated with the new medium for 12 h. Then the medium and the cells were 
collected separately. Human TNFα ELISA kit (eBioscience) was used for quantifying 
TNFα in the medium and the cells following the manufacturer‟s instructions. 
Percentage of secreted TNFα was calculated by the TNFα in the medium versus total 
TNFα in the medium and the cells. 
Crystal violet assay. The cells were seeded onto 12-well plates at low density (3,000 
cells/well). After 48 h, the medium was removed and glucose free DMEM medium 
with 10% heat inactivated FBS was added into each well for another 72 h. The cells 
were washed two times with cold PBS, and then fixed with cold methanol for 10 min. 
After removing the methanol, the crystal violet staining solution (0.2% in 2% ethanol 
solution) was added and incubated for 5 min. The cells were then washed with water 
until all excess dye was removed. Crystal violet dye that remained with the cells was 
solubilized by incubating with 0.5% SDS in 50% ethanol solution. The absorption of 
crystal violet was measured at 550 nm. 
Collection of secreted protein in MEFs. The MEFs were cultured to 90% 
confluence. The medium was removed and the cells were washed 3 times with PBS 
and then 3 times with serum-free DMEM medium. Then the cells were cultured in 
serum free DMEM medium for 12 h. The medium was collected and first centrifuged 
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at 500 g for 5 min to pellet floating cells. Then a second centrifugation at 3,000 g for 
10 min was carried out to remove cell debris. The supernatant containing total secreted 
proteins was transferred into Amicon Ultra-15 Centrifugal Filter Units with 10 kDa 
cutoff for concentration. The concentrated secreted proteins (100-150 times 
concentrated) were used for SDS-PAGE analysis and Stable Isotope Labeling by 
Amino acids in Cell culture (SILAC). 
SILAC. Sirt6 KO MEFs were cultured in DMEM with [
13
C6, 
15
N2]-L-lysine and [
13
C6, 
15
N4]-L-arginine for 5 generations. Sirt6 WT MEFs, Sirt6 KO MEFs expressing 
SIRT6 WT, G60A, or H133Y were cultured in normal DMEM for 5 generations. Then 
the secreted proteins were collected using the same method described above. After 
quantifying the concentration of total secreted proteins by Bradford assay, 40 µg of 
proteins of each pair of samples (heavy labeled and light labeled) was mixed. 
Disulfide reduction and protein denaturation were performed in 6 M urea, 10 mM 
DTT, 50 mM Tris-HCl pH 8.0 at room temperature for 1 h. Iodoacetamide was added 
(final concentration 40 mM) and incubated at room temperature for 1 h. DTT was then 
added and incubated at room temperature for 1 h to stop alkylation. After diluting the 
sample 7 times with 50 mM Tris-HCl pH 8.0 and 1 mM CaCl2, trypsin digestion was 
performed at 37  C for 18 h. Digestion was quenched with 0.1 % trifluoroacetic acid 
and the mixture was desalted using Sep-Pak C18 cartridge. The lyophilized peptides 
were used for LC-MS/MS analysis. 
Nano LC-MS/MS analysis. The lyophilized peptides were dissolved in 2% 
acetonitrile with 0.5% formic acid for nano LC-ESI-MS/MS analysis, which was 
carried out on a LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, San 
Jose, CA). The Orbitrap was interfaced with Dionex UltiMate3000 MDLC system 
(Thermo Dionex, Sunnyvale, CA). Protein samples were injected onto a Acclaim 
PepMap nano Viper C18 trap column (5 µm, 100 µm  2 cm, Thermo Dionex) at a 
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flow rate of 20 µL/min for on-line desalting and then separated on C18 RP nano 
column (5 µm, 75 µm  50 cm, Magic C18, Bruker). The gradient for HPLC condition 
was 5-38% acetonitrile with 0.1% formic acid in 120 min. The flow rate was 0.3 
µL/min. The Orbitrap Elite was operated in positive ion mode with spray voltage 1.6 
kV and source temperature 275 ˚C. Data-dependent acquisition (DDA) mode was used 
by one precursor ions MS survey scan from m/z 300 to 1800 at resolution 60,000 
using FT mass analyzer, followed by up to 10 MS/MS scans at resolution 15,000 on 
10 most intensive peaks. All data were acquired in Xcalibur 2.2 operation software 
(Thermo Fisher Scientific). 
RNA extraction, reverse transcription and PCR analysis of the mRNA levels of 
target genes. Sirt6 WT MEFs, Sirt6 KO MEFs, Sirt6 KO MEFs expressing SIRT6 
WT, G60A, or H133Y were collected and used for RNA extraction. Total RNAs were 
extracted using RNeasy Mini kit (QIAGEN). Reverse transcription were performed 
with SuperScript III First-Strand Synthesis kit (Invitrogen) following the 
manufacturer‟s instructions. For PCR amplication, Herculase II Fusion Enzyme with 
dNTPs Combo kit (Agilent) was used following the manufacturer‟s instructions. For 
real-time PCR analysis, iTaq Universal SYBR Green Supermix (Biorad) was used 
following the manufacturer's instructions. The reaction was monitored using 
LightCycle 480 II system (Roche). 
SIRT6 localization by subcellular fractionation and confocal imaging. Subcellular 
fractionation and immunofluorescence were performed according to the reported 
procedures
25,26
. Confocal imaging was performed by Zeiss LSM880 
confocal/multiphoton microscope. 
Intrinsic tryptophan fluorescence of SIRT6 WT and mutants. Fluorescence 
emission was monitored by Cary Eclipse Fluorescence Spectrophotometer (Agilent). 
The excitation wavelength was set as 295 nm (slit 2.5 nm), and the emission spectra 
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were monitored from 320 to 390 nm (slit 5 nm). 3 µM SIRT6 WT, S56Y, G60A, 
R65A or H133Y in 25 mM Tris-HCl pH 7.4, 150 mM NaCl and 10% glycerol was 
used for measuring NAD
+
 binding. Increasing concentrations of NAD
+
 were added to 
3 µM SIRT6 WT and mutants solution (0-100 µM NAD
+
 for SIRT6 H133Y, 0-500 
µM NAD
+
 for SIRT6 WT and S56Y, and 0-5 mM NAD
+
 for SIRT6 G60A and R65A), 
and the emission spectra were monitored. To measure SIRT6 WT and G60A binding 
to NAD
+
 with saturated acetyl peptide, 1 mM Ac-H3K9 (without tryptophan) was 
mixed with 3 µM SIRT6 WT or G60A, then increasing concentrations of NAD
+
 were 
added and the emission spectra were monitored. The peak maximum for each 
experiment was obtained. The following equation was used for calculating the fraction 
of NAD
+
 bound (NB): 
   
    
       
 
where F is the maximum fluorescence intensity at each NAD
+ 
concentration, F0 is the 
maximum fluorescence intensity with 0 µM of NAD
+
, and Fsat is the maximum 
fluorescence intensity with saturated NAD
+
. The NB values were plotted against 
NAD
+ 
concentrations, and the curves were fitted to following equation (one-site 
binding) using GraphPad Prism: 
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where [E] is SIRT6 concentration (3 µM), [NAD
+
] is NAD
+
 concentration, and Kd is 
the dissociation constant. 
To measure the emission spectra of SIRT6 WT and G60A with and without saturated 
Ac-H3K9 and Myr-H3K9, 3 µM SIRT6 WT or G60A was mixed with 1 mM Ac-
H3K9 (without tryptophan) or 0.1 mM Myr-H3K9 (without tryptophan) and then the 
emission spectra were monitored. The emission spectra of blank buffer and 1 mM Ac-
H3K9 or 0.1 mM Myr-H3K9 in blank buffer were also monitored as control. 
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HPLC analysis of SIRT6 binding to NAD
+
.  10 µM of SIRT6 WT, G60A or 
H133Y was incubated with 10 µM NAD
+ 
in 50 µL of buffer (25 mM Tris-HCl pH 8.0, 
50 mM NaCl) at room temperature for 30 min. Then 450 µL of buffer was added and 
all the 500 µL of buffer with SIRT6 and NAD
+
 was transferred to Amicon Ultra-0.5 
centrifugal filter unit with ultracel-10 membrane. After centrifuge at 15,000 g for 20 
min, all filtrate (~400 µL) was collected and lyophilized. The lyophilized powder was 
dissolved in 50 µL water and used for HPLC analysis. 
Thermal Shift Assay. 5 µM of SIRT6 WT or G60A was mixed with or without 1 mM 
H3K9 acetyl or 100 µM H3K9 myristoyl peptide in the reaction buffer (25 mM Tris-
HCl pH 8.0, 50 mM NaCl). The temperature was set from 37 to 62 ˚C for 3 min in the 
PCR Thermocycler. Then the samples were centrifuged at 15,000 g for 20 min, the 
supernatant was analyzed by SDS-PAGE and proteins were visualized by Coomassie 
blue staining. 
Isolation of microvesicles and exosomes. After two 150 mm dishes of the cells grow 
to 90% confluence, the medium was removed and the cells were washed 3 times with 
PBS and 3 times with serum-free DMEM medium. Then the culture medium was 
changed to serum-free medium and the cells were cultured for another 12 h. The 
medium was collected and subjected to two centrifuges: 500 g for 5 min (to pellet 
floating cells) and 3,000 g for 20 min (to pellet cell debris). The supernatant was 
subjected to 0.2 µm syringe filter with low flow rate (<1 drop/second), the vesicles 
retained on the filter (microvesicles) were washed once by PBS. The microvesicles 
were then lysed on the filter by Nonidet P-40 lysis buffer (25 mM Tris-HCl pH 7.4, 
150 mM NaCl, 10% glycerol, and 1 % Nonidet P-40) with protease inhibitor cocktail 
(1:100 dilution). The filtrate was subjected to ultracentrifuge at 100,000 g for 2 h. The 
supernatant was vesicle free medium. The pellets were exosomes and were washed 
once by PBS and subjected to another ultracentrifuge at 100,000 g for 2 h. To get 
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proteins from the exosomes, the exosome pellets were lysed by Nonidet P-40 lysis 
buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% glycerol, and 1 % Nonidet P-40) 
with protease inhibitor cocktail (1:100 dilution). For cell proliferation experiment, the 
exosome pellets were suspended in serum-free DMEM. Exosome concentrations were 
determined by nanoparticle tracking analysis (NTA) according to the reported 
procedures
27
. 
Statistical Analysis. Data were expressed as mean ± s.d. (standard deviation, shown 
as error bars). Differences were examined by two-tailed Student‟s t-test between two 
groups; *p < 0.05, **p < 0.01, ***p < 0.005. 
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CHAPTER 3 
SIRT6 REGULATES RAS-RELATED PROTEIN R-RAS2 BY 
LYSINE DEFATTY-ACYLATION
a
 
 
Abstract 
The Ras family of GTPases are important in cell signaling and frequently mutated in 
human tumors. Understanding their regulation is thus important for studying biology 
and human diseases. Here we report that a novel posttranslational mechanism, 
reversible lysine fatty-acylation, regulates R-Ras2, a member of the Ras family. 
SIRT6, a sirtuin with established tumor suppressor function, regulates the lysine fatty-
acylation of R-Ras2. In mouse embryonic fibroblasts (MEFs), Sirt6 knockout (KO) 
increased R-Ras2 lysine fatty-acylation. Lysine fatty-acylation promotes the plasma 
membrane localization of R-Ras2 and its interaction with phosphatidylinositol 3-
kinase PI3K, leading to activated Akt and increased cell proliferation. Our study 
establishes lysine fatty-acylation as a previously unknown mechanism that regulates 
the Ras family of GTPases and provides an important mechanism by which SIRT6 
functions as a tumor suppressor. 
 
 
 
 
 
 
 
 
a
 This is a revised version of our published paper: Zhang X, et al. SIRT6 regulates Ras-related 
protein R-Ras2 by lysine defatty-acylation. eLife, 6 (2017) e25158 
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Introduction 
SIRT6 (sirtuin 6) belongs to the Sir2 (silencing information regulator 2) family of 
nicotinamide adenine dinucleotide (NAD
+
)-dependent protein lysine deacylases. It 
plays important roles in a variety of biological processes, including DNA damage and 
repair 
1-3
, glucose metabolism 
4
, and cell proliferation 
5
. Sirt6 knockout (KO) mice 
display multiple defects and die a few weeks after birth. Underlying its biological 
functions, SIRT6 has multiple enzymatic activities. It can deacetylate histone H3 
lysine 9 (Ac-H3K9), lysine 18 (Ac-H3K18), and lysine 56 (Ac-H3K56) 
6-9
, to suppress 
target gene expression of several transcription factors, including NF-κB 10, HIF-1α 4, 
c-Jun 
11
, and c-Myc 
5
. SIRT6 has also been reported to be an adenosine diphosphate 
(ADP)-ribosyltransferase 
2,12
. We have recently identified SIRT6 as an efficient lysine 
defatty-acylase that regulates the secretion of tumor necrosis factor (TNFα) 13. 
Mechanistically, lysine fatty-acylation promotes TNFα targeting to lysosome and thus 
decreases its secretion 
14
. However, it remains unclear whether SIRT6 regulates other 
proteins by defatty-acylation. 
The Ras family of proteins plays important roles in numerous biological pathways, 
including signal transduction, membrane trafficking, nuclear export/import, and 
cytoskeletal dynamics 
15
. Five branches of the Ras superfamily (Ras, Rho, Rab, Arf 
and Ran) are classified according to sequence similarity. Ras proteins can exist in two 
conformational states: a GDP-bound inactive state and a GTP-bound active state. In 
the GTP-bound state, Ras proteins can recruit effector proteins and turn on specific 
signaling pathways 
16,17
. Protein post-translational modifications (PTMs) play 
important roles in regulating the Ras family of proteins 
18
. Ras and Rho families of 
GTPases are modified by prenylation (farnesylation or geranylgeranylation) on their 
C-terminal CaaX motif at the cysteine residue. Some proteins from Ras and Rho 
families, such as H-Ras and N-Ras, contain cysteine palmitoylation as a second 
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lipidation. Both prenylation and palmitoylation serve as important membrane targeting 
signals 
19,20
. Other proteins from Ras and Rho families, such as K-Ras4B, do not have 
cysteine palmitoylation, and are thought to use a C-terminal polybasic sequence for 
membrane targeting 
19,20
. 
Here we demonstrate that a Ras family protein, R-Ras2 (also called TC21 because it 
was cloned from a human teratocarcinoma cDNA library)
21
, which is able to transform 
cells and is up-regulated in several human cancers 
22-25
, is regulated by a novel PTM, 
lysine fatty-acylation. Importantly, SIRT6 is identified as the defatty-acylase of R-
Ras2. SIRT6 defatty-acylates R-Ras2 and attenuates its plasma membrane 
localization, therefore inhibits its ability to activate PI3K signaling pathway and cell 
proliferation. 
 
Results and discussion 
Defatty-acylation contributes to SIRT6’s tumor-suppressor function 
SIRT6 has been reported to be a tumor suppressor 
5
. Decreased SIRT6 expression 
levels are found in several human cancers. Enhanced glycolysis is observed in SIRT6-
deficient cells and tumors, which is thought to drive tumor formation in vivo 
5
. 
Interestingly, the tumor formation promoted by the loss of SIRT6 is oncogene HRAS-
independent. However, the exact role of SIRT6 in cancer is still not well understood. 
In particular, which enzymatic activity is important for the tumor suppression function 
is not clear. 
We have recently identified a single point mutation (G60A) of SIRT6 that maintains 
the defatty-acylase activity but exhibits no detectable deacetylase activity in cells 
26
. 
Utilizing this mutant, we first investigated whether the defatty-acylase activity of 
SIRT6 contributes to tumor suppression and aimed to identify the defatty-acylation 
substrate protein that is important for this function. We stably expressed SIRT6 wild 
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type (WT) (exhibits both deacetylase and defatty-acylase activities), G60A (exhibits 
only defatty-acylase activity in cells), or H133Y (exhibits neither activity in cells) into 
Sirt6 KO mouse embryonic fibroblasts (MEFs) and tested their effects on cell 
proliferation. Sirt6 KO MEFs expressing SIRT6 WT showed decreased cell 
proliferation compared to those without SIRT6 expression (Figure 3.1a), consistent 
with the reported role of SIRT6 in suppressing cell proliferation. In contrast, 
expressing the H133Y mutant had no significant effect on cell proliferation. 
Interestingly, expression of the G60A mutant, which only exhibits the defatty-acylase 
activity in cells, also decreased cell proliferation, similar to the expression of SIRT6 
WT (Figure 3.1a). The suppression of cell proliferation by SIRT6 WT was only 
slightly better than that by the G60A mutant. This suggests that although both 
deacetylase and defatty-acylase activities of SIRT6 contribute, the defatty-acylase 
activity plays a major role in regulating cell proliferation. 
 
Identification of SIRT6 defatty-acylation targets 
To identify the lysine defatty-acylation targets of SIRT6 that contribute to its tumor 
suppressing function, we used a quantitative mass spectrometry method, stable isotope 
labeling with amino acids in cell culture (SILAC), to identify proteins with different 
lysine fatty-acylation levels in Sirt6 WT and KO MEFs. We used fatty acid analogs to 
metabolically label fatty-acylated proteins and enriched these proteins by 
incorporating a biotin tag through the copper(I)-catalyzed alkyne-azide cycloaddition 
(typically called click chemistry) followed by streptavidin pull-down (Figure 3.1b). 
Two fatty acid analogs were used for cross comparison: Alk12 which better mimics 
myristic acid and Alk14 which better mimics palmitic acid
27
. When processing the 
samples, we used IpaJ, a cysteine protease from Shigella flexneri that has been 
reported to hydrolyze the peptide bond after N-myristoylated glycine 
28
, to reduce the 
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labeling background from N-myristoylation. We also used NH2OH as nucleophile to 
remove fatty-acylation on cysteine residues. 
There were 865 proteins identified in Alk12 SILAC and 1285 proteins identified in 
Alk14 SILAC. To narrow down the target lists, we filtered the data using 4 criteria 
(Figure 3.1c): 1) Protein score ≥ 10, and the number of unique peptide ≥ 2; 2) The 
target was present in both SILAC experiments, which could decrease the N-
myristoylation background (proteins present only in Alk12 SILAC) and S-
palmitoylation background (proteins present only in Alk14 SILAC); 3) Heavy/Light 
ratio ≥ 1.5, which allowed us to pick proteins that exhibited higher lysine fatty-
acylation in Sirt6 KO MEFs than in Sirt6 WT MEFs; 4) The target had similar protein 
levels in Sirt6 WT and KO MEFs by comparing the data from a total protein SILAC 
experiment, which was to make sure that proteins with higher Heavy/Light ratios in 
Alk12 and Alk14 SILAC were not due to increased protein levels. With these criteria, 
we narrowed down the target lists to 5 proteins (Figure 3.1c). 
Interestingly, a Ras-related small GTPase, R-Ras2, was one of the possible defatty-
acylation targets of SIRT6. R-Ras2, like its cousins (H-, N-, and K-Ras), is known to 
be highly relevant to cancer
24,29-31
. We thus hypothesized that the tumor suppressing 
function of SIRT6 could be through regulating R-Ras2. To test this hypothesis, we 
knocked down R-Ras2 in Sirt6 WT and KO MEFs and examined the cell proliferation. 
Knockdown of R-Ras2 in both Sirt6 WT and KO MEFs by two different shRNAs 
significantly decreased cell proliferation (Figure 3.1d), suggesting that R-Ras2 is 
important for cell proliferation in MEFs. 
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Figure 3.1. Identification of defatty-acylation targets of SIRT6 that contribute to its 
function in cell proliferation.  (a) Cell proliferation of Sirt6 KO MEFs stably 
expressing pCDH empty vector, SIRT6 WT, G60A, or H133Y. Cell proliferation was 
assayed and quantified using crystal violet staining. Values with error bars indicate 
mean ± s.d. of three biological replicates. * indicates p < 0.05 and “ns” indicates no 
statistical significant when comparing to Sirt6 KO MEFs with pCDH. (b) Schematic 
overview of the SILAC experiment to identify SIRT6 lysine defatty-acylation targets. 
(c) Data analysis and filter of SILAC results. (d) Effects of R-Ras2 knockdown on the 
proliferation of Sirt6 WT and KO MEFs. Values with error bars indicate mean ± s.d. 
of three biological replicates. *** indicates p < 0.005 for comparing to Sirt6 KO 
MEFs with ctrl shRNA. 
 
R-Ras2 is SIRT6 defatty-acylation target 
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We then validated whether R-Ras2 has lysine fatty-acylation. We first examined R-
Ras2 mRNA and proteins levels in Sirt6 WT and KO MEFs. The results showed that 
SIRT6 did not affect the transcription and translation of R-Ras2 (Figure 3.2a). We 
then used the fatty acid analog Alk14 to metabolically label an overexpressed FLAG-
tagged R-Ras2. After FLAG immunoprecipitation, we conjugated a fluorescent dye 
(520-BODIPY-azide) through click chemistry to allow visualization of fatty-acylated 
R-Ras2 by in-gel fluorescence (Figure 3.2b) . We used hydroxylamine (NH2OH) to 
remove potential cysteine fatty-acylation. Thus, the in-gel fluorescence signal should 
be mainly attributed to fatty-acylation on lysine residues. R-Ras2 exhibited increased 
lysine (NH2OH-resistant) fatty-acylation in Sirt6 KO MEFs than in WT MEFs 
(Figure 3.2c). We also observed increased R-Ras2 lysine fatty-acylation in Human 
Embryonic Kidney (HEK) 293T cells after knocking down SIRT6 with two different 
Sirt6 shRNAs, but not with a control shRNA (Figure 3.2d).We then used an 
alternative method to detect lysine fatty-acylation on overexpressed FLAG-tagged R-
Ras2. We treated the cells with Alk14, and then incorporated a biotin tag on fatty-
acylated proteins (including R-Ras2) through click chemistry. We pulled down the 
fatty-acylated proteins using streptavidin beads and then removed S-palmitoylation 
from the streptavidin beads by NH2OH treatment. The proteins on beads were then 
resolved by gel electrophoresis and the level of R-Ras2 was detected by FLAG 
western blot. This method also revealed more lysine fatty-acylation on overexpressed 
R-Ras2 in Sirt6 KO MEFs than in Sirt6 WT MEFs (Figure 3.2e). 
Using a similar method, we set out to examine whether endogenous R-Ras2 was 
regulated by lysine fatty-acylation. Endogenous R-Ras2 labeled with Alk4 was 
conjugated to biotin and pulled down with streptavidin beads. More fatty-acylated 
endogenous R-Ras2 was pulled down from Sirt6 KO MEFs than from WT MEFs 
(Figure 3.2f), suggesting that endogenous R-Ras2 contained more lysine fatty-
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acylation in Sirt6 KO MEFs. 
To confirm that SIRT6 could defatty-acylate R-Ras2 directly, we overexpressed 
FLAG-tagged R-Ras2 in Sirt6 KO MEFs, metabolically labeled with Alk14, and then 
purified R-Ras2 protein from total cell lysates. We then incubated R-Ras2 with SIRT6 
in the presence of NAD
+
 and subsequently performed click chemistry to detect R-Ras2 
lysine fatty-acylation. In the presence of NAD
+
, SIRT6 removed most of the lysine 
fatty-acylation signal from R-Ras2 (Figure 3.2g). We also used a previously 
established 
32
P-NAD
+
 assay, in which the newly generated fatty-acyl adenosine 
diphosphate ribose (ADPR) product could be easily detected on thin layer 
chromatography (TLC) plate, to detect lysine fatty-acylation on R-Ras2. SIRT6 WT, 
but not the catalytic mutant SIRT6 H133Y, generated the fatty-acyl ADPR spot in the 
presence of R-Ras2 isolated from Sirt6 KO MEFs and NAD
+
 (Figure 3.2h). These 
data suggested that R-Ras2 was fatty-acylated on lysine residues and SIRT6 could 
directly remove the fatty-acylation in vitro. 
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Figure 3.2. Validation of R-Ras2 as the defatty-acylation target of SIRT6. (a) mRNA 
and protein levels of R-Ras2 in Sirt6 WT and KO MEFs. (b) Scheme showing the in-
gel fluorescence method with Alk14 metabolic labeling to identify R-Ras2 as a lysine 
fatty-acylated protein. (c) In-gel fluorescence (with NH2OH treatment) showing that 
R-Ras2 has higher lysine fatty-acylation level in Sirt6 KO MEFs than in Sirt6 WT 
MEFs. Right histogram shows the quantification of bands on the fluorescence gel. 
Values with error bars indicate mean ± s.d. of three biological replicates. * indicates p 
< 0.05. (d) Detection of R-Ras2 lysine fatty-acylation levels in control and SIRT6 
knockown HEK 293T cells by in-gel fluorescence. Right histogram shows the 
quantification of bands on the fluorescence gel. Values with error bars indicate mean ± 
s.d. of three biological replicates. * indicates p < 0.05. (e) Lysine fatty-acylation levels 
of overexpressed R-Ras2 in Sirt6 WT and KO MEFs. (f) Lysine fatty-acylation levels 
of endogenous R-Ras2 in Sirt6 WT and KO MEFs. (g, h) SIRT6 defatty-acylated R-
Ras2 in a NAD
+
-dependent manner in vitro. In-gel fluorescence was used to detect R-
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Ras2 lysine fatty-acylation (e). A 
32
P-NAD
+
 assay was used to detect fatty-acyl ADPR 
product from defatty-acylation reaction. (f).  
 
R-Ras2 is fatty-acylated on C-terminal lysine residues 
Next, we set out to identify which lysine residues of R-Ras2 were fatty-acylated. We 
noticed that there are four lysine residues in the C-terminal hypervariable region 
(HVR) of R-Ras2: K192, K194, K196, and K197 (Figure 3.3a). This region is known 
as a C-terminal polybasic sequence and is generally believed to help anchor Ras 
proteins to the membrane through electrostatic interaction
18
. We suspected that some 
of these lysine residues might be fatty-acylated. We thus mutated these four lysine 
residues to arginine (the 4KR mutant), which should maintain the positive charge and 
thus, should not disrupt the membrane association provided by the positive charge. We 
examined the lysine fatty-acylation of R-Ras2 WT and 4KR in Sirt6 KO MEFs and 
found that the 4KR mutant significantly decreased the lysine fatty-acylation signal 
(Figure 3.3a). 
We then utilized mass spectrometry (MS) to directly identify the modification site 
using FLAG-tagged R-Ras2 purified from Alk14 treated Sirt6 KO MEFs. A peptide 
(residue 193-197) carrying Alk14 modification on K194 was detected (Figure 3.3b). 
Interestingly, when we mutated each of these four lysine residues to arginine and 
detected their Alk14 labeling by in-gel fluorescence, the hydroxylamine-resistant 
labeling of all the single mutants was similar to that of WT (Figure 3.3c). This result 
suggested that K192, K194, K196, and K197 are likely to be fatty-acylated 
redundantly, although the MS result implied that K194 is preferentially fatty-acylated 
on WT R-Ras2 protein. 
R-Ras2 is known to have palmitoylation on cysteine 199, which is close to the fatty-
acylated lysine cluster. It is possible that lysine fatty-acylation occurs via acyl transfer 
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from the nearby acylated cysteine. To test this possibility, we mutated cysteine 199 to 
serine (the C199S mutant) and assayed its Alk14 labeling in HEK 293T cells. Alk14 
labeling still occurred on R-Ras2 C199S mutant, which was NH2OH resistant (Figure 
3.3d), suggesting that cysteine fatty-acylation of R-Ras2 is not required for the 
occurrence of its lysine fatty-acylation. 
 
 
Figure 3.3. R-Ras2 is fatty-acylated on C-terminal lysine residues. (a) In-gel 
fluorescence (with NH2OH treatment) showing that mutation of four lysine residues at 
the C-terminus of R-Ras2 significantly decreased lysine fatty-acylation in Sirt6 KO 
MEFs. Right histogram shows the quantification of bands on the fluorescence gel. 
Values with error bars indicate mean ± s.d. of three biological replicates. * indicates p 
< 0.05. (b) Tandem mass (MS/MS) spectrum of doubly charged Alk14 modified (on 
K194) R-Ras2 peptide. The b- and y- ions are shown along with the peptide sequence. 
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(c) In-gel fluorescence (with NH2OH treatment) showing that single mutation of four 
lysine residues at the C-terminus of R-Ras2 did not affect R-Ras2 lysine fatty-
acylation. (d) In-gel fluorescence showing lysine fatty-acylation level of 
overexpressed R-Ras2 WT and C199S mutant in HEK 293T cells with SIRT6 
knockdown. C, control shRNA. S6, SIRT6 shRNA#1. 
 
Lysine fatty-acylation targets R-Ras2 to plasma membrane 
To investigate the function of R-Ras2 lysine fatty-acylation, we first examined the 
subcellular localization of R-Ras2 WT and 4KR in both Sirt6 WT and KO MEFs by 
confocal imaging. In Sirt6 WT MEFs, both R-Ras2 WT and 4KR were localized in the 
plasma membrane and intracellular vesicles (Figure 3.4a).  In contrast, in Sirt6 KO 
MEFs, R-Ras2 WT was mainly localized in the plasma membrane, while R-Ras2 4KR 
was localized in both the plasma membrane and intracellular vesicles (Figure 3.4a). 
Considering that R-Ras2 WT in Sirt6 KO MEFs has the highest lysine fatty-acylation 
level (Figure 3.2c and 3.3a), this data suggests that lysine fatty-acylation helps 
targeting R-Ras2 to the plasma membrane. 
In addition, we performed subcellular fractionation of HEK 293T cells overexpressing 
FLAG-tagged R-Ras2. Under normal conditions, SIRT6 was present and removed 
most fatty-acyl group from R-Ras2 lysine residues, and thus we did not observe 
obvious difference in plasma membrane and cytosol localizations between WT R-
Ras2 and the 4KR mutant (Figure 3.4b). When we treated the cells with palmitic acid 
(to increase R-Ras2 lysine fatty-acylation) or SIRT6 inhibitor TM3 (to inhibit SIRT6 
defatty-acylase activity)
32
, we observed decreased cytosolic localization of WT R-
Ras2, but not the 4KR mutant (Figure 3.4b). This data also supports that lysine fatty-
acylation of R-Ras2 targets it to the plasma membrane. 
To further confirm that SIRT6 regulates R-Ras2 by defatty-acylation and not 
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deacetylation, we expressed SIRT6 G60A, which exhibits no detectable deacetylase 
activity in cells, in Sirt6 KO MEFs and examined the lysine fatty-acylation and 
subcellular localization of R-Ras2. Expressing the G60A mutant in Sirt6 KO MEFs 
decreased R-Ras2 lysine fatty-acylation to the same level as expressing WT SIRT6 
(Figure 3.5a). In vitro, the G60A mutant removed fatty-acylation from R-Ras2 similar 
to WT SIRT6 (Figure 3.5b). Confocal imaging results showed that in Sirt6 KO MEFs, 
expression of the G60A mutant promoted R-Ras2 dissociation from the plasma 
membrane, similar to the expression of WT SIRT6 (Figure 3.5c). Subcellular 
fractionation of endogenous R-Ras2 showed that, similar to WT SIRT6, the G60A 
mutant decreased the plasma membrane-localized endogenous R-Ras2 and increased 
the cytosol-localized endogenous R-Ras2 (Figure 3.5d). These data collectively 
demonstrated that the defatty-acylase activity of SIRT6 is sufficient to regulate R-
Ras2. 
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Figure 3.4. Lysine fatty-acylation targets R-Ras2 to plasma membrane. (a) Confocal 
imaging showed that R-Ras2 WT was mainly localized in the plasma membrane in 
Sirt6 KO MEFs. R-Ras2 WT in Sirt6 WT MEFs as well as R-Ras2 4KR in Sirt6 WT 
and KO MEFs was localized in both the cytosol and plasma membrane (n = 5, 5, 5, 6 
cells for each sample from left to right, respectively). (b) Subcellular fractionation of 
R-Ras2 WT and 4KR in HEK 293T cells with palmitic acid or TM3 treatment. 
GAPDH was used as the marker of cytosol fraction and Na,K-APTase was used as the 
marker of plasma membrane fraction. 
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Figure 3.5. SIRT6 defatty-acylase activity is required for regulating R-Ras2 lysine 
fatty-acylation and subcellular localization. (a) Detection of R-Ras2 lysine fatty-
acylation levels in Sirt6 KO MEFs expressing pCDH empty vector, SIRT6 WT, G60A 
or H133Y by in-gel fluorescence. (b) In-gel fluorescence showed that SIRT6 WT and 
G60A defatty-acylated R-Ras2 in a NAD
+
-dependent manner in vitro. (c) Confocal 
imaging showing the localization of R-Ras2 WT-GFP in Sirt6 KO MEFs expressing 
pCDH empty vector, SIRT6 WT, G60A or H133Y (n = 5, 6, 5, 5 cells for each sample 
from left to right, respectively). (d) Subcellular fractionation showing the localization 
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of endogenous R-Ras2 in Sirt6 WT MEF, Sirt6 KO MEFs, and Sirt6 KO MEFs 
expressing SIRT6 WT, G60A or H133Y.  
 
Lysine fatty-acylation of R-Ras2 activates PI3K/Akt and promotes cell 
proliferation 
We next investigated how lysine fatty-acylation of R-Ras2 affected its downstream 
signaling effect. There are two well-studied effector pathways of R-Ras2, the 
PI3K/Akt pathway 
31,33
 and the Raf/MAPK pathway 
30
. We first examined whether R-
Ras2 can activate the Raf/MAPK pathway in MEFs. We used Raf RBD-conjugated 
argarose beads to pull-down the active GTP-bound form of R-Ras2. The endogenous 
total Ras (H-Ras, N-Ras and K-Ras), but not the overexpressed or endogenous R-
Ras2, was pulled down by Raf RBD (Figure 3.6), suggesting that in MEFs, R-Ras2 
was unlikely to activate the Raf/MAPK pathway. We then examined the PI3K/Akt 
pathway by co-immunoprecipitation (co-IP). We overexpressed FLAG-tagged R-Ras2 
WT and 4KR in Sirt6 WT and KO MEFs, immunoprecipitated R-Ras2 and examined 
p110α, one isoform of the catalytic subunit of PI3K, which has been reported to 
interact with R-Ras2 
34
. WT R-Ras2 in Sirt6 KO MEFs, which was shown to have the 
highest level of lysine fatty-acylation (Figure 3.2c and 3.3a), had more p110α 
interaction than the WT R-Ras2 in Sirt6 WT MEFs or the 4KR mutant in either Sirt6 
WT or KO MEFs (Figure 3.7a). This data suggested that lysine fatty-acylation of R-
Ras2 promotes its interaction with p110α. 
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Figure 3.6. Raf-RBD binding assay showed that both overexpressed and endogenous 
R-Ras2 did not bind Raf RBD-conjugated argarose beads. Total endogenous Ras (H-
Ras, N-Ras and K-Ras) was used as the positive control. 
 
Then we examined whether the interaction of R-Ras2 with p110α could activate its 
downstream kinase Akt. Sirt6 KO MEFs showed higher phosphorylated Akt on 
Thr308 (p-Akt Thr308), but not on Ser473 (p-Akt Ser473), when compared to Sirt6 
WT MEFs (Figure 3.7b). Knockdown of R-Ras2 in Sirt6 WT MEFs did not affect p-
Akt Thr308, while knockdown of R-Ras2 in Sirt6 KO MEFs decreased p-Akt Thr308 
to the same level as that in Sirt6 WT MEFs (Figure 3.7b). We further found that 
expressing WT SIRT6 or the G60A mutant in Sirt6 KO MEFs decreased p-Akt 
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Thr308 levels (Figure 3.7c), suggesting that the defatty-acylation activity of SIRT6 is 
important for regulating p-Akt Thr308. All the data combined suggested that SIRT6 
defatty-acylates R-Ras2 and attenuates its interaction with p110α, resulting in 
decreased Akt phosphorylation on Thr308. 
Finally, to confirm that lysine fatty-acylation of R-Ras2 is important for its role in 
promoting cell proliferation, we overexpressed R-Ras2 WT and 4KR in Sirt6 WT and 
KO MEFs and measured the cell proliferation. Expression of R-Ras2 WT in Sirt6 KO 
MEFs significantly increased cell proliferation compared with vector control (Figure 
3.7d), while expressing R-Ras2 4KR in Sirt6 KO MEFs did not increase cell 
proliferation (Figure 3.7d). In Sirt6 WT MEFs, neither overexpressing WT R-Ras2 
nor the 4KR mutant increased cell proliferation compared with vector control (Figure 
3.7d). These data suggested that lysine fatty-acylation of R-Ras2 is important for 
promoting MEFs cell proliferation. 
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Figure 3.7. Lysine fatty-acylation of R-Ras2 activates PI3K-Akt pathway and 
promotes cell proliferation in MEFs. (a) Co-IP experiment showed that R-Ras2 WT in 
Sirt6 KO MEFs had more p110α interaction than R-Ras2 WT in Sirt6 WT MEFs and 
R-Ras2 4KR in Sirt6 WT or KO MEFs. (b) Knockdown of R-Ras2 in Sirt6 KO MEFs 
decreased p-Akt Thr308, but not p-Akt Ser473, to a level similar to that in Sirt6 WT 
MEFs. Right histogram shows the quantification of bands on the western blot 
membrane. Values with error bars indicate mean ± s.d. of three biological replicates. * 
indicates p < 0.05. (c) Expressing SIRT6 WT or SIRT6 G60A in Sirt6 KO MEFs 
decreased p-Akt Thr308, but not p-Akt Ser473. Right histogram shows the 
quantification of bands on the western blot membrane. Values with error bars indicate 
mean ± s.d. of three biological replicates. * indicates p < 0.05. (d) R-Ras2 WT but not 
R-Ras2 4KR promoted cell proliferation in Sirt6 KO MEFs. Values with error bars 
indicate mean ± s.d. of three biological replicates. *** indicates p < 0.005. 
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In this study, we found that the defatty-acylase activity of SIRT6 is important for 
regulating cell proliferation. Using a proteomics approach, we identified a small 
GTPase, R-Ras2, as a defatty-acylation target of SIRT6. R-Ras2 has a higher lysine 
fatty-acylation level in Sirt6 KO MEFs than that in Sirt6 WT MEFs. Lysine fatty-
acylation targets R-Ras2 to the plasma membrane, facilitates its interaction with 
p110α, and activates the Akt signaling pathway. This is important for the proliferative 
phenotype of Sirt6 KO MEFs because when we knocked down R-Ras2 or decreased 
its lysine fatty-acylation in Sirt6 KO MEFs, the p-Akt Thr308 level and cell 
proliferation became similar to those in Sirt6 WT MEFs. 
Previously, the function of SIRT6 was mainly explained through transcriptional 
regulation, which typically occurs at the end of signal transduction pathways. Now we 
showed that SIRT6 can also function at the top of the signal transduction pathway by 
regulating a GTPase in the Ras family. SIRT6 is known to be a tumor suppressor and 
down-regulated in many different human cancers
5
. Our study suggests that Sirt6 KO 
increases lysine fatty-acylation of R-Ras2 and activates the PI3K-Akt pathway, 
leading to higher cell proliferation. Thus, the defatty-acylation and suppression of R-
Ras2 is a major contributor to the tumor suppressor role of SIRT6. 
For the Ras proteins that do not have palmitoylated cysteine (such as K-Ras4B), they 
are thought to use polybasic sequences for membrane targeting 
16,35
. Interestingly, in 
addition to palmitoylation on Cys199 and farnesylation on Cys201, R-Ras2 contains 
several lysine residues at the C-terminus (Lys192, 194, 196, 197). One question is, if 
these lysine residues also help to target R-Ras2 to membranes via electrostatics, why 
cells use lysine instead of arginine? Our study has shed lights onto this question and 
identified a novel regulatory mechanism for this family of proteins, which may help to 
develop new strategies to pharmacologically target R-Ras2 to treat human diseases. In 
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a recent paper, the lysine residues at the C-terminal of K-Ras4B have been shown to 
play important roles for phospholipid binding and K-Ras4B signal output
36
. The lysine 
to arginine mutant had distinct lipid binding capacity, suggesting that simple 
electrostatic interaction may not be the mechanism how polybasic sequences target to 
the membrane. It is possible that the lysine residues at the C-terminal of K-Ras4B are 
similarly regulated by fatty-acylation, which could explain the distinct lipid binding 
capacity of the lysine-to-arginine mutant. However, we could not completely rule out 
that the lysine residues at the C-terminal of R-Ras2 may also function in phospholipid 
binding and thus affect its signaling output, in addition to being regulated by lysine 
fatty-acylation and SIRT6. 
Many Ras family of small GTPases contain polybasic sequences at the C-termini. It is 
possible that lysine fatty-acylation also occur on these GTPases and regulate their 
localization and activities. If so, study how these GTPases are regulated by lysine 
fatty-acylation and whether sirtuins also serve as deacylases for these proteins is an 
ongoing direction in our laboratory. 
Our study also expands the biological significance of protein lysine fatty-acylation. 
Protein lysine fatty-acylation was first reported in 1992
37
. Since then, only a few 
proteins were known to have this modification and whether this PTM has important 
biological function or not was not known. We previously identified that lysine fatty 
ayclation regulates protein secretion (e.g. TNFα and ribosomal proteins)13,26. The 
finding that lysine fatty-acylation regulates the Ras family of proteins suggest that this 
PTM may have very broad and important biological functions. 
 
Methods 
Reagents. Anti-FLAG affinity gel (#A2220, RRID: AB_10063035) and anti-FLAG 
antibody conjugated with horseradish peroxidase (#A8592, RRID: AB_439702) were 
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purchased from Sigma. Human/mouse SIRT6 (#12486), p110α (#4249, RRID: 
AB_2165248), p-Akt Thr308 (#13038, RRID: AB_2629447), p-Akt Ser473 (#4060, 
RRID: AB_2315049), Akt (#4691, RRID: AB_915783), HSP90 (#4877, RRID: 
AB_2121214) and Na,K-ATPase (#3010, RRID: AB_2060983) antibodies were 
purchased from Cell Signaling Technology. β-Actin (sc-4777) and GAPDH (sc-
20357, RRID:AB_641107) antibodies were purchased from Santa Cruz 
Biotechnology. R-Ras2 antibody (#H00022800-M01, RRID:AB_547895) was 
purchased from Novus Biologicals. 
32
P-NAD
+
 was purchased from PerkinElmer.  3X 
FLAG peptide, Azide-PEG3-biotin, Tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (TBTA), Tris(2-carboxyethyl)phosphine (TCEP), hydroxylamine, 
NAD
+
, and protease inhibitor cocktail were purchased from Sigma. Sequencing grade 
modified trypsin and FuGene 6 transfection reagent were purchased from Promega. 
ECL plus western blotting detection reagent and Streptavidin agarose beads were 
purchased from Thermo Scientific Pierce. Sep-Pak C18 cartridge and polyester-
backed silica plate were purchased from Waters. 520-BODIPY azide was purchased 
from Active Motif. Ras assay kit (Raf-1 RBD, agarose) was purchased from EMD 
Millipore. R-Ras2 and SIRT6 shRNA lentiviral plasmids (pLKO.1-puro vector) were 
purchased from Sigma, the sequence of shRNA was: R-Ras2 shRNA#1: 
TRCN0000306170 (ccggtaagagtcccttgaggtttagctcgagctaaacctcaagggactcttatttttg); R-
Ras2 shRNA#2: TRCN0000077748 
(ccggcgctagatattgactgttatactcgagtataacagtcaatatctagcgtttttg); SIRT6 shRNA#1: 
TRCN0000378253 (ccggcagtacgtccgagacacagtcctcgaggactgtgctcggacgtactgtttttg); 
SIRT6 shRNA#2: TRCN0000232528 
(ccgggaagaatgtgccaagtgtaagctcgagcttacacttggcacattcttctttttg). Alk12 and Alk14 were 
synthesized according to reported procedures
27
. Plasmid of IpaJ in pET2-8b vector 
was a kind gift from Prof. Neal M. Alto at Department of Microbiology, University of 
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Texas Southwestern Medical Center. IpaJ was purified according to reported 
procedures
28
. 
Cell Culture. Sirt6 wild type (WT) and knockout (KO) MEFs were kindly provided 
by Prof. Raul Mostoslavsky at Massachusetts General Hospital Cancer Center, 
Harvard Medical School, which were prepared and authenticated by the authors as 
described previously
5
. Human Embryonic Kidney (HEK) 293T cells were purchased 
from ATCC (RRID: CVCL_0063). All the cell lines have been tested for mycoplasma 
contamination by PCR-based mycoplasma detection kit (Sigma, MP0025) and showed 
no contamination. Sirt6 WT, Sirt6 KO MEFs and Sirt6 KO MEFs expressing SIRT6 
WT, G60A or H133Y were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
with 10% fetal bovine serum (FBS). HEK 293T cells were cultured in DMEM 
medium with 10% FBS. 
Cloning, expression and purification of SIRT6 WT, G60A and H133Y from 
Escherichia coli (E. coli). Human SIRT6 was inserted into pET-28a vector. SIRT6 
G60A and H133Y mutants were made by QuikChange. The plasmids of SIRT6 WT 
and mutants were transformed into E. coli BL21 (DE3) cells. The proteins were 
purified according to reported procedures
13
. 
Cloning, expression and purification of R-Ras2 WT and 4KR from Sirt6 KO 
MEFs and HEK 293T cells. Human R-Ras2 was inserted into lentiviral vector 
(pCDH-CMV-MCS-EF1-Puro) with N-FLAG tag. R-Ras2 4KR mutant was made by 
QuikChange. R-Ras2 lentivirus was generated by co-transfection of R-Ras2, pCMV-
dR8.2, and pMD2.G into HEK 293T cells. After transfection for 48 h, the medium was 
collected and used for infecting Sirt6 KO MEFs or HEK 293T cells. To obtain the R-
Ras2 stable overexpressed cells, the cells were treated by 1.5 mg/mL of puromycin 48 
h after infection and cultured for 1 week while passing cells every 2-3 days. To purify 
R-Ras2 from Sirt6 KO MEFs or HEK 293T cells, the cells were collected at 500 g for 
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5 min and then lysed in Nonidet P-40 lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM 
NaCl, 10% glycerol and 1 % Nonidet P-40) with protease inhibitor cocktail (1:100 
dilution). Anti-FLAG affinity gel was used to enrich the R-Ras2 protein from total cell 
lysates. Then R-Ras2 was eluted and purified by 3X FLAG peptide following the 
manual. 
Stable overexpression of SIRT6 WT, G60A or H133Y in Sirt6 KO MEFs. Human 
SIRT6 WT was inserted into pCDH-CMV-MCS-EF1-Puro vector without tag. SIRT6 
G60A and H133Y mutants were made by QuikChange. SIRT6 lentivirus was 
generated by co-transfection of SIRT6, pCMV-dR8.2, and pMD2.G into HEK 293T 
cells. After transfection for 48 h, the medium was collected and used for infecting 
Sirt6 KO MEFs. Sirt6 KO MEFs with stable expressed SIRT6 WT, G60A or H133Y 
was selected by 1.5 mg/mL of puromycin. Empty pCDH vector was used as the 
negative control. 
Labeling of R-Ras2 in MEFs with Alk14 and detection of lysine fatty-acylation on 
R-Ras2 by in-gel fluorescence. R-Ras2 WT or 4KR was transfected into MEFs or 
HEK 293T cells by FuGene 6 transfection reagent. After 24 h, the cells were treated 
with 50 µM of Alk14 for 6 h. The cells were collected at 500 g for 5 min and then 
lysed in Nonidet P-40 lysis buffer (25 mM Tris-HCl pH 7.4, 150 mM NaCl, 10% 
glycerol, and 1 % Nonidet P-40) with protease inhibitor cocktail. The total lysate was 
incubated with anti-FLAG affinity gel at 4 ˚C for 1 h. The affinity gel was then 
washed three times by immunoprecipitation (IP) washing buffer (25 mM Tris-HCl pH 
7.4, 150 mM NaCl and 0.2% Nonidet P-40) and then re-suspended in 18 µL of IP 
washing buffer. The click chemistry reaction was performed by adding the following 
reagents: 520-BODIPY azide (0.8 µL of 1.5 mM solution in DMF), TBTA (1.2 µL of 
10 mM solution in DMF), CuSO4 (1 µL of 40 mM solution in H2O) and TCEP (1 µL 
of 40 mM solution in H2O). The reaction was allowed to proceed at room temperature 
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for 45 min. Then the SDS loading buffer was added and heated at 95 ˚C for 10 min. 
After centrifugation at 15,000 g for 2 min, the supernatant was collected and treated 
with 300 mM hydroxylamine at 95 ˚C for 7 min. The samples were resolved by 12% 
SDS-PAGE. In-gel fluorescence signal was recorded by Typhoon 9400 Variable Mode 
Imager (GE Healthcare Life Sciences). 
Detection of lysine fatty-acylation of endogenous R-Ras2 in MEFs. Sirt6 WT and 
KO MEFs were treated with 50 µM Alk14 for 6 h. Cells were collected and lysed by 
Nonidet P-40 lysis buffer using the same method descried above. The total lysates 
were subjected to click chemistry reaction by adding the following reagents: Azide-
PEG3-biotin (final concentration was 100 µM), TBTA (final concentration was 0.5 
mM), CuSO4 (final concentration was 1 mM) and TCEP (final concentration was 1 
mM). The reaction was allowed to proceed at room temperature for 45 min, and then 
the total proteins were precipitated by methanol/chloroform (2.5/1) and washed by ice-
cold methanol. The protein pellets were re-solubilized in 1.5% SDS, 1% Brij97, 100 
mM NaCl and 50 mM triethanolamine. Streptavidin agarose beads were added and 
incubated at room temperature for 1 h. After washing the beads three times by 0.2% 
SDS in PBS buffer, the beads were treated with 1 M hydroxylamine (pH 7.4) at room 
temperature for 1 h. Then the beads were washed three times with 0.2% SDS in PBS 
buffer. The SDS loading buffer was added to the beads, heated at 95 ˚C for 10 min, 
and then used for western blot. 
Defatty-acylation of R-Ras2 by SIRT6 in vitro. R-Ras2 WT was transfected into 
Sirt6 KO MEFs treated with 50 µM Alk14 for 6 h and purified using the method 
described above. The in vitro assay was proceeded in the assay buffer (50 mM Tris-
HCl pH 8.0, 100 mM NaCl, 2 mM MgCl2, 1 mM DTT, 1 mM NAD
+
) with 15 μM of 
SIRT6 and incubated at 37 °C for 2 h. Proteins were precipitated by 
methanol/chloroform (2.5/1) and washed by ice-cold methanol. The protein pellets 
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were re-solubilized in 4% SDS, 150 mM NaCl and 50 mM triethanolamine. Then click 
chemistry reaction and in-gel fluorescence were carried out as described above. 
32
P-NAD
+
 assay. R-Ras2 WT was transfected into Sirt6 KO MEFs and purified by 
FLAG affinity gel. Purified R-Ras2 on the FLAG affinity gel was used for 
32
P-NAD
+
 
assay. 10 μL of reaction buffer containing 50 mM Tris pH 8.0, 150 mM NaCl, 1 mM 
DTT, 5 μM SIRT6 WT or H133Y, and 0.1 μCi of 32P-NAD was mixed with R-Ras2 
protein. The reaction was allowed to proceed at 37 ˚C for 2 h. 2 μL of the reaction 
mixture was spotted onto the polyester-backed silica plate. The plate was developed in 
30:70 (v/v) 1 M ammonium bicarbonate/95% ethanol. Then the plate was exposed in 
the phosphor imaging screen (GE Healthcare) for 4 h. The signal was detected using 
Typhoon 9400 Variable Mode Imager. H3K9 myristoyl and H3K9 palmitoyl peptides 
were incubated with SIRT6 in the same reaction buffer as positive control for fatty-
acyl ADPR. H2BK12 acetyl peptide was incubated with SIRT1 in the same reaction 
buffer as positive control for acetyl ADPR. All the peptides were synthesized 
according to the reported procedures
38
. 
Western blot. The proteins were resolved by 12% SDS-PAGE and transferred to 
polyvinylidene fluoride (PVDF) membrane. The membrane was incubated with 5% 
bovine serum albumin (BSA) in TPBS buffer (0.1% Tween-20 in PBS solution) at 
room temperature for 60 min. Then the antibody was diluted with fresh 5% BSA in 
TPBS buffer and incubated with the membrane for different time points according to 
the manual. After washing three times by TPBS buffer, the secondary antibody was 
diluted with fresh 5% BSA in TPBS buffer and then incubated with the membrane at 
room temperature for 1 h. The chemiluminescence signal in membrane was recorded 
after developing in ECL plus western blotting detection reagents using Typhoon 9400 
Variable Mode Imager. 
Crystal violet cell proliferation assay. Cells were seeded in 12-well plates (5,000 
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cells/well) or 24-well plates (2,500 cells/well), and then maintained in DMEM 
medium with 10% FBS for 5 days. After washing twice with ice-cold PBS, cells were 
fixed by ice-cold methanol for 10 min. Then methanol was removed and crystal violet 
(0.2% in 2% ethanol solution) was added and incubated for 5 min. Cells were then 
washed with water until all excess dye was removed. Crystal violet dye that remained 
with the cells was solubilized by 0.5% SDS in 50% ethanol solution. The absorption 
of crystal violet was measured at 550 nm. 
SILAC. Sirt6 KO MEFs were cultured in DMEM medium with [
13
C6, 
15
N2]-L-lysine 
and [
13
C6, 
15
N4]-L-arginine for 5 generations. Sirt6 WT MEFs were cultured in normal 
DMEM medium for 5 generations. The cells were treated with 50 µM Alk12 or Alk14 
for 6 h. After quantifying the concentration of total proteins by Bradford assay, 2.5 mg 
of total proteins from each sample were mixed. IpaJ was added (final concentration 
was 150 µg/mL) and incubated with the total lysate at 30 ˚C for 1 h. The click 
chemistry reaction was then performed by adding the following reagents: Azide-
PEG3-biotin (final concentration was 100 µM), TBTA (final concentration was 0.5 
mM), CuSO4 (final concentration was 1 mM) and TCEP (final concentration was 1 
mM). The reaction was allowed to proceed at room temperature for 45 min, and then 
the total proteins were precipitated by methanol/chloroform (2.5/1) and washed by ice-
cold methanol. After re-solubilize the protein pellets in 1.5% SDS, 1% Brij97, 100 
mM NaCl and 50 mM triethanolamine, streptavidin agarose beads were added and 
incubated with the lysates at room temperature for 1 h. After washing the beads three 
times by 0.2% SDS in PBS buffer, the beads were treated with 0.5 M hydroxylamine 
(pH 7.4) at room temperature for 1 h. Then the beads were washed three times with 
0.2% SDS in PBS buffer. The beads were incubated with 6 M urea and 10 mM TCEP 
in PBS at 37 ˚C for 30 min, then 400 mM iodoacetamide was added and incubated 
with the beads at 37 ˚C for 30 min. After washing the beads with 2 M urea in PBS, the 
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beads were incubated with 2 µg trypsin in 2 M urea in PBS at 37 ˚C for 8 h. The 
digestion reaction was quenched with 0.1% trifluoroacetic acid and the mixture was 
desalted using a Sep-Pak C18 cartridge. The lyophilized peptides were used for nano 
LC-MS/MS analysis. LC-MS/MS analysis was performed using LTQ-Orbitrap Elite 
mass spectrometer. The lyophilized peptides were dissolved in 2% acetonitrile 
containing 0.5% formic acid. The Orbitrap was interfaced with a Dionex 
UltiMate3000 MDLC system. The peptide samples were injected onto C18 RP nano 
column (5 µm, 75 µm50 cm, Magic C18, Bruker) at a flow rate of 0.3 µL/min. The 
gradient for HPLC condition was 5-38% acetonitrile containing 0.1% formic acid in 
120 min. The Orbitrap Elite was operated in positive ion mode with spray voltage 1.6 
kV and source temperature 275 ˚C. Data-dependent acquisition (DDA) mode was used 
by one precursor ions MS survey scan from m/z 300 to 1800 at resolution 60,000 
using FT mass analyzer, followed by up to 10 MS/MS scans at resolution 15,000 on 
10 most intensive peaks. All data were acquired in Xcalibur 2.2 operation software. 
Detection of lysine fatty-acylation on R-Ras2 by mass spectrometry. Sirt6 KO 
MEFs stably expressing FLAG R-Ras2 were used for detecting lysine fatty-acylation 
on R-Ras2. Cells were treated with 50 µM Alk14 for 6 h, collected and lysed by 
Nonidet P-40 lysis buffer using the same method described above. 40 mg of total 
protein lysates were used for FLAG IP. After washing the FLAG resin three times 
with IP washing buffer, R-Ras2 protein was eluted by heating at 95 ºC for 10 min in 
buffer containing 1% SDS and 50 mM Tris-HCl pH 8.0. The supernatant was treated 
with 300 mM NH2OH pH 7.4 at 95 ºC for 10 min. R-Ras2 protein was then 
precipitated by methanol/chloroform and processed for disulfide reduction, 
denaturing, alkylation and neutralization using the same method described above. The 
processed R-Ras2 protein was digested with 1.5 µg of trypsin in a glass vial at 37˚C 
for 2 h, and then desalted using Sep-Pak C18 cartridge. For the LC-MS/MS analysis of 
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lysine fatty-acylated peptides, the same settings as SILAC experiment was applied 
except the LC gradient, which was 5-95% ACN with 0.1% trifluoroacetic acid from 0-
140 min. All data were acquired in Xcalibur 2.2 operation software. 
RNA extraction, reverse transcription and PCR analysis of mRNA levels. Total 
RNAs were extracted using RNeasy Mini kit (QIAGEN). Reverse transcription was 
performed using SuperScript III First-Strand Synthesis kit (Invitrogen). PCR 
amplification was performed using Herculase II Fusion Enzyme with dNTPs Combo 
kit (Agilent). 
R-Ras2 localization by subcellular fractionation and confocal imaging. 
Subcellular fractionation and confocal imaging were performed according to reported 
procedures
39
. Confocal imaging was performed on a Zeiss LSM880 
confocal/multiphoton microscope. 
Statistical Analysis. Data were expressed as mean ± s.d. (standard deviation, shown 
as error bars). Differences were examined by two-tailed Student‟s t-test between two 
groups; *p < 0.05, **p < 0.01, ***p < 0.005. 
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CHAPTER 4 
GLOBAL MAP OF KRAS4A AND KRAS4B INTERACTING 
PROTEINS 
 
Abstract 
Ras proteins are tumor drivers and play pivotal roles in numerous biological processes. 
KRAS mutant is the most prevalent mutant oncogene in different types of cancer. It 
has two alternatively spliced gene products which are translated into two proteins, 
KRas4a and KRas4b. Currently, the shared and unique signaling pathways and 
biological functions of the two KRas proteins are poorly understood. Here we report 
the nucleotide-dependent interaction map of KRas4a and KRas4b to understand the 
signaling pathways regulated by KRas4a and KRas4b. In addition to known 
interacting proteins, we identified many previously unknown KRas4a and KRas4b 
interacting proteins that belong to diverse functional classes. We found that some 
proteins interact with both isoforms while others prefer one of the two isoforms. For 
example, v-ATPase a2 and eIF2Bδ interact with only KRas4b. Biochemical studies 
suggested that KRas4b C-terminal hypervariable region (HVR) determines the binding 
specificity. By comparing WT and G12D mutant of KRas, we were also able to 
examine the difference in the effector proteins of the two KRas isoforms. 
Interestingly, we found that KRas4a has a stronger RAF1 interaction than KRas4b. 
Correspondingly, KRas4a can better promote ERK phosphorylation and anchorage-
independent cell growth of NIH 3T3 cells than KRas4b. In addition, we identified 
mTOR as a novel KRas4a/b interacting protein. KRas4a/b forms a new mTOR 
complex without raptor and rictor in cells. The KRas4a and KRas4b interactome data 
from this study thus represents a useful resource to understand the functional 
differences between KRas4a and KRas4b and to discover the new biological functions 
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for them. As the Ras superfamily of small GTPases contain more than 150 members 
that function similarly to KRas, the interactome approach described here represents a 
powerful method that can be used to understand the functions of these small GTPases 
and to discover previously unknown functions of these GTPases. 
 
Introduction 
The Ras superfamily of small GTPases consists of more than 150 members and plays 
important roles in numerous biological processes such as signal transduction, 
membrane trafficking, nuclear export/import, and cytoskeletal dynamics
1
. Among all 
these members, four Ras proteins (HRas, NRas, KRas4a, and KRas4b) encoded by 
three RAS genes (HRAS, NRAS, and KRAS) attract attention because their 
deregulation is frequently found in various human cancers
2
. It is well established that 
mutant Ras proteins are cancer drivers
3
. Ras proteins are active in GTP-bound state 
and inactive in GDP-bound state. Guanine nucleotide exchange factors (GEFs) and 
GTPase-activating proteins (GAPs) are two types of proteins that regulate the GTP 
and GDP exchange on Ras proteins
4
. GEFs facilitate the formation of GTP-bound Ras, 
while GAPs activate Ras intrinsic GTP hydrolysis and promote the formation of GDP-
bound Ras. GTP loading on Ras protein induces a conformational change in switch I 
region, which allows the recruitment of effector proteins, therefor turning on Ras 
signaling
5
. Four Ras proteins share high sequence identities in their conserved domain 
(residues 1-165), which include nucleotide and effector binding regions. Ras proteins 
also have C-terminal hypervariable region (HVR), which have low sequence 
identities. The C-terminal HVR plays important roles in membrane targeting, protein-
protein interaction, as well as signal transduction
6
. Different Ras proteins share many 
effector proteins, such as RAF1, RalGDS, PI3K, and PLCε5, and were originally 
thought to have similar biological functions. However, accumulating evidence has 
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shown that different Ras proteins exhibit different signaling and biological functions. 
For example, HRas, NRas, and KRas exhibit different leukemogenic potentials in 
mice
7
. KRas but not HRas can translocate from the plasma membrane (PM) to the 
Golgi complex and early/recycling endosomes in a Ca
2+
/calmodulin dependent 
manner
8
. The different functions of Ras proteins suggest that they may recruit 
different proteins that determine the signaling outputs, or bind to the same effector 
protein with different affinities which could also lead to different signaling outputs. 
Even KRas4a and KRas4b, two alternatively spliced products from KRAS gene, were 
shown to have different subcellular localizations and biological functions
9,10
. 
However, the molecular basis for the different signaling functions of different Ras 
proteins, especially the two KRas isoforms, is poorly understood. 
mTOR is a central energy regulator in mammals, which forms functional complex in 
cells. Currently, there are two well established mTOR complexes: mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2), depending on whether mTOR interacts 
with raptor (to form mTORC1) or rictor (to form mTORC2)
11
. Both mTOR complexes 
interact with another essential component mLST8 (also known as GβL)11. Recently, 
ubiquitination of mLST8 has been show to regulate the balance between mTORC1 
and mTORC2
12
. Crystal (PDB: 4JSN) and cryo-EM (PDB: 5FLC) structures of mTOR 
provide molecular basis of how mTOR interacts with raptor and mLST8 in 
mTORC1
13,14
. mTORC1 and mTORC2 activate different signalings and therefore 
regulate different cellular functions. mTORC1 senses amino acids and functions in 
translation, autophagy, and transcription regulation
11
. Localization to the lysosome is 
essential for mTORC1 activation
15
. The GTPases RagA/C heterodimer has been 
shown to regulate the lysosome localization of mTORC1
15
. Recent studies identified 
CASTOR as the arginine sensor
16
 and Sestrin2 as the leucine sensor
17
 that integrate 
cellular arginine and leucine status to GATOR1, the GAP of RagA/C
18
, therefore 
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regulating mTORC1-mediated amino acids sensing. Active mTORC1 phosphorylates 
two key proteins S6K and 4E-BP1, and promotes global protein synthesis
19,20
. Another 
important substrate of mTORC1 is ULK1, mTOR prevents autophagy by 
phosphorylating ULK1
21
. Rapamycin is a frequently used mTORC1 inhibitor. It binds 
to FKBP12, then the rapamycin-FKBP12 complex serves as an allosteric inhibitor to 
disrupt mTORC1 assembly
14
. mTORC2 is mainly regulated by growth factors and is 
not affected by rapamycin (rapamycin-FKBP12 does not bind to mTORC2). 
Compared with mTORC1, mTORC2 is less studied, especially how it is regulated in 
cells. The currently identified mTORC2 substrates include Akt
22
, PKC
23
 and SGK
24
. 
The interactome of a protein of interest can provide important functional clues for that 
protein, thereby facilitating the discoveries of new functions for the protein. This is 
especially important for proteins whose functions mainly rely on recruiting other 
proteins, such as the Ras proteins. Currently, the most well established protein 
interactome database is BioPlex 2.0, which includes interactome data for almost half 
of the human proteome
25
. However, for each single protein, only the most abundant 
and high-confident interacting proteins are present in the database. For example, we 
searched KRas interacting proteins in BioPlex 2.0 and only found RIN1 and BRAF 
(http://bioplex.hms.harvard.edu), two known Ras interacting proteins
26,27
. No 
additional information is available for KRas in the interactome database, and the 
number of KRas interacting proteins is far fewer than the number of known KRas 
interacting proteins. Moreover, a lot of protein-protein interactions are protein state 
dependent. For example, Ras-effector interaction is dependent on the nucleotide 
binding state. Knowing the state-dependent interactome is thus important for 
understanding protein functions. Such state-dependent protein-protein interaction 
information is not available in the reported interactome database. In this study, we 
report the state-dependent interaction map of the two KRas isoforms, KRas4a and 
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KRas4b, acquired using stable isotope labeling with amino acids in cell culture 
(SILAC) and affinity-purification mass spectrometry (AP-MS). These interactions not 
only can explain some of the functional differences between KRas4a and KRas4b, but 
can also facilitate the discovery of new signaling functions of the two KRas isoforms. 
 
Results and discussion 
Identify KRas4a and 4b interacting proteins in HEK293T cells by SILAC and 
AP-MS 
We utilized SILAC and AP-MS to construct the interactome network of FLAG-tagged 
wild-type (WT) and constitutively active Gly12Asp mutant (G12D) of KRas4a and 4b. 
It has been shown that most WT KRas is in the GDP-bound state in cells (~93%)
28
. In 
contrast, mutation of KRas Gly12 to any other amino acids except proline blocks GAP 
arginine finger assisted GTP hydrolysis, leading to most mutant KRas bound to 
GTP
29
. It has been shown that different Gly12 mutants have different GTP-loading 
percentages. We chose G12D mutant for the interactome study because KRas G12D 
has been found as the most abundant mutation in many types of cancer, such as 
pancreatic ductal adenocarcinoma (PDAC) and colon and rectal carcinoma (CRC)
2
. 
Comparing the interactome of KRas4a/b WT and G12D mutant may reveal KRas4a/b 
GTP- or GDP-bound state dependent interacting proteins. The usage of SILAC will 
help rule out the unspecific interacting proteins and efficiently reduce the false 
positives, which is a common problem for AP-MS based interactome studies. We 
transiently transfected tag-free KRas4a/b WT or G12D into „light‟ HEK293T cells, 
and FLAG-tagged KRas4a/b WT or G12D into „heavy‟ HEK293T cells (Figure 4.1a). 
Each FLAG-tagged protein had similar expression level, which was reflected by 
similar peptide number (KRas4a WT: 21, KRas4a G12D: 21, KRas4b WT: 22, 
KRas4b G12D: 24) and sequence coverage (KRas4a WT: 75%, KRas4a G12D: 75%, 
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KRas4b WT: 83%, KRas4b G12D: 83%) in MS. To enhance the data reliability and 
reduce false positive hits, we performed reverse SILAC in parallel, in which the 
„heavy‟ and „light‟ samples were swapped. We plotted KRas4a/b interacting proteins 
(with ≥2 unique peptides identified) against their heavy/light ratios in both forward 
and reverse SILAC to get the overall interacting proteins (Figure 4.1b). We set 
heavy/light >1.5 in forward SILAC and heavy/light <0.67 in reverse SILAC as the 
filter criteria (50% more proteins enriched in FLAG-tagged protein than tag-free 
protein) to obtain a list of confident KRas4a/b WT and G12D interacting proteins. 
Over 85% of proteins from original mass spectrometry result list were ruled out, 
leaving comparable numbers of interacting proteins for each KRas protein (KRas4a 
WT: 103 proteins, KRas4a G12D: 96 proteins, KRas4b WT: 94 proteins, KRas4b 
G12D: 110 proteins, Figure 4.1c, d). By comparing with previously published 
proteomics data of global protein expression levels in HEK293T cells
30
, our data 
suggested that KRas4a/b interacting proteins spanned a broad range in abundance 
across the HEK293T proteome (Figure 4.1e). Many known KRas4a/b interacting 
proteins were identified (Figure 4.1f), suggesting the reliability of the dataset. Some 
proteins are present in only one but not the other SILAC (either forward or reverse), or 
have low peptide number, which might be due to low protein expression levels. They 
may still be KRas4a/b interacting proteins. Therefore, we also considered these 
proteins as potential KRas4a/b interacting proteins and subjected them for biochemical 
validation if they have interesting functional implications. 
For each KRas isoform, comparison of WT and G12D indicated that more than half of 
interacting proteins were shared (Figure 4.1g), suggesting that GTP/GDP exchange on 
KRas affected some but not the majority of interacting protein profile. Among 
interacting proteins that were not shared between WT and G12D, we found many 
known KRas4a/b effector proteins that only interacted with G12D, such as ARAF and 
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BRAF (Figure 4.1f). This indicated that by comparing WT and G12D interactome, we 
may identify new KRas4a/b effector proteins. Comparison of different KRas isoforms 
(KRas4a versus KRas4b, or KRas4a G12D versus KRas4b G12D) suggested that more 
than half of interacting proteins were isoform specific (Figure 4.1g). We combined 
WT and G12D interactome for each KRas isoform and analyzed their biological 
processes. We found many shared biological processes such as nucleotide-binding and 
alternative splicing (Figure 4.1h). Some biological processes showed KRas isoform 
specificity. For example, KRas4a is involved in mitosis, DNA damage, and ion 
transport, while KRas4b is involved in neurodegeneration, mRNA transport, lipid 
metabolism, and protein biosynthesis (Figure 4.1h). 
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Figure 4.1. Identify KRas4a and 4b interacting proteins in HEK293T cells by SILAC 
and AP-MS. (a) Scheme showing identification of KRas4a/b interacting proteins in 
HEK293T cells by SILAC and AP-MS. (b) Plotting KRas4a/b interacting proteins 
(with ≥2 peptides) against their heavy/light ratios. (c) Nonspecific versus confident 
interacting proteins of KRas4a/b WT/G12D in HEK293T cells. (d) Heatmap showing 
the heavy/light ratios of KRas4a/b WT/G12D interacting proteins in HEK293T cells. 
(e) iBAQ values (from HEK293T cells) showing the abundance distribution of 
KRas4a/b WT/G12D interacting proteins. (f) Heavy/light ratio and peptide number 
(within brackets) of known KRas4a/b interacting proteins. (g) Venn diagram showing 
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the numbers of shared and unique interacting proteins of KRas4a/b WT/G12D in 
HEK293T cells. (h) Biological process analysis of KRas4a and KRas4b interacting 
proteins. Categories were assigned based on DAVID analysis UP_KEYWORDS. 
 
We noticed that some proteins only interacted with one KRas isoform. KRas4a and 4b 
are alternatively spliced isoforms, their conserved domains are 99% identical (residues 
1-150 are 100% identical), but their C-terminal HVR are highly diverse. Hence, we 
hypothesized that for any proteins that show KRas4a/b interaction specificity, the C-
terminal HVR should contribute to the interaction. We chose two proteins for 
validation. The first protein is v-ATPase a2, which only interacted with KRas4b but 
not KRas4a (Figure 4.2a). We transfected FLAG-tagged KRas4a and 4b into 
HEK293T cells. Immunoprecipitation of FLAG-tagged KRas4b, but not KRas4a, 
pulled out endogenous v-ATPase a2 (Figure 4.2b). We also found that FLAG-tagged 
HRas did not interact with endogenous v-ATPase a2 (Figure 4.2c). To confirm 
whether KRas4b C-terminal HVR contributed to the interaction, we made FLAG-
tagged HRas-KRas4a/b chimeric protein constructs by adding KRas4a/b C-terminal 
HVR (residues 165-189 on KRas4a and residues 165-188 on KRas4b) after the HRas 
conserved domain (residues 1-164) (Figure 4.2c). We transfected FLAG-tagged HRas 
(1-164)-KRas4a (165-189) and HRas (1-164)-KRas4b (165-188) into HEK293T cells. 
Immunoprecipitation of FLAG-tagged HRas (1-164)-KRas4b (165-188), but not 
FLAG-tagged HRas (1-164)-KRas4a (165-189), pulled out endogenous v-ATPase a2 
to the similar level as FLAG-tagged KRas4b did (Figure 4.2c), suggesting that 
KRas4b C-terminal HVR accounted for specific binding to v-ATPase a2. The unique 
KRas4b-v-ATPase a2 interaction suggested that v-ATPase a2 is unlikely a KRas4b 
effector protein. We then confirmed this by examining the interactions between v-
ATPase a2 and KRas4a G12D (constitutively active, always binds to effector protein) 
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or S17N (dominant negative, cannot bind to effector protein)
31
. KRas4b G12D and 
S17N showed comparable v-ATPase a2 interactions (Figure 4.2d), suggesting that v-
ATPase a2 is not the effector protein of KRas4b. The other protein we chose for 
validation is eukaryotic initiation factor 2B subunit δ (eIF2Bδ), which only interacted 
with KRas4b but not KRas4a (Figure 4.2e). Co-immunoprecipitation (Co-IP) 
confirmed that endogenous eIF2Bδ interacted with FLAG-tagged KRas4b but not 
KRas4a in HEK293T cells (Figure 4.2f). Furthermore, immunoprecipitation of 
FLAG-tagged HRas (1-164)-KRas4b (165-188), but not FLAG-tagged HRas (1-164)-
KRas4a (165-189), pulled out endogenous eIF2Bδ to the similar level as FLAG-
tagged KRas4b did (Figure 4.2g), suggesting that KRas4b C-terminal HVR 
contributed to the interaction with eIF2Bδ. Similar as v-ATPase a2, the eIF2Bδ-
KRas4b interaction was not dependent on KRas4b nucleotide binding state because in 
HEK293T cells, both KRas4b G12D and S17N showed comparable eIF2Bδ 
interactions (Figure 4.2h). 
These previously unknown KRas4a/b interacting proteins uncovered by our 
interactome data may facilitate the discovery of new KRas4a/b functions. For 
example, v-ATPase is known to localize on the surface of lysosome membrane
32
. The 
interaction between KRas4b and v-ATPase indicated that KRas4b may also localize 
on the lysosome. Although KRas4b is reported to mainly localize on the plasma 
membrane, our study suggested that KRas4b may localize on the lysosome and 
participate in v-ATPase related functions. eIF2B is the GEF of eIF2α and plays pivotal 
roles in translation initiation
33. It consists of five subunits (eIF2Bα, eIF2Bβ, eIF2Bγ, 
eIF2Bδ, and eIF2Bε)34. Indeed, all the other four eIF2B subunits were identified as 
KRas4b specific interacting proteins (Figure 4.2i), suggesting that KRas4b may 
regulate translation initiation by interacting with eIF2B. 
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Figure 4.2. KRas4b interacts with v-ATPase a2 and eIF2Bδ through its C-terminal 
HVR. (a) Heavy/light ratio of v-ATPase a2 in KRas4a/b SILAC and primary mass 
spectra of one v-ATPase a2 peptide (residues 638-650) in forward and reverse SILAC. 
(b) Immunoprecipitation of FLAG-tagged KRas4b, but not KRas4a, pulled out 
endogenous v-ATPase a2 in HEK293T cells. LAMP1 was used as a negative control. 
(c) Immunoprecipitation of FLAG-tagged HRas (1-164)+KRas4b (165-188), but not 
FLAG-tagged HRas (1-164)+KRas4a (165-189), pulled out endogenous v-ATPase a2 
as FLAG-tagged KRas4b did. (d) Immunoprecipitation of both FLAG-tagged KRas4b 
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G12D and S17N pulled out similar levels of endogenous v-ATPase a2. RAF1 was 
used as a positive control, which only interacted with KRas4b G12D but not S17N. (e) 
Heavy/light ratio of eIF2Bδ in KRas4a/b SILAC. (f) Immunoprecipitation of FLAG-
tagged KRas4b, but not KRas4a, pulled out endogenous eIF2Bδ in HEK293T cells. 
(g) Immunoprecipitation of FLAG-tagged HRas (1-164)+KRas4b (165-188), but not 
HRas (1-164)+KRas4a (165-189), pulled out endogenous eIF2Bδ as FLAG-tagged 
KRas4b did. (h) Immunoprecipitation of FLAG-tagged KRas4b WT, G12D and S17N 
pulled out similar levels of endogenous eIF2Bδ. (i) Heavy/light ratios of eIF2Bα, 
eIF2Bβ, eIF2Bγ and eIF2Bε in KRas4a/b SILAC. 
 
KRas4a has more RAF1 interaction than KRas4b in cells 
We next asked whether we could identify the KRas4a/b interacting proteins that 
contribute to the different biological functions of KRas4a and 4b. We found that 
RAF1, a well characterized Ras effector protein, had more peptide number and higher 
protein score in the KRas4a WT interactome than in the KRas4b WT interactome 
(Figure 4.1f, peptide number: 13 vs. 5, protein score: 42.7 vs. 16.6), suggesting that 
KRas4a had more RAF1 interaction than KRas4b. Moreover, RAF1 was identified in 
KRas4a WT reverse SILAC but not in KRas4b WT reverse SILAC, which was likely 
due to the low interaction abundance in the KRas4b WT sample. Although both 
KRas4a G12D and KRas4b G12D pulled out similar levels of RAF1 (Figure 4.1f), we 
reasoned that the high percentage of GTP-loading on overexpress KRas4a/b G12D 
may saturate RAF1 binding and obscure the difference in binding. We first validated 
KRas4a/b and RAF1 interaction in HEK293T cells. Immunoprecipitation of FLAG-
tagged KRas4a WT pulled out more endogenous RAF1 than FLAG-tagged KRas4b 
WT did (Figure 4.3a). We also included FLAG-tagged HRas and NRas in our co-IP 
experiment and found that KRas4a had the highest RAF1 interaction among four Ras 
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proteins (Figure 4.3a). Immunoprecipitation of FLAG-tagged KRas4a G12D and 
KRas4b G12D had comparable RAF1 interactions (Figure 4.3a), which is consistent 
with the SILAC result. To reduce the effect of saturated RAF1 binding on KRas4a/b 
G12D, we lowered KRas4a/b G12D expression levels by stably expressing them in 
NIH 3T3 cells. NIH 3T3 cells were also a better cell model and wildely used for 
studying Ras related cancer biology than HEK293T cells
35
. We selected the cells that 
expressed similar levels of endogenous and overexpressed Ras proteins (Figure 4.3b), 
to reduce the artifact caused by too much protein overexpression. We first examined 
KRas4a/b G12D and RAF1 interactions in NIH 3T3 cells. Immunoprecipitation of 
KRas4a G12D pulled out more RAF1 than KRas4b G12D and HRas G12D did 
(Figure 4.3c). The other two members of RAF family, ARAF and BRAF, showed 
comparable interactions with KRas4a G12D and KRas4b G12D (Figure 4.3c), 
suggesting that the increased RAF-KRas4a interaction was specific to RAF1. These 
different RAF1 interactions might be attributed to KRas4a and 4b C-terminal HVRs. 
To test this, we transfected FLAG-tagged HRas (1-164)-KRas4a (165-189) and HRas 
(1-164)-KRas4b (165-188) into HEK293T cells. Immunoprecipitation of FLAG-
tagged HRas (1-164)-KRas4a (165-189) pulled out more endogenous RAF1 than 
FLAG-tagged HRas (1-164)-KRas4b (165-188) did (Figure 4.3d). ARAF was 
included as a control and it showed similar bindings for these chimeric proteins 
(Figure 4.3d). This result suggested that besides switch I region, KRas4a C-terminal 
HVR also contributed to RAF1 binding, which led to increased KRas4a-RAF1 
interaction. In addition, we found that in KRas4a G12D expressed cells, ERK, a well-
established RAF kinase downstream protein
36
, had higher phosphorylation than that in 
KRas4b G12D or HRas G12D expressed cells (Figure 4.3e), suggesting that the 
increased KRas4a-RAF1 interaction also led to increased RAF-MEK-ERK signaling 
as expected. 
 119 
Next, we set out to look for different KRas4a and 4b related phenotypes that may 
potentially be attributed to different KRas4a/b-RAF1 bindings. As a tumor driver and 
the most common mutated gene in human cancer, KRAS plays crucial roles in 
tumorigenesis and tumor growth
37
. However, which KRas isoform plays more 
important roles remains a matter of debate
9
. Therefore, we employed two classical and 
widely used assays, anchorage-independent growth and anchorage-dependent growth, 
to evaluate the tumorigenesis and growth of KRas4a and 4b transformed cells. Both 
anchorage-independent and anchorage-dependent growths are integrated phenotypes 
that are attributed by different molecular signaling events but they are generally 
thought to be mainly regulated by RAF-MEK-ERK and PI3K-Akt-mTOR pathways
38
. 
Anchorage-dependent cell proliferation assay showed that KRas4a G12D and KRas4b 
G12D increased NIH 3T3 cell proliferation to similar extents (Figure 4.3f), suggesting 
that the differential KRas4a/b-RAF1 interaction was unlikely to contribute to the 
anchorage-dependent cell growth in this context. Indeed, we examined PI3K-Akt-
mTOR pathway which was also known as Ras effector pathway
39
, and found that 
HRas, KRas4a, and KRas4b activated this pathway similarly. All three Ras proteins 
increased p-Akt (Thr308), p-Akt (Ser473), p-S6K (Thr389) and p-4E-BP1 (Thr37,46) 
to similar extents (Figure 4.3g), suggesting that PI3K-Akt-mTOR pathway likely 
played more important role in anchorage-dependent cell growth in KRas4a/b 
transformed NIH 3T3 cells. On the other hand, anchorage-independent soft agar assay 
showed that KRas4a G12D expressed NIH 3T3 cells had significantly higher colony 
numbers than KRas4b G12D or HRas G12D expressed cells (Figure 4.3h). This result 
suggested that in KRas4a/b transformed NIH 3T3 cells, the differential KRas4a/b-
RAF1 interaction may contribute to differential anchorage-independent growth, and 
increased KRas4a-RAF1 may lead to improved tumorigenic capability (Figure 4.3i). 
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Figure 4.3. KRas4a has more RAF1 interaction than KRas4b in cells. (a) Detection of 
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interactions between endogenous RAF1 and FLAG-tagged WT and G12D HRas, 
NRas, KRas4a and KRas4b in HEK293T cells. (b) FLAG-tagged KRas4a/b G12D and 
endogenous Ras expression levels in NIH 3T3 cells. FLAG-tagged KRas4a/b had 
higher molecular weight and therefore produced band shift. (c) Immunoprecipitation 
of FLAG-tagged KRas4a G12D pulled out more endogenous RAF1, but not ARAF 
and BRAF, than FLAG-tagged HRas G12D and KRas4b G12D did in NIH 3T3 cells. 
(d) Immunoprecipitation of FLAG-tagged HRas(1-164)+KRas4a(165-189) pulled out 
more endogenous RAF1 than FLAG-tagged HRas(1-164)+KRas4b(165-188) did in 
HEK293T cells. (e) p-ERK (Thr202, Tyr204) and ERK levels in NIH 3T3 cells 
expressing pCDH vector, FLAG-tagged HRas G12D, KRas4a G12D, or KRas4b 
G12D. (f) Anchorage-dependent cell proliferation of NIH 3T3 cells expressing pCDH 
vector, FLAG-tagged HRas G12D, KRas4a G12D, or KRas4b G12D. (g) FLAG-
tagged HRas G12D, KRas4a G12D and KRas4b G12D increased several key players 
(p-Akt Thr308, p-Akt Ser473, p-S6K Thr389 and p-4E-BP1 Thr37,46) in PI3K-Akt-
mTOR pathway similarly in NIH 3T3 cells. (h) Anchorage-independent soft agar 
assay showing KRas4a G12D expressed NIH 3T3 cells had higher colony number 
than HRas G12D or KRas4b G12D expressed NIH 3T3 cells. (i) In NIH 3T3 cells, 
increased KRas4a-RAF1 interaction may contribute to increased anchorage-
independent cell growth. 
 
mTOR interacts with KRas4a and 4b 
We noticed that a serine/threonine-protein kinase mTOR was identified as a KRas4a 
and 4b interacting protein (Figure 4.4a) and decided to investigate this interaction 
further. mTOR is an essential energy regulator. Although KRas4a/b is known to 
activate mTOR through PI3K-Akt-mTOR and MAPK pathways
11,40
, currently no 
studies have shown a direct connection between KRas4a/b and mTOR. 
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We first set out to validate the KRas4a/b-mTOR interaction by transiently transfecting 
FLAG-tagged HRas, NRas, or KRas4a/b into HEK293T cells followed by FLAG 
immnuprecipitation. Immunoprecipitation of both FLAG-tagged KRas4a and 4b 
pulled out endogenous mTOR (Figure 4.4b). In contrast, HRas showed little mTOR 
interaction (Figure 4.4b). NRas had slightly increased mTOR interaction compared 
with HRas but the interaction was still much lower than KRas4a/b (Figure 4.4b), 
suggesting that mTOR interacts with KRas4a/b better than with HRas and NRas. We 
also transfected FLAG-tagged KRas4a/b in mouse cells (NIH 3T3 cells) and observed 
interactions between FLAG-tagged KRas4a/b and endogenous mouse mTOR (Figure 
4.4c). Alternatively, immunoprecipitation of endogenous mTOR pulled out FLAG-
tagged KRas4b in HEK293T cells (Figure 4.4d). We next examined if this interaction 
occurred on endogenous KRas4a/b and mTOR. We used HCT116 and HT29 cell lines 
since both cells express relatively high levels of KRas
9
. We tested several commercial 
KRas antibodies for immunoprecipitation but none of them efficiently pulled out 
endogenous KRas4a/b from the proteome, therefore we used a pan-Ras antibody 
(Y13-259) that had been shown to work well for endogenous KRas 
immnoprecipitation in many studies
41,42
. In both HCT116 and HT29 cells, 
immnoprecipitation of endogenous Ras pulled out endogenous mTOR (Figure 4.4e), 
suggesting that this interaction also occurred for endogenous KRas and mTOR. We 
then performed a KRas4a/b and mTOR in vitro binding assay. We transfected FLAG-
tagged KRas4a/b into HEK293T cells and purified KRas4a/b protein using anti-FLAG 
beads. Endogenous mTOR was purified by immunoprecipitating FLAG-tagged Raptor 
in 0.3% CHAPS lysis buffer followed by 1% NP40 lysis buffer elution (see Figure 
4.10 in Methods). Incubation of the purified mTOR with FLAG-tagged KRas4a/b on 
FLAG beads led to pull down of mTOR on FLAG beads (Figure 4.4f). 
Next we examined whether KRas4a/b and mTOR interaction depended on KRas4a/b 
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GTP or GDP bound state. Immunoprecipitation of WT, G12D, and S17N FLAG-
tagged KRas4a/b showed comparable mTOR interactions (Figure 4.4g), suggesting 
that the nucleotide binding state did not affect KRas4a/b-mTOR interaction. This 
result also suggested that the mTOR binding region of KRas4a/b was likely located 
away from switch I, which is the Ras effector binding region
43
. To further understand 
how KRas4a/b interacts with mTOR, we examined which domain of mTOR was 
important for the interaction. We transfected FLAG-tagged KRas4a/b and full-length 
or truncated (residues 1-1482, 1271-2008, or 1750-2549) Myc-tagged mTOR into 
HEK293T cells. Immunoprecipitation of full-length mTOR pulled out FLAG-tagged 
KRas4a/b, while truncated mTOR pulled out little KRas4a/b (Figure 4.4h), 
suggesting that the KRas4a/b-mTOR interaction requires the full length mTOR. 
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Figure 4.4. mTOR interacts with KRas4a and 4b. (a) Heavy/light ratio and peptide 
number of mTOR in KRas4a/b SILAC and primary mass spectra of one mTOR 
peptide (residues 1219-1235) in forward and reverse KRas4a WT SILAC. (b) 
Immunoprecipitation of FLAG-tagged KRas4a and 4b pulled out endogenous mTOR 
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in HEK293T cells. Right histogram shows the quantification of bands in western blot. 
Values with error bars indicate mean ± s.d. of three biological replicates. (c) 
Immunoprecipitation of FLAG-tagged KRas4a and 4b pulled out endogenous mTOR 
in NIH 3T3 cells. (d) Immunoprecipitation of endogenous mTOR pulled out 
overexpressed FLAG-tagged KRas4b in HEK293T cells. (e) Immunoprecipitation of 
endogenous RAS pulled out endogenous mTOR in both HCT116 and HT29 cells. (f) 
FLAG-tagged KRas4a and 4b interacts with mTOR in vitro. (g) Immunoprecipitation 
of WT, G12D and S17N of FLAG-tagged KRas4a and 4b pulled out similar levels of 
endogenous mTOR in HEK293T cells. RAF1 was used as a positive control, which 
only showed interaction with G12D KRas4a and 4b but not S17N KRas4a and 4b. (h) 
Immunoprecipitation of Myc-tagged full-length mTOR pulled out more FLAG-tagged 
KRas4a and 4b than Myc-mTOR-N (1-1482), Myc-mTOR-M (1271-2008), and Myc-
mTOR-C (1750-2549) did. 
 
To map the KRas4a/b and mTOR binding region, we used disuccinimidyl sulfoxide 
(DSSO) crosslinker combined with mass spectrometry to identify the crosslinked 
peptides from purified FLAG-tagged KRas4b G12D and mTOR protein. DSSO has 
been used to study protein-protein interaction because its C-S bonds can be cleaved 
during collision-induced dissociation (CID) or higher-energy collisional dissociation 
(HCD) (Figure 4.5a), generating signature ions from crosslinked peptide
44,45
. We 
identified one intermolecular crosslinked peptide with high confidence (mTOR2218-2224 
and KRas4b124-135) (Figure 4.5a). The identification of crosslinked peptide further 
supported that KRas4a/b interacts with mTOR directly. We noticed that near the 
crosslinked KRas4b lysine residue (Lys128), there were five amino acids that were not 
conserved between KRas4a/b and HRas (Figure 4.5b). Since HRas had little mTOR 
interaction (Figure 4.4b), we wondered if these five amino acids contributed to 
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KRas4a/b and mTOR interaction. We mutated these five amino acids on KRas4b to 
HRas sequence (M1: P121A+S122A, M2: E126D+S127T+R128K, M3: M1+M2, 
Figure 4.5c) and examined their interactions with mTOR. However, we did not 
observe abolished mTOR interaction (Figure 4.5c). Similar result was observed when 
we examined KRas4a M3 mutant-mTOR interaction (Figure 4.5c). We also mutated 
the five amino acids on HRas to KRas4a/b sequence (M3‟: A121P, A122S, D126E, 
T127S and K128R) but this again did not rescue the interaction with mTOR (Figure 
4.5d). These results suggested that although KRas4a/b Lys128 was close to mTOR 
Lys2218 upon binding (the distance is likely around 10 Å because the fully expanded 
DSSO spacer length is ~10 Å), they may not be indispensable for the interaction. 
Other regions on KRas4a/b may also be important for binding to mTOR, especially 
the C-terminal HVR whose sequence information was missing in cross-linking 
experiment due to its polylysine clusters (generating either multiple DSSO crosslinks 
on the same peptide or short single DSSO crosslinked peptide). We then examined if 
KRas4a/b C-terminal HVR was important for binding to mTOR. We transfected 
FLAG-tagged HRas (1-164)-KRas4a (165-189), HRas (1-164)-KRas4b (165-189), 
HRas, KRas4a, and KRas4b into HEK293T cells. Immunoprecipitation of FLAG-
tagged HRas (1-164)-KRas4a (165-189) and HRas (1-164)-KRas4b (165-189) pulled 
out similar amount of endogenous mTOR as FLAG-tagged KRas4a/b did (Figure 
4.5e), suggesting that KRas4a/b C-terminal HVR was important for binding to mTOR. 
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Figure 4.5. Identify KRas and mTOR binding region by DSSO crosslinker. (a) 
Specific fragmentation pattern of DSSO crosslinked interpeptide under CID. The 
signature MS precursor ion was then subjected to CID-HCD fragmentation for 
identifying the sequence from crosslinked interpeptide. (b) Sequence alignment 
between KRas4a/b (residues 119-140) and HRas (residues 119-140). (c) 
Immunoprecipitation of FLAG-tagged KRas4a/b WT, M1 (P121A,S122A), M2 
(E126D, S127T, R128K) and M3 (M1+M2) pulled out similar amounts of endogenous 
mTOR in HEK293T cells. (d) Immunoprecipitation of FLAG-tagged HRas4b WT, 
M1‟ (A121P,S122S), M2‟ (D126E, T127S, K128R) and M3‟ (M1‟+M2‟) did not pull 
out endogenous mTOR in HEK293T cells. (e) Immunoprecipitation of FLAG-tagged 
HRas (1-164)+KRas4a (165-189) and HRas (1-164)+KRas4b (165-188) pulled out 
similar levels of endogenous mTOR as FLAG-tagged KRas4a/b did. 
 
KRas forms a new mTOR complex in the absence of raptor and rictor 
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The next question we asked was whether KRas4a/b was present in mTORC1 or 
mTORC2. We first examined the proteomics data and found that mLST8, an essential 
component of both mTORC1 and mTORC2, was identified as KRas4a/b interacting 
protein (Figure 4.6a). We validated KRas4a/b and mLST8 interaction by co-IP. In 
both HEK293T and NIH 3T3 cells, immunoprecipitation of FLAG-tagged KRas4a/b 
pulled out endogenous mLST8 (Figure 4.6b and 4.7a). We further found that HRas 
did not interact with mLST8 (Figure 4.6c), and replacing the HVR of HRas with that 
of KRas4a/b fully rescued its interaction with mLST8 (Figure 4.6c), suggesting that 
mLST8 and mTOR had similar interaction patterns with KRas4a/b (see discussion in 
Figure 4.8). 
 
Figure 4.6. KRas4a/b interact with mLST8. (a) Heavy/light ratio and peptide number 
of mLST8 in KRas4a/b SILAC and primary mass spectra of one mLST8 peptide 
(residues 37-54) in forward and reverse SILAC. (b) Immunoprecipitation of FLAG-
tagged KRas4a and 4b pulled out endogenous mLST8 in NIH 3T3 cells. (c) 
Immunoprecipitation of FLAG-tagged HRas (1-164)+KRas4a (165-189) and HRas (1-
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164)+KRas4b (165-188) pulled out endogenous mLST8, similar to FLAG-tagged 
KRas4a and 4b. FLAG-tagged HRas did not pull out endogenous mLST8. 
 
We did not find raptor and rictor in our proteomics data. It is known that mTOR-raptor 
and mTOR-rictor interactions are sensitive to detergents such as NP40 and Triton 
X100
46,47
. When performing SILAC experiment, we used 1% NP40 buffer to lyse the 
cells, suggesting the absence of raptor and rictor could be due to the lysis method we 
used. We then used 0.3% CHAPS lysis buffer, which had been shown to maintain 
mTOR complexes
46,47
, to lyse the cells. To our surprise, neither raptor nor rictor was 
pulled out by FLAG-tagged KRas4a/b immunoprecipitation (Figure 4.7a). 
Alternatively, we transfected FLAG-tagged KRas4b into HEK293T cells. 
Immunoprecipitation of endogenous raptor or rictor pulled out endogenous mTOR but 
not FLAG-tagged KRas4b (Figure 4.7b). In contrast, endogenous mTOR 
immunoprecipitation pulled out endogenous raptor, rictor, and FLAG-tagged KRas4b 
(Figure 4.7b). This result suggested that KRas may form an mTOR complex without 
raptor or rictor. We noticed that the Western blot signals of endogenous raptor and 
rictor were not strong. The absence of KRas4a/b-raptor and KRas4a/b-rictor 
interactions may be due to low protein expression or low antibody sensitivity. To test 
this, we co-transfected FLAG-tagged raptor and tag-free KRas4a/b in HEK293T cells 
to obtain high protein expressions for both raptor and KRas4a/b (Figure 4.7c). 
Immunoprecipitation of raptor efficiently pulled out mTOR and mLST8, but not 
KRas4a/b (Figure 4.7c), again suggesting that KRas4a/b did not form complex with 
mTORC1. Similarly, co-transfection of Myc-tagged rictor and tag-free KRas4a/b 
followed by Myc-tag immunoprecipitation pulled out mTOR and mLST8, but not 
KRas4a/b (Figure 4.7d), suggesting that KRas4a/b did not interact with mTORC2. 
We also examined whether KRas4a/b and mTOR interaction was sensitive to 
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rapamycin, an allosteric mTORC1 inhibitor. The result suggested that rapamycin 
treatment did not affect KRas4a/b binding to mTOR (Figure 4.7e). The next question 
we asked was whether KRas4a/b changed mTOR kinase activity through this 
interaction. We purified mTOR protein in the absence of raptor and rictor (see Figure 
4.10 in Methods) and performed in vitro kinase activity assay using HA-tagged S6K 
as a substrate. Neither KRas4a nor 4b changed mTOR activity in vitro (Figure 4.7f), 
suggesting that KRas4a/b may not directly alter mTOR kinase activity. 
 
 
Figure 4.7. KRas4a/b and mTOR form a complex without of raptor and rictor. (a) 
Immunoprecipitation of FLAG-tagged KRas4a and 4b pulled out endogenous mTOR 
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and mLST8 but not raptor and rictor in HEK293T cells. (b) Immunoprecipitation of 
endogenous raptor and rictor did not pull out FLAG-tagged KRas4b in HEK293T 
cells. Immunoprecipitation of endogenous mTOR pulled out FLAG-tagged KRas, 
raptor and rictor. (c) Immunoprecipitation of FLAG-tagged raptor pulled out mTOR 
and mLST8, but not KRas4a and 4b in HEK293T cells. (d) Immunoprecipitation of 
Myc-tagged rictor pulled out mTOR and mLST8, but not KRas4a and 4b in HEK293T 
cells. (e) Rapamycin treatment did not affect KRas4a/b-mTOR interaction in 
HEK293T cells. The weaker KRas4b-mTOR interaction compared to the KRas4a-
mTOR interaction was likely due to lower KRas4b expression level (indicated by 
coomassie blue stain membrane). (f) mTOR in vitro kinase activity assay with or 
without KRas4a/b. Purified HA-tagged S6K was used as an mTOR substrate. 
 
We then proposed a KRas4a/b-mTOR interaction model using published cryo-EM 
structure of mTORC1 (PDB: 5FLC) and full-length crystal structure of KRas4b (PDB: 
5TAR). First, the cross-linking result suggested that the crosslinked KRas4b peptide 
(residues 124-135) was from its α4 helix, which is on the back side of KRas4b effector 
and nucleotide binding regions (P-loop, switch I and II). Given that KRas4a/b-mTOR 
interaction was nucleotide binding state-independent (Figure 4.4g), the KRas4b 
effector and nucleotide binding region may not participate in mTOR interaction and 
likely point away from the mTOR binding surface. Secondly, the crosslinked mTOR 
peptide (residues 2218-2224) was located away from mTOR catalytic loop (residues 
2335-2344) and activation loop (residues 2357-2380), suggesting that KRas4a/b-
mTOR interaction is unlikely to affect mTOR activation and catalysis, which was 
supported by mTOR in vitro kinase activity assay (Figure 4.7f). Our study suggested 
that the KRas4a/b-mTOR interaction was insensitive to rapamycin. Rapamycin is 
known to interact with FKBP12, and the rapamycin-FKBP12 complex binds to mTOR 
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FKBP-rapamycin-binding (FRB) domain, which is located near the mTOR active 
cleft
14
. This data further supported the model that that KRas4a/b may bind to a region 
on mTOR that is not involved in mTOR kinase activity. Based on above information, 
we docked KRas4b (PDB: 5TAR) onto mTOR (PDB: 5FLC). A large groove on 
mTOR serves as the binding pocket for KRas4b α4 helix (Figure 4.8), with KRas4b 
switch I and II exposed. The absence of raptor and rictor in KRas4a/b-mTOR complex 
suggested that KRas4a/b binding to mTOR may affect mTOR-raptor and mTOR-rictor 
interaction. It is known that raptor and rictor interact with mTOR HEAT repeats 
domain
11
. In mTOR-raptor cryo-EM structure, the raptor binding site is > 60 Å away 
from mTOR-KRas4b crosslinked lysine residue (Lys2218), which is longer than the 
diameter of correctly folded KRas4b conserved region (residues 1-165, < 40 Å). Since 
KRas4a/b C-terminal HVR is a flexible domain, which can extend ~ 33 Å from 
KRas4a/b conserved region, the full-length KRas4a/b may reach raptor binding region 
on mTOR through its C-terminal tail. Therefore, KRas4b C-terminal HVR likely 
pointed towards raptor binding site on mTOR (Figure 4.8). Our data suggested that 
KRas4a/b interacted with mLST8 through its C-terminal HVR (Figure 4.6c). Since 
mLST8 interacts with mTOR near the active cleft, mLST8 is likely an indirect 
interacting protein of KRas4a/b that is mediated by mTOR (Figure 4.8). Overall, the 
HEAT repeats domain and the rest of mTOR formed a clam-like structure that held 
KRas4b protein by interacting with both KRas4b C-terminal HVR and α4 helix. Our 
data suggested that none of mTOR truncates (1-1482, 1271-2008, and 1750-2549) 
showed comparable KRas4a/b interactions to full-length mTOR, which further 
confirmed the importance of whole mTOR structure. Mutation of several amino acids 
on or near the α4 helix of KRas4a/b did not abolish KRas4a/b-mTOR interaction 
(Figure 4.5c), but fusing KRas4a/b C-terminal HVR (165-188/9) on HRas conserved 
domain (1-164) gained the ability to interact with mTOR (Figure 4.5e). We reasoned 
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that KRas4a/b C-terminal HVR may form stronger mTOR interaction than α4 helix. 
One possibility was that KRas4a/b contained more charged residues in C-terminal 
HVR than HRas and NRas (HRas: 5, NRas: 5, KRas4a: 10, KRas4b: 13), these 
charged residues may form strong electrostatic interactions with mTOR on its HEAT 
repeats. 
 
 
Figure 4.8. A proposed KRas4b-mTOR interaction model. Full-length KRas4b (PDB: 
5TAR) was docked onto mTOR (PDB: 5FLC) in PyMOL. Red color indicated the 
crosslinked peptides from KRas4b and mTOR. 
 
In this study, we performed state-dependent KRas4a and KRas4b interactome study 
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and identified many previously unknown KRas4a and KRas4b interacting proteins. 
Comparison of KRas4a and KRas4b interactome also revealed many proteins that 
showed isoform selectivity, which may help understand the signaling and functional 
differences of KRas4a and KRas4b. Interestingly, KRas4a had higher RAF1 
interaction than KRas4b, which led to increased RAF1-MEK-ERK signaling cascade. 
This could contribute to more colonies formed in KRas4a transformed cells than in 
KRas4b transformed cell. Moreover, KRas4a and KRas4b interactome revealed 
mTOR as a KRas4a/b interacting protein. Interestingly, KRas4a/b forms an mTOR 
complex without raptor or rictor, indicating that KRas4a/b-mTOR complex may 
regulate a new pathway differently from mTORC1 and mTORC2. Indeed, we 
examined the effect of KRas4a/b on some well-studied mTORC1 and mTORC2 
substrates in NIH 3T3 cells and HEK293T cells, including S6K, 4E-BP1, ULK1, and 
Akt (Figure 4.9). Although overexpression of KRas4a and KRas4b increased the 
phosphorylations of S6K, 4E-BP1 and Akt, overexpression of HRas had the similar 
effect. Since HRas has negligible mTOR interaction compared with KRas4a/b (Figure 
4.4b, 4.5c and 4.5d), it is likely the increased phorphorylation by KRas4a/b is due to 
other signaling pathways shared by HRas. Therefore, the KRas4a/b-mTOR complex 
identified in this study may have a completely different signaling cascade from 
mTORC1 and mTORC2. 
We noticed that the KRas4a/b-mTOR interaction does not depend on KRas4a/b 
nucleotide-binding state (Figure 4.4g), suggesting that mTOR is unlikely a KRas4a/b 
effector protein. This also means the exposed KRas4a/b switch I is able to recruit 
another effector protein in KRas4a/b-mTOR complex. Identification of this effector 
protein may help uncover the function of KRas4a/b-mTOR complex. On the other 
hand, our data showed that KRas4a/b-mTOR binding site is away from mTOR active 
cleft (Figure 4.7e and 4.7f). This suggests that the purpose of KRas4a/b-mTOR 
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interaction is not to change mTOR activity directly. Instead, KRas4a/b in KRas4a/b-
mTOR complex is more likely an anchor protein to recruit mTOR to a specific region 
in cells, where mTOR phosphorylates its substrate. This is similar as mTORC1-
RagA/C-the role of RagA/C is to recruit mTORC1 to the lysosome but not change 
mTORC1 kinase activity. Investigation of where KRas4a/b-mTOR interaction occurs 
may help identify the substrate of KRas4a/b-mTOR complex and therefore illustrate 
its functional outputs. 
 
 
Figure 4.9. HRas, KRas4a and KRas4b increase the phosphorylation of some well-
studied mTORC1 and mTORC2 substrates to the similar extents. 
 
Methods 
Antibodies. LAMP1 (#9091), ERK (#4696), p-ERK Thr202,Tyr204 (#4370), Akt 
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(#4691), p-Akt Thr308 (#13038), p-Akr Ser473 (#4060), S6K (#9202), p-S6K Thr389 
(#9234), 4E-BP1 (#9644), p-4E-BP1 Thr37,46 (#2855), mTOR (#2983 for western 
blot, #2972 for immunoprecipitation), mLST8 (#3274), raptor (#2280), rictor (#2114 
for western blot, #5379 for immunoprecipitation), Myc-tag (#2278), HA-tag (#3724) 
antibodies were purchased from Cell Signaling Technology. ARAF (sc-408), BRAF 
(sc-166), RAF1 (sc-227), KRas (sc-30), β-Actin (sc-4777) antibodies were purchased 
Santa Cruz Biotechnology. eIF2Bδ (11332-1-AP) antibody was purchased from 
Proteintech. v-ATPase a2 (GTX111275) antibody was purchased from GeneTex. pan-
RAS (OP01) antibody was purchased from EMD Millipore. Anti-c-Myc agarose 
(#20168) and anti-HA agarose (26181) were purchased from ThermoFisher. Anti-
FLAG affinity gels (#A2220) and FLAG antibody (#A8592) were purchased from 
Sigma.  
Reagents. DSSO crosslinker was synthesized as described previously
45
. HA peptide, 
3X FLAG peptide, protease inhibitor cocktail, puromycin, crystal violet, [
13
C6, 
15
N2]-
L-lysine, [
13
C6, 
15
N4]-L-arginine, L-lysine, L-arginine were purchased from Sigma. 
Rapamycin was purchased from Cell Signaling Technology. FuGENE 6 transfection 
reagent and sequencing grade modified trypsin and were purchased from Promega. 
MEM non-essential amino acids and ECL plus western blotting detection reagent were 
purchased from ThermoFisher. Sep-Pak C18 cartridge was purchased from Waters. 
Cell culture. Human Embryonic Kidney (HEK) 293T cells were cultured in 
Dulbecco's Modified Eagle Medium (DMEM) medium (ThermoFisher) with 10% heat 
inactivated FBS (ThermoFisher). Mouse embryonic fibroblast NIH 3T3 cells were 
cultured in DMEM medium with 15% heat inactivated FBS and MEM non-essential 
amino acids. HCT116 cells and HT29 cells were cultured McCoy's 5A medium 
(ThermoFisher) with 10% heat inactivated FBS. All the cell lines have been tested for 
mycoplasma contamination and showed no mycoplasma contamination. 
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Cloning, transfection and transduction. Human HRAS, NRAS, KRAS4A and 
KRAS4B were inserted into pCMV5 and pCDH-CMV-MCS-EF1-Puro vectors with 
N-terminal FLAG tag. All mutants were generated by QuikChange site-directed 
mutagenesis. All transient transfections were performed using FuGENE 6 transfection 
reagent according to manufacturer‟s protocol. HRas G12D, KRas4a G12D and 
KRas4b G12D lentivirus were generated by co-transfection of HRas/KRas4a/KRas4b 
G12D, pCMV-dR8.2, and pMD2.G into HEK293T cells. To obtain the 
HRas/KRas4a/KRas4b G12D stably overexpressed NIH 3T3 cells, cells were treated 
with 2 mg/mL of puromycin 48 h after lentivirus infection. 
Co-immunoprecipitation. Cells were collected and lysed in 1% NP40 lysis buffer 
(1% NP40, 25 mM Tris-HCl pH 7.4, 150 mM NaCl and 10% glycerol) or 0.3% 
CHAPS lysis buffer (0.3% CHAPS, 40 mM HEPES pH 7.4, 150 mM NaCl and 2 mM 
EDTA) with protease inhibitor cocktail (1:100 dilution) on ice for 30 min. After 
centrifuging at 15,000 g for 10 min, supernatant (total lysates) was collected for 
FLAG, Myc, HA or endogenous protein immunoprecipitation following 
manufacturer‟s protocol. The affinity gel was washed three times with NP40 washing 
buffer (0.2% NP40, 25 mM Tris-HCl pH 7.4 and 150 mM NaCl) or 0.3% CHAPS 
lysis buffer. To detect the interacting proteins, the affinity gel was heated at 95 °C for 
10 min in 2X protein loading buffer, followed by western blot analysis. For SILAC, 
the affinity gel was heated at 95 °C for 10 min in 1% SDS elution buffer (1% SDS, 25 
mM Tris-HCl pH 7.4 and 150 mM NaCl), followed by methanol/chloroform protein 
precipitation. 
Western blot. Western blot analysis was performed according to previously published 
paper
48
. The proteins of interest were detected and visualized using the Typhoon FLA 
7000 (GE Healthcare). 
SILAC and nano LC-MS/MS analysis. „Heavy‟ HEK293T cells were cultured in 
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DMEM with [
13
C6, 
15
N2]-L-lysine, [
13
C6, 
15
N4]-L-arginine and 10% dialysed FBS for 5 
generations. „Light‟ HEK293T cells were cultured in DMEM with normal L-lysine, L-
arginine and 10% dialysed FBS for 5 generations. After transient transfection of 
desired plasmids, „heavy‟ and „light‟ cells were lysed in 1% NP40 lysis buffer 
separately according to the protocol described above separately. 8 mg input of each 
„heavy‟ and „light‟ total lysate was subjected for FLAG immunoprecipitation. After 
washing the affinity gel three times with NP40 washing buffer, „heavy‟ and „light‟ 
samples were mixed and washed two more times with NP40 washing buffer. To elute 
FLAG-tagged protein with its interacting proteins, the affinity gel was heated at 95 °C 
for 10 min in 1% SDS elution buffer (1% SDS, 25 mM Tris-HCl pH 7.4 and 150 mM 
NaCl), followed by methanol/chloroform protein precipitation. The protein pellets 
were denatured in 6 M urea, 10 mM DTT and 50 mM Tris-HCl pH 8.0 at room 
temperature for 1 h. The proteins were alkylated by incubating with 40 mM 
iodoacetamide at room temperature for 1 h. DTT was then added to stop alkylation at 
room temperature for 1 h. After diluting protein sample 7 times with 50 mM Tris-HCl 
pH 8.0 and 1 mM CaCl2, 1 μg of trypsin was added and incubated with the protein at 
37 °C for 18 h. 0.1 % trifluoroacetic acid was added to quench the trypsin digestion, 
followed by desalting using Sep-Pak C18 cartridge. The lyophilized peptide powders 
were collected for LC-MS/MS analysis (LTQ-Orbitrap Elite mass spectrometer 
coupled with nanoLC). The lyophilized peptide powders were dissolved in 2% 
acetonitrile (ACN) with 0.5% formic acid (FA). The reconstituted peptides were 
injected into Acclaim PepMap nano Viper C18 trap column (5 µm, 100 µm × 2 cm, 
Thermo Dionex) and separated in C18 RP nano column (5 µm, 75 µm × 50 cm, Magic 
C18, Bruker). The flow rate was set as 0.3 µL/min. The gradient was set as following: 
5-38% ACN with 0.1% FA (0-120 min), 38-95% ACN with 0.1% FA (120-127 min), 
95% ACN with 0.1% FA (127-135 min). Positive ion mode was used in LTQ-Orbitrap 
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Elite mass spectrometer (spray voltage 1.6 kV, source temperature 275 ˚C). The 
precursor ions scan from m/z 375 to 1800 at resolution 120,000 using FT mass 
analyzer. Collision-induced dissociation (CID) was used for MS/MS scan at resolution 
15,000 on 10 most intensive peaks, isolation width was set as 2.0 m/z and normalized 
collision energy was set as 35%. Xcalibur 2.2 operation software was used for 
collecting the data. The MS data was further processed using Sequest HT in Proteome 
Discoverer 1.4.1.14 (PD 1.4, Thermo Scientific). 
Purification of endogenous mTOR. HEK293T cells stably expressing FLAG-tagged 
raptor were lysed in 0.3% CHAPS lysis buffer with protease inhibitor cocktail. FLAG-
tagged raptor was immunoprecipitated and washed as described above. The affinity 
gel was incubated three times with 1% NP40 lysis buffer to elute endogenous mTOR 
from the affinity gel. 
 
Figure 4.10. Purification of endogenous mTOR from HEK 293T cells. WCL, whole 
cell lysates. S, supernatant. B, FLAG beads. 
 
Purification of FLAG-tagged KRas4a/b. HEK293T cells transiently expressing 
FLAG-tagged KRas4a/b were lysed in 1% NP40 lysis buffer with protease inhibitor 
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cocktail. FLAG-tagged KRas4a/b was immunoprecipiated and washed as described 
above. FLAG-tagged KRas4a/b was eluted by 3X FLAG peptide following 
manufacturer‟s protocol. 
Purification of HA-tagged S6K. HEK293T cells transiently expressing HA-tagged 
S6K were lysed in 1% NP40 lysis buffer with protease inhibitor cocktail. HA-tagged 
S6K was immunoprecipitated and washed as described above. HA-tagged S6K was 
eluted by HA peptide following manufacturer‟s protocol. 
Anchorage-dependent cell proliferation assay. NIH 3T3 cells stably expressing 
pCDH, HRas G12D, KRas4a G12D or KRas4b G12D were seeded into 12-well plate 
(200 cells/well). The medium was changed every 48 h. After 9 days of culture, the 
cells were washed with PBS and fixed with ice-cold methanol for 10 min. After 
removing the methanol, the cells were stained with crystal violet staining solution 
(0.2% in 2% ethanol) for 5 min. Then the cells were rinsed with water to remove extra 
crystal violet. The absorption of crystal violet was measured at 550 nm after 
solubilizing the stained cells with 0.5% SDS in 50% ethanol. 
Anchorage-independent soft agar assay. 1.5 mL of 0.6% base low-melting point 
agarose was added into 6-well plate. After the agarose was solidified, 5.0 × 10
3 
of NIH 
3T3 cells stably expressing pCDH, HRas G12D, KRas4a G12D or KRas4b G12D 
were mixed with 0.3% low-melting point agarose and plated into 6-well plate on top 
of the 0.6% base agarose layer. 150 μL of normal culture medium was added on top of 
the 0.3% low-melting point agarose. The medium was changed every 48 h. After 14 
days of culture, colonies were stained with crystal violet staining solution (0.1% in 
25% methanol) for 30 min. Then the cells were rinsed with 50% methanol to remove 
extra crystal violet. 
mTOR and KRas4a/b in vitro binding assay. Purified endogenouso mTOR was 
incubated with purified FLAG-tagged KRas4a/b (on-beads) at room temperature for 
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30min. The affinity gel was washed three times with NP40 washing buffer and another 
three times with high salt NP40 washing buffer (0.2% NP40, 25 mM Tris-HCl pH 7.4 
and 500 mM NaCl). The affinity gel was then heated at 95 °C for 10 min in 2X protein 
loading buffer, followed by western blot analysis. 
DSSO crosslinking. Purified FLAG-tagged KRas4b and endogenous mTOR were 
subjected for buffer exchange in PBS until the final concentration of Tris was lower 
than 20 μM. DSSO crosslinking reaction was performed by mixing mTOR, KRas4b 
and 2mM DSSO at room temperature for 1h. 25 mM Tris was added to quench the 
reaction. The crosslinked protein was precipitated by methanol/chloroform. The 
protein pellets were denatured, alkylated, neutralized, trypsinized, and then analyzed 
by LC-MS/MS according to the protocol described above. 
In vitro mTOR kinase activity assay. FLAG-tagged KRas4a/b and endogenous 
mTOR were purified as described above. In vitro mTOR kinase activity assay was 
performed as described previously
46
. 
Statistical analysis. Quantitative data were expressed as mean ± SD (standard 
deviation, represent by error bar). Differences were examined by two-tailed Student‟s 
t-test; *p < 0.05, **p < 0.01, ***p < 0.005. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
In my thesis work, I first investigated the functional contributions of different SIRT6 
enzymatic activities, especially the newly discovered lysine defatty-acylase activity. I 
found that SIRT6 defatty-acylase activity regulates protein secretion, protein sorting 
into the exosomes, and cell proliferation. Proteomics studies led to the identification of 
R-Ras2 as a SIRT6 defatty-acylation target that contributes to SIRT6‟s role as a tumor 
suppressor. I also investigated the novel signaling and biological functions of KRas4a 
and KRas4b by proteomics. This study led to the identification of many previously 
unknown KRas4a and KRas4b interacting proteins that could not only explain the 
functional differences between KRas4a and KRas4b, but also help to uncover new 
signaling functions of the two KRas isoforms. 
In Chapter 2, I described the discovery of the SIRT6 Gly60Ala mutant, which 
abolishes lysine deacetylase activity and maintains lysine defatty-acylase activity. This 
mutant could be used to differentiate the functional contributions of different SIRT6 
deacylase activities. Using this mutant, I found that SIRT6 defatty-acylase activity 
regulates the secretion of numerous proteins and the sorting of ribosomal proteins into 
the exosomes. However, the SIRT6 defatty-acylation target(s) that mediate these 
functions remain unclear. I initially hypothesized that SIRT6 may directly defatty-
acylate these secreted proteins and regulate their secretions, similar to the regulation of 
TNFα secretion1. However, I chose several proteins for validation and did not observe 
lysine fatty-acylation on these proteins, suggesting that this hypothesis is not true. 
Identification of SIRT6 defatty-acylation targets that contribute to these functions will 
uncover the missing molecular mechanisms. To do this, one approach is to directly 
identify SIRT6 defatty-acylation target(s) by proteomics as described in Chapter 3. 
However, none of the proteins from the high confident SIRT6 defatty-acylation targets 
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list has been implicated in protein secretion or vesicle trafficking (Figure 3.1c). One 
possibility is that the regulation of protein secretion is a novel function for these high 
confidence proteins. Another possibility is that the target(s) has low abundance and 
was not identified with high confidence. In any case, selection of proteins from the 
lysine fatty-acylation proteomics list for validation could be a useful direction to 
figure out the missing mechanisms. An alternative approach to address this question is 
conducting phenotypic screening (Figure 6.1). For example, I showed that the 
ribosomal proteins were sorted into the exosomes more efficiently in Sirt6 KO MEFs 
than in Sirt6 WT MEFs. To identify the proteins that cause this phenotype, one can 
conjugate a molecular barcode (eg. GFP) to a certain ribosomal protein. The GFP 
signal from the culture medium could be used as the readout to indicate the secretion 
status of this ribosomal protein. Then siRNA screening could be performed to identify 
which gene/protein is essential for this phenotype in Sirt6 KO MEFs but not in Sirt6 
WT MEFs. The identified genes/proteins could help establish the novel signaling 
cascade that regulates the sorting of ribosomal proteins into the exosomes and also 
uncover the potential SIRT6 defatty-acylation targets. 
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Figure 5.1. Identification of proteins that regulate the sorting of ribosomal proteins 
(RPs) into the exosomes by RNAi screening. 
 
In Chapter 3, I described the identification of R-Ras2 as a SIRT6 lysine defatty-
acylation target that contributes to SIRT6‟s tumor suppressor function. Interestingly, 
from the proteomics study where R-Ras2 is identified (Figure 3.1b), a few more 
metabolic enzymes were also identified as potential SIRT6 defatty-acylation targets 
(Figure 3.1c). Previous studies showed that SIRT6 regulates different metabolic 
processes such as glucose metabolism
2
 and lipid homeostasis
3
. One interesting future 
direction to investigate is whether SIRT6 regulates these metabolic enzymes via 
defatty-acylation. This may further uncover the mechanisms by which SIRT6 serves 
as a cell metabolism regulator. 
In Chapter 4, I described the KRas4a and KRas4b interactome study. KRas is a well-
known tumor driver and plays important roles in numerous biological processes. Most 
current studies about KRas are mainly focused on one isoform KRas4b. But 
accumulating evidence suggests that KRas4a is also an important player in 
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tumorigenesis and possibly other biological processes.
4
 To identify the shared and 
unique signaling pathways and biological functions of the two KRas isoforms, I 
performed state-dependent KRas4a and KRas4b interactome study. Some proteins 
were identified to specifically interact with only one isoform, such as v-ATPase a2 
(interact with KRas4b) and eIF2Bδ (interact with KRas4b), whiles others interact with 
both KRas4a and KRas4b, such as mTOR. I further demonstrated that KRas4a has 
higher RAF1 interaction than KRas4b, and the increased RAF1-KRas4a interaction 
may lead to increased anchorage-independent cell growth in KRas4a transformed 
cells. Lastly, from the interactome study, mTOR was identified as a KRas4a/b 
interacting protein, and KRas4a/b forms a new mTOR complex without raptor or 
rictor. 
The KRas4a and KRas4b interactome study reveals many previously unknown 
KRas4a and KRas4b interacting proteins that could play crucial roles in various 
biological processes. As mentioned earlier, v-ATPase a2 and eIF2Bδ were identified 
as KRas4b specific interacting proteins. These interactions were validated by co-
immunoprecipitation in my thesis work. It will be interesting to further investigate the 
functional outputs of these interactions. v-ATPase functions to pump protons from 
cytosol to the late endosome and lysosome, and is also an essential component in 
mTORC1-mediated amino acid sensing. It is known that KRas4b is mainly localized 
on the plasma membrane to activate its downstream signaling
5
. The interactome study 
suggests that KRas4b may also localize on the late endosome and lysosome, and 
participate in v-ATPase related functions. eIF2B is the GEF for eIF2α6, and both 
proteins are indispensable in protein translation initiation. The interaction between 
KRas4b and eIF2B indicates that KRas4b may function in translation initiation, which 
could be important for KRas-driven cancers because these cancers need more protein 
synthesis to maintain high proliferation rate. 
 149 
In addition, the KRas4a and KRas4b interactome study identified many potential 
KRas effector proteins. Ras is known to recruit several GEFs to turn on other small 
GTPases, such as RIN (GEF for Rab), RalGDS (GEF for Ral), and Tiam1 (GEF for 
Rac)
7
. The KRas4a/b interactome identified Rap1GDS1 (GEF for Rap), ARFGEF3 
(GEF for Arf), and FARP2 (GEF for Rho) as potential KRas4a/b effector proteins 
(Figure 6.2). This suggests that besides Rab, Ral, and Rac, KRas4a/b may also 
activate Rap, Arf, and Rho through recruiting these previously unknown effector 
proteins. Investigation of these interactions could reveal new signaling cascade of 
KRas4a/b. 
 
 
Figure 5.2. Potential KRas4a/b effector proteins that server as GEFs for other small 
GTPases. 
 
In my thesis work, mTOR was identified as a KRas4a/b interacting protein. Several 
pieces of evidence together allow me to propose a unique KRas4a/b-mTOR complex 
model. In this model, KRas4a/b, mTOR, and mLST8 form a complex in the absence 
of raptor and rictor. However, the function of this complex is still unknown at this 
point. Since KRas4a/b-mTOR interaction does not seem to affect the phosphorylation 
of some well-studied mTOR substrates (Figure 4.9), it is likely that this new mTOR 
complex has different substrates from mTORC1 and mTORC2. To identify these new 
substrates, mTOR phosphorylome study with or without KRas4a/b can be performed. 
Knowing the substrates of KRas4a/b-mTOR complex could reveal the new signaling 
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functions of KRas and mTOR. 
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